{
    "0RX.F": {
        "short_name": "REDX PHARMA  LS -,01",
        "long_name": "Redx Pharma Plc",
        "summary": "Redx Pharma Plc engages in drug discovery, pre-clinical development, and licensing activities in the United Kingdom. It discovers and develops small molecule drugs for treating anti-cancer and fibrosis targets in the areas of unmet medical needs. The company is developing RXC004, a porcupine inhibitor, which has completed Phase I clinical development for the treatment of colorectal, pancreatic, biliary, and gastric cancers, as well as melanoma; ROCK inhibitor for treating inflammatory intestinal fibrosis; RXC007, a Rho-associated protein kinase 2 inhibitors for the treatment of orphan disease, idiopathic pulmonary fibrosis, non-alcoholic steatohepatitis, and other systemic fibrotic conditions; and Porcupine (RXC006), which is in Phase I for the treatment of lung fibrosis. Redx Pharma Plc has a research collaboration agreement with Jazz Pharmaceuticals plc to discover and develop drug candidates for two cancer targets in the Ras/Raf/MAP kinase pathway. The company was founded in 2010 and is based in Macclesfield, the United Kingdom.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "FRA",
        "market": "dr_market",
        "country": "United Kingdom",
        "city": "Macclesfield"
    },
    "1JS.F": {
        "short_name": "SHIELD THERAPEUT. LS-,015",
        "long_name": "Shield Therapeutics plc",
        "summary": "Shield Therapeutics plc, a specialty pharmaceutical company, engages in the development and commercialization of late-stage pharmaceuticals to treat unmet medical needs. The company's lead product is Ferric Maltol, marketed in the European Union as Feraccru, a non-salt based novel therapy for the treatment of iron deficiency anemia in patients with inflammatory bowel disease. Its advanced pipeline asset is PT20, a novel therapy that has completed its Phase II pivotal study for the treatment of hyperphosphatemia in patients with chronic kidney disease. The company also develops PT30 to treat hypo-allergenic IV iron therapy; and PT40, the first generic version of iron sucrose. Shield Therapeutics plc was founded in 2008 and is based in Gateshead, the United Kingdom.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Drug Manufacturers\u2014Specialty & Generic",
        "exchange": "FRA",
        "market": "dr_market",
        "country": "United Kingdom",
        "city": "Gateshead"
    },
    "1PK.F": {
        "short_name": "DECHRA PHARMACEUT. LS-,01",
        "long_name": "Dechra Pharmaceuticals PLC",
        "summary": "Dechra Pharmaceuticals PLC develops, manufactures, regulates, markets, and sells veterinary pharmaceuticals and related products for veterinarians worldwide. It operates through three segments: European Pharmaceuticals, North American Pharmaceuticals, and Pharmaceuticals Research and Development. The company offers various endocrinology, dermatology, analgesia and anesthesia, cardiovascular, and critical care products for dogs and cats; water soluble antibiotics, poultry vaccines, and pain management for poultry, pigs, and cattle; and lameness and pain management products for horses and ponies. It also provides pet nutrition products for supporting cats and dogs with various therapeutic conditions, such as allergies, obesity, heart, and kidney diseases. In addition, the company distributes veterinary pharmaceuticals and equipment; offers financial services; markets pet diets; and develops, regulates, manufactures, and markets crop protection. It markets its products through wholesaler and distributor networks. Dechra Pharmaceuticals PLC was incorporated in 1997 and is headquartered in Northwich, the United Kingdom.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Drug Manufacturers\u2014General",
        "exchange": "FRA",
        "market": "dr_market",
        "country": "United Kingdom",
        "city": "Northwich"
    },
    "1RC.SG": {
        "short_name": "Creo Medical Group PLC Register",
        "long_name": "Creo Medical Limited",
        "summary": "Creo Medical Limited engages in the research and development of electrosurgical medical devices relating to the field of surgical endoscopy in the United Kingdom. It is developing Speedboat RS2, a medical instrument through a combination of bipolar radiofrequency and microwave energy in a single platform for tissue dissection, resection, ablation, and coagulation. Creo Medical Limited was formerly known as MicroOncology Ltd. The company was founded in 2003 and is headquartered in Chepstow, the United Kingdom. Creo Medical Limited is a subsidiary of Creo Medical Group plc.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Medical Devices",
        "exchange": "STU",
        "market": "dr_market",
        "country": "United Kingdom",
        "city": "Chepstow"
    },
    "1RT.F": {
        "short_name": "NUFORMIX PLC  LS -,001",
        "long_name": "Nuformix plc",
        "summary": "Nuformix plc, a pharmaceutical development company, develops drugs using cocrystal technology in the United Kingdom. Its lead programs include NXP001, which is used for oncology supportive care; and NXP002 for use in the treatment of fibrosis. The company is also developing NXP004, which is under the pre-clinical stage for the treatment of multiple forms of fibrosis in various human tissues. It has an agreement with VistaGen Therapeutics, Inc. to develop co-crystal-based formulations of AV-101 for the treatment of various central nervous system conditions. The company also has an option agreement with Oxilio Ltd. to provide consultancy services for developing and exploiting NXP001 for the treatment of cancer. Nuformix plc was founded in 2008 and is headquartered in Cambridge, the United Kingdom.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "FRA",
        "market": "dr_market",
        "country": "United Kingdom",
        "city": "Cambridge"
    },
    "25I.F": {
        "short_name": "IMMUPHARMA PLC  LS-,10",
        "long_name": "ImmuPharma plc",
        "summary": "ImmuPharma plc, a biopharmaceutical company, discovers and develops peptide-based therapeutics. Its peptide-based therapeutics are used in the therapy areas of autoimmunity, anti-infectives, metabolism, and cancer. The company's lead product candidate is the Lupuzor, an autophagy immunomodulator, which is in Phase III clinical trial for the treatment of lupus, an autoimmune chronic inflammatory disease. Its other product candidate includes IPP-204106, a peptide to modulate angiogenesis with application in cancer and ophthalmology; and BioGlucagon a therapy for low sugar events in diabetes. ImmuPharma plc has a collaboration arrangement with Centre National de la Recherche Scientifique for the development of a peptide technology platform for treating diabetes with glucagon-like peptide -1 agonists, as well as development of peptides as glucagon antagonists to treat type I and type II diabetes; and license and development agreement with Avion Pharmaceuticals LLC. The company was founded in 1999 and is headquartered in London, the United Kingdom.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "FRA",
        "market": "dr_market",
        "country": "United Kingdom",
        "city": "London"
    },
    "2CV.F": {
        "short_name": "CONVATEC GROUP WI LS -,10",
        "long_name": "Convatec Group Plc",
        "summary": "ConvaTec Group Plc develops, manufactures, and markets medical products and technologies worldwide. It offers advanced wound dressings and skin care products for the management of chronic wounds resulting from various conditions, such as diabetes, immobility, and venous disease, as well as from traumatic injury, burns, invasive surgery, and other causes. The company also provides devices, accessories, and services for people with a stoma resulting from colorectal cancer, inflammatory bowel disease, bladder cancer, obesity, and other causes. In addition, it offers continence and critical care products, including intermittent urinary catheters; and products for people with urinary continence issues related to spinal cord injuries, multiple sclerosis, spina bifida, and urological disorders, as well as devices and products use in intensive care units and hospital settings. Further, the company provides advanced systems for managing acute fecal incontinence, as well as for monitoring urine production output and intra-abdominal pressure; and various disposable medical devices, such as wound drainage systems, urine collection bags and catheters, airway management and oxygen/aerosol therapy devices, suction handles and tubes, gastroenterology tubes, and securement devices. Additionally, it offers disposable infusion sets to the manufacturers of insulin pumps for diabetes, as well as similar pumps that are used in continuous infusion treatments for other conditions; and various products to hospitals and the home healthcare sector. The company sells its products to pharmacies, hospitals, and other acute and post-acute healthcare service providers directly or through distributors and wholesalers. It serves a range of customers, including healthcare providers, patients, and manufacturers. ConvaTec Group Plc was incorporated in 2016 and is headquartered in Reading, the United Kingdom.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Medical Instruments & Supplies",
        "exchange": "FRA",
        "market": "dr_market",
        "country": "United Kingdom",
        "city": "Reading"
    },
    "2CVU.F": {
        "short_name": "CONVATEC GRP UNSP.ADR /4",
        "long_name": "Convatec Group Plc",
        "summary": "ConvaTec Group Plc develops, manufactures, and markets medical products and technologies worldwide. It offers advanced wound dressings and skin care products for the management of chronic wounds resulting from various conditions, such as diabetes, immobility, and venous disease, as well as from traumatic injury, burns, invasive surgery, and other causes. The company also provides devices, accessories, and services for people with a stoma resulting from colorectal cancer, inflammatory bowel disease, bladder cancer, obesity, and other causes. In addition, it offers continence and critical care products, including intermittent urinary catheters; and products for people with urinary continence issues related to spinal cord injuries, multiple sclerosis, spina bifida, and urological disorders, as well as devices and products use in intensive care units and hospital settings. Further, the company provides advanced systems for managing acute fecal incontinence, as well as for monitoring urine production output and intra-abdominal pressure; and various disposable medical devices, such as wound drainage systems, urine collection bags and catheters, airway management and oxygen/aerosol therapy devices, suction handles and tubes, gastroenterology tubes, and securement devices. Additionally, it offers disposable infusion sets to the manufacturers of insulin pumps for diabetes, as well as similar pumps that are used in continuous infusion treatments for other conditions; and various products to hospitals and the home healthcare sector. The company sells its products to pharmacies, hospitals, and other acute and post-acute healthcare service providers directly or through distributors and wholesalers. It serves a range of customers, including healthcare providers, patients, and manufacturers. ConvaTec Group Plc was incorporated in 2016 and is headquartered in Reading, the United Kingdom.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Medical Instruments & Supplies",
        "exchange": "FRA",
        "market": "dr_market",
        "country": "United Kingdom",
        "city": "Reading"
    },
    "2EM.DE": {
        "short_name": "ERGOMED PLC  LS -,01",
        "long_name": "Ergomed plc",
        "summary": "Ergomed plc, together with its subsidiaries, provides clinical trial planning, management, and monitoring; and drug safety and medical information services in the United Kingdom and Rest of Europe, the Middle East, Africa, North America, Asia, and Australia. It operates through two segments, Clinical Research Outsourcing and Pharmacovigilance. The company provides and manages clinical development, trial management, and pharmacovigilance services for pharmaceutical and generics companies, as well as small and mid-sized drug development companies. It focuses on various therapeutic areas, including oncology, haematology, allergy, respiratory, neurology, and CNS, as well as develops orphan drugs. The company also provides site support services. Ergomed plc was formerly known as Ergomed Clinical Research Limited and changed its name to Ergomed plc in June 2014. Ergomed plc was founded in 1997 and is headquartered in Guildford, the United Kingdom.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "GER",
        "market": "de_market",
        "country": "United Kingdom",
        "city": "Guildford"
    },
    "2EM.F": {
        "short_name": "ERGOMED PLC  LS -,01",
        "long_name": "Ergomed plc",
        "summary": "Ergomed plc, together with its subsidiaries, provides clinical trial planning, management, and monitoring; and drug safety and medical information services in the United Kingdom and Rest of Europe, the Middle East, Africa, North America, Asia, and Australia. It operates through two segments, Clinical Research Outsourcing and Pharmacovigilance. The company provides and manages clinical development, trial management, and pharmacovigilance services for pharmaceutical and generics companies, as well as small and mid-sized drug development companies. It focuses on various therapeutic areas, including oncology, haematology, allergy, respiratory, neurology, and CNS, as well as develops orphan drugs. The company also provides site support services. Ergomed plc was formerly known as Ergomed Clinical Research Limited and changed its name to Ergomed plc in June 2014. Ergomed plc was founded in 1997 and is headquartered in Guildford, the United Kingdom.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "FRA",
        "market": "dr_market",
        "country": "United Kingdom",
        "city": "Guildford"
    },
    "2O9.F": {
        "short_name": "RENALYTIX AI PLC LS-,0025",
        "long_name": "Renalytix AI plc",
        "summary": "Renalytix AI plc develops artificial intelligence-enabled in vitro diagnostic solutions for kidney diseases. The company offers KidneyIntelX, a diagnostic platform that employs an artificial intelligence-enabled algorithm that combines various data inputs, including validated blood-based biomarkers, inherited genetics and personalized patient data from electronic health record, and systems to generate a unique patient risk score. Renalytix AI plc has a license agreement with Mount Sinai Health System to develop and commercialize licensed products in connection with the application of artificial intelligence for the diagnosis of kidney disease; Joslin Diabetes Center, Inc. for developing and commercializing products for diagnosing and predicting kidney disease using biomarkers; and Kantaro Biosciences LLC for developing and commercializing laboratory tests for the detection of antibodies against SARS-CoV-2. Its products are used in kidney disease diagnosis and prognosis, clinical care, patient stratification for drug clinical trials, and drug target discovery. The company was founded in 2018 and is based in Cardiff, the United Kingdom.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Diagnostics & Research",
        "exchange": "FRA",
        "market": "dr_market",
        "country": "United Kingdom",
        "city": "Cardiff"
    },
    "3HY.F": {
        "short_name": "ARIX BIOSCIENCE LS-,00001",
        "long_name": "Arix Bioscience plc",
        "summary": "Arix Bioscience plc is a venture capital firm specializing in all stages of growth, seed stage, preclinical and clinical stage assets, startup, early stage, mid venture, late stage, growth capital investments as well as private and public equity. The firm seeks to invest in biotech companies, novel therapeutics, innovative technologies, medical innovation comprising healthcare and life sciences. It seeks to invest globally. The firm employs an evergreen approach to funding. It primarily makes investments from its own balance sheet. The firm prefers to take board seat. The firm exit when the optimum value has been reached. Arix Bioscience plc is formerly known as Perceptive Bioscience Investments Limited. Arix Bioscience plc was founded in 2015 and is based in London, United Kingdom.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "FRA",
        "market": "dr_market",
        "country": "United Kingdom",
        "city": "London"
    },
    "3N9.F": {
        "short_name": "AMRYT PHARMA PLC  LS -,06",
        "long_name": "Amryt Pharma plc",
        "summary": "Amryt Pharma plc, a biopharmaceutical company, develops and commercializes therapeutics to treat patients suffering from serious and life-threatening rare diseases. The company offers Lomitapide for the treatment of homozygous familial hypercholesterolemia; and Metreleptin for the treatment of generalized and partial lipodystrophy. It also develops FILSUVEZ drug candidate for the treatment of severe epidermolysis bullosa (EB), a rare and genetic skin disease; and AP103 for the treatment of patients with recessive dystrophic EB, a subset of EB. The company sells its products in the Americas, Europe, and the Middle East. Amryt Pharma plc was founded in 2015 and is based in London, the United Kingdom.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Drug Manufacturers\u2014Specialty & Generic",
        "exchange": "FRA",
        "market": "dr_market",
        "country": "United Kingdom",
        "city": "London"
    },
    "3N9A.F": {
        "short_name": "AMRYT PHARMA PLC SP.ADR/5",
        "long_name": "Amryt Pharma plc",
        "summary": "Amryt Pharma plc, a biopharmaceutical company, develops and commercializes therapeutics to treat patients suffering from serious and life-threatening rare diseases. The company offers Lomitapide for the treatment of homozygous familial hypercholesterolemia; and Metreleptin for the treatment of generalized and partial lipodystrophy. It also develops FILSUVEZ drug candidate for the treatment of severe epidermolysis bullosa (EB), a rare and genetic skin disease; and AP103 for the treatment of patients with recessive dystrophic EB, a subset of EB. The company sells its products in the Americas, Europe, and the Middle East. Amryt Pharma plc was founded in 2015 and is based in London, the United Kingdom.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Drug Manufacturers\u2014Specialty & Generic",
        "exchange": "FRA",
        "market": "dr_market",
        "country": "United Kingdom",
        "city": "London"
    },
    "4KM.SG": {
        "short_name": "Kromek Group PLC Registered Sha",
        "long_name": "Kromek Group plc",
        "summary": "Kromek Group plc, together with its subsidiaries, develops, manufactures, and sells radiation detection products for medical imaging, nuclear detection, and security screening markets in the United Kingdom, North America, Asia, Europe, and Australasia. Its solutions provide high-resolution information on material composition and structure to enable the identification of cancerous tissues and hazardous materials, as well as for the analysis of radioactive materials. The company also provides a range of radiation detectors that use cadmium zinc telluride (CZT) or scintillator technology, such as handheld rugged gamma detectors, thermal neutron detectors, gamma-ray detector spectrometers, scintillator detectors, preamplifiers for radiation detectors and detector electronics, and EV-CPG compact gamma ray detectors, as well as quant GR1 shielded gamma detectors, multichannel analyzers, CZT-based gamma ray imagers, quant air, scalable x-ray CZR linear array, gamma-ray spectroscopy software, gamma ray radionuclide detectors, and voltage to frequency converters. In addition, it offers medical imaging products, including CZT gamma detector for SPECT imaging, CZT bone mineral densitometry detectors, and photon-counting spectral CT. Further, the company provides security products, such as D3 PRD high accuracy, D3M, and D3S PRD personal radiation detectors; D3S wearable RIID gamma neutron detectors; D3S NET networked radiation detectors and static node; static radiation detector; vehicle mounted radiation detectors; UAV radiation mapping drone and AARM system; liquid explosive detection algorithm; and Identifier liquid explosive detectors. Additionally, it engages in scientific research and development activities. The company sells its products through distributors, OEM, and direct sales. Kromek Group plc was incorporated in 2013 and is headquartered in Sedgefield, the United Kingdom.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Medical Devices",
        "exchange": "STU",
        "market": "dr_market",
        "country": "United Kingdom",
        "city": "Sedgefield"
    },
    "4UU.F": {
        "short_name": "DIURNAL GROUP PLC LS -,05",
        "long_name": "Diurnal Group plc",
        "summary": "Diurnal Group plc operates as a specialty pharma company worldwide. The company develops hormone therapeutics for the treatment of chronic endocrine conditions, including congenital adrenal hyperplasia, adrenal insufficiency, hypogonadism, and hypothyroidism. The company offers Alkindi, a replacement therapy for paediatric adrenal insufficiency in Europe. It also develops Chronocort, which completed Phase III clinical trials targeting congenital adrenal hyperplasia and adrenal insufficiency. The company's early stage pipeline products comprise Native Oral Testosterone, a replacement treatment for patients suffering from hypogonadism; siRNA, a short interfering RNA oligonucleotide therapy for patients suffering from adrenocorticotropin-dependent Cushing's syndrome; and T3 modified, a modified-release preparation of T3 (levothyroxine) hormone for patients suffering from hypothyroidism. Diurnal Group plc was incorporated in 2015 and is headquartered in Cardiff, the United Kingdom.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Drug Manufacturers\u2014Specialty & Generic",
        "exchange": "FRA",
        "market": "dr_market",
        "country": "United Kingdom",
        "city": "Cardiff"
    },
    "51B.F": {
        "short_name": "BIOVENTIX PLC  LS -,05",
        "long_name": "Bioventix PLC",
        "summary": "Bioventix PLC creates, manufactures, and supplies sheep monoclonal antibodies (SMAs) for diagnostic applications worldwide. The company offers a portfolio of purified SMAs for thyroid, vitamin D, cardiac, drugs of abuse, fertility, infectious disease, oncology, and miscellaneous indications. It also provides contract SMAs and recombinant services. The company was founded in 2003 and is based in London, the United Kingdom.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "FRA",
        "market": "dr_market",
        "country": "United Kingdom",
        "city": "London"
    },
    "54I.SG": {
        "short_name": "Instem PLC Registered Shares LS",
        "long_name": "Instem plc",
        "summary": "Instem plc, together with its subsidiaries, provides information technology applications to the life sciences healthcare market worldwide. The company offers solutions for data collection, management, and analysis to meet the needs of life science and healthcare organizations for data-driven decision making. Its solutions include ALPHADAS, an eSource EDC system for early phase clinical trials; Ames Study Manager, an integrated suite of software for conducting the Bacterial Reverse Mutation Test; Toxicology Resource Planning, a toxicology solution; Comet Assay IV, a live video imaging system for reproducible comet slide scoring; Cyto Study Manager, a data acquisition and reporting solution; lead scope for computational toxicology; Logbook, a repository for information; NOTOCORD-hem software platforms to acquire, display, and analyze physiological signals; and Provantis, a Windows-based system for organizations and universities that are engaged in non-clinical evaluation studies. The company also provides Samarind RMS to manage medical product information; Sorcerer Colony Counter for automatic plate counter; SEND Explorer, a web-based application with optional data warehousing capabilities; submit platform that provides a suite of integrated tools and services for the creation and management of SEND datasets and associated documents for contract research organizations and sponsors; and SENDTrial, a full Web based solution that can be accessed through a subscription. In addition, it offers data management, cloud, safety assessment, regulatory information management, solution deployment, and validation services. Further, the company provides software solutions for extracting intelligence from research and development related healthcare data; and develops, manufactures, and supplies software and hardware products for in vitro study data collection and study management. Instem plc was founded in 1969 and is headquartered in Stone, the United Kingdom.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Health Information Services",
        "exchange": "STU",
        "market": "dr_market",
        "country": "United Kingdom",
        "city": "Stone"
    },
    "5HU.F": {
        "short_name": "HEMOGENYX PHARM.PLC LS-01",
        "long_name": "Hemogenyx Pharmaceuticals Plc",
        "summary": "Hemogenyx Pharmaceuticals Plc, a preclinical-stage biotechnology company, focuses on the discovery, development, and commercialization of novel therapies and treatments for blood diseases. It is developing products for bone marrow/hematopoietic stem cell BM/HSC transplant market, including CDX bi-specific antibody and CAR-T therapy for eliminating relapsed and/or refractory acute myeloid leukaemia, acute lymphoblastic leukaemia, and myelodysplastic syndrome; and Human Postnatal Hemogenic Endothelial Cells, a cell therapy product for BM/HSC transplants. Hemogenyx Pharmaceuticals Plc has collaboration with GlobalCo. Hemogenyx Pharmaceuticals Plc was founded in 2013 and is headquartered in London, the United Kingdom.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "FRA",
        "market": "dr_market",
        "country": "United Kingdom",
        "city": "London"
    },
    "5KW.F": {
        "short_name": "SKINBIO THERAP  LS-,01",
        "long_name": "SkinBioTherapeutics Plc",
        "summary": "SkinBioTherapeutics plc, a life science company, engages in the research and development of lysates derived from the human microbiome on skin. The company focuses on the development of SkinBiotix technology for use in cosmetic, infection control, and eczema applications. It has an agreement with Croda International Plc for the design and manufacture of a new active cosmetic skincare ingredient based on its SkinBiotix skin microbiome technology. The company was formerly known as Skinbiotix Ltd and changed its name to SkinBioTherapeutics plc in December 2016. SkinBioTherapeutics plc was incorporated in 2015 and is based in Macclesfield, the United Kingdom.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "FRA",
        "market": "dr_market",
        "country": "United Kingdom",
        "city": "Macclesfield"
    },
    "5MPA.F": {
        "short_name": "MIDATECH PHARMA LS-,001",
        "long_name": "Midatech Pharma plc",
        "summary": "Midatech Pharma plc focuses on the research and development of oncology and rare disease products in the United Kingdom, rest of Europe, and internationally. The company is developing MTD201, a long acting dose of Octreotide for the treatment of acromegaly and neuroendocrine tumors; and MTX110, a direct delivery treatment for diffuse intrinsic pontine glioma. It also offers drug delivery platforms, such as Q-Sphera, a microencapsulation and polymer-depot sustained release drug delivery platform; MidaSolve, an oligosaccharide nanotechnology used to solubilize drugs so that they can be administered in liquid form directly and locally into tumors; and MidaCore, a gold nanoparticle used for targeting sites of disease by using chemotherapeutic agents or immunotherapeutic agents. Midatech Pharma plc was founded in 2000 and is headquartered in Cardiff, the United Kingdom.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "FRA",
        "market": "dr_market",
        "country": "United Kingdom",
        "city": "Cardiff"
    },
    "5MPD.F": {
        "short_name": "MIDATECH PHARMA SP.ADR/5",
        "long_name": "Midatech Pharma plc",
        "summary": "Midatech Pharma plc focuses on the research and development of oncology and rare disease products in the United Kingdom, rest of Europe, and internationally. The company is developing MTD201, a long acting dose of Octreotide for the treatment of acromegaly and neuroendocrine tumors; and MTX110, a direct delivery treatment for diffuse intrinsic pontine glioma. It also offers drug delivery platforms, such as Q-Sphera, a microencapsulation and polymer-depot sustained release drug delivery platform; MidaSolve, an oligosaccharide nanotechnology used to solubilize drugs so that they can be administered in liquid form directly and locally into tumors; and MidaCore, a gold nanoparticle used for targeting sites of disease by using chemotherapeutic agents or immunotherapeutic agents. Midatech Pharma plc was founded in 2000 and is headquartered in Cardiff, the United Kingdom.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "FRA",
        "market": "dr_market",
        "country": "United Kingdom",
        "city": "Cardiff"
    },
    "63V.F": {
        "short_name": "VERICI DX PLC  LS-,001",
        "long_name": "Verici Dx plc",
        "summary": "Verici Dx plc engages in developing and commercializing clinical diagnostics kidney transplant tests. The company was incorporated in 2020 and is based in Penarth, United Kingdom. As of July 10, 2020, Verici Dx plc is a former subsidiary of Renalytix AI plc.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Diagnostics & Research",
        "exchange": "FRA",
        "market": "dr_market",
        "country": "United Kingdom",
        "city": "Penarth"
    },
    "6A3A.F": {
        "short_name": "AUTOLUS THERAP. SP.ADR/1",
        "long_name": "Autolus Therapeutics plc",
        "summary": "Autolus Therapeutics plc, a clinical-stage biopharmaceutical company, develops T cell therapies for the treatment of hematological malignancies and solid tumors. The company is developing AUTO1 and AUTO3 for B cell malignancies; AUTO2 for the treatment of multiple myeloma; AUTO4 and AUTO 5 for T cell lymphoma; and AUTO6 and AUTO7 to treat solid tumors. The company was founded in 2014 and is headquartered in London, the United Kingdom.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "FRA",
        "market": "dr_market",
        "country": "United Kingdom",
        "city": "London"
    },
    "71M.F": {
        "short_name": "MYOVANT SCIENC. DL-,00001",
        "long_name": "Myovant Sciences Ltd.",
        "summary": "Myovant Sciences Ltd., a clinical-stage biopharmaceutical company, focuses on developing and commercializing therapies for women's health and endocrine diseases. The company's lead product is relugolix, an oral, once-daily, small molecule that acts as a gonadotropin-releasing hormone receptor antagonist for the treatment of heavy menstrual bleeding related with uterine fibroids, endometriosis-associated pain, and advanced prostate cancer. It is also developing MVT-602, an oligopeptide kisspeptin agonist, for the treatment of female infertility as part of assisted reproduction. Myovant Sciences Ltd. has collaboration with Pfizer Inc. to develop and commercialize relugolix in oncology and women's health. The company was formerly known as Roivant Endocrinology Ltd. and changed its name to Myovant Sciences Ltd. in May 2016. The company was founded in 2016 and is based in London, the United Kingdom. As of December 27, 2019, Myovant Sciences Ltd. operates as a subsidiary of Sumitovant Biopharma Ltd.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "FRA",
        "market": "dr_market",
        "country": "United Kingdom",
        "city": "London"
    },
    "7DC.F": {
        "short_name": "DIACEUTICS PLC  LS-,002",
        "long_name": "Diaceutics PLC",
        "summary": "Diaceutics Plc provides data, data analytics, and implementation services for pharmaceutical companies worldwide. It offers diagnostic landscape services, such as patient journey, lab mapping, diagnostic regulation, turnaround time, and sample availability analysis services; diagnostic tracking services, including lab tracking, patient insights, and physician segmentation services; and diagnostic payers research, diagnostic clinical landscape, integrated mapping research, buying process research, and testers/non-testers research services. The company also provides diagnostic planning services consisting of strategic and tactical planning, launch planning, diagnostic partner selection, and financial forecast services; commercialization services comprising content creation; LabEd/workshops, diagnostic adboards, conference support, and proficiency testing services; and Diagnostic reimbursement services. Diaceutics Plc was founded in 2005 and is headquartered in Belfast, the United Kingdom.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "FRA",
        "market": "dr_market",
        "country": "United Kingdom",
        "city": "Belfast"
    },
    "82C.F": {
        "short_name": "CIRCASSIA GROUP PLC",
        "long_name": "Circassia Group Plc",
        "summary": "Circassia Group Plc, a specialty pharmaceutical company, focuses on the development and commercialization of respiratory products. It operates through three segments: NIOX, Chronic Obstructive Pulmonary Disease (COPD), and LungFit. The company markets NIOX and NIOX VERO for use in asthma diagnosis and management; Tudorza for the treatment of COPD; and Duaklir, a fixed-dose combination of the long-acting muscarinic antagonist aclidinium bromide and long-acting beta agonist formoterol fumarate, which is administered twice-daily through the breath actuated Pressair inhaler for the maintenance treatment of COPD. It is also developing LungFit, a portable ventilator-compatible system that utilizes an electric voltage to produce precise quantities of nitric oxide from the nitrogen and oxygen in air. The company markets its products directly to specialists in the United States, the United Kingdom, China, Italy, and Germany, as well as through a network of partners internationally. Circassia Group Plc has a collaboration agreement with AstraZeneca to promote Tudorza and Duaklir for COPD treatment; and the United States and Chinese commercial rights to LungFit. The company was formerly known as Circassia Pharmaceuticals plc and changed its name to Circassia Group Plc in May 2020. Circassia Group Plc was founded in 2006 and is headquartered in Oxford, the United Kingdom.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "FRA",
        "market": "dr_market",
        "country": "United Kingdom",
        "city": "Oxford"
    },
    "8EV.F": {
        "short_name": "EVGEN PHARMA PLC LS-,0025",
        "long_name": "Evgen Pharma plc",
        "summary": "Evgen Pharma plc, a clinical stage drug development company, engages in developing sulforaphane based medicines for the treatment of multiple diseases. Its core technology is Sulforadex, which include synthetic and stabilized analogues of the naturally occurring compound sulforaphane. The company's lead product is SFX-01, a synthetic version of sulforaphane stabilised that is in Phase II clinical trials for the treatment of metastatic breast cancer and subarachnoid haemorrhage, as well as in preclinical stage for multiple sclerosis and clinical stage to treat prostate cancer, autism, non-alcoholic steatohepatitis, and chronic kidney diseases. Evgen Pharma plc was founded in 2007 and is headquartered in Wilmslow, the United Kingdom.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "FRA",
        "market": "dr_market",
        "country": "United Kingdom",
        "city": "Wilmslow"
    },
    "A1V.F": {
        "short_name": "APTORUM GROUP LTD A DL1",
        "long_name": "Aptorum Group Limited",
        "summary": "Aptorum Group Limited, a pharmaceutical company, engages in the discovery, development, and commercialization of therapeutic assets to treat diseases with unmet medical needs, particularly infectious diseases and cancers. Its pipeline through the establishment of drug discovery platforms enable the discovery of new therapeutics assets, such as systematic screening of existing approved drug molecules, and microbiome-based research platform for treatments of metabolic diseases. The company is also pursuing therapeutic and diagnostic projects in neurology, gastroenterology, metabolic disorders, women's health, and other disease areas. It also has projects focused on surgical robotics and natural supplement for women undergoing menopause and experiencing related symptoms. Aptorum Group Limited was incorporated in 2010 and is headquartered in London, the United Kingdom.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "FRA",
        "market": "dr_market",
        "country": "United Kingdom",
        "city": "London"
    },
    "A8C1.F": {
        "short_name": "ABCAM PLC  LS -,002",
        "long_name": "Abcam plc",
        "summary": "Abcam plc, a life sciences company, researches, develops, and distributes biological reagents and tools for research, drug discovery, and diagnostics in the United States, China, Japan, Europe, the Middle East, Africa, and rest of Asia Pacific. The company offers various research products, including primary and secondary antibodies; ELISA and matched antibody pairs; cell and tissue imaging tools; cellular and biochemical assays; proteins and peptides; proteomics tools; agonists, antagonists, activators, and inhibitors; lysates; and multiplex assays. Its research products are used in the areas of cancer, cardiovascular, cell biology, developmental biology, epigenetics, nuclear signaling, immunology, metabolism, microbiology, neuroscience, signal transduction, and stem cells. Further, the company offers diagnostic and therapeutic solutions. The company also sells its products online. Abcam plc was founded in 1998 and is headquartered in Cambridge, the United Kingdom.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "FRA",
        "market": "dr_market",
        "country": "United Kingdom",
        "city": "Cambridge"
    },
    "A8C3.F": {
        "short_name": "ABCAM PLC SP.ADR 1 LS-002",
        "long_name": "Abcam plc",
        "summary": "Abcam plc, a life sciences company, researches, develops, and distributes biological reagents and tools for research, drug discovery, and diagnostics in the United States, China, Japan, Europe, the Middle East, Africa, and rest of Asia Pacific. The company offers various research products, including primary and secondary antibodies; ELISA and matched antibody pairs; cell and tissue imaging tools; cellular and biochemical assays; proteins and peptides; proteomics tools; agonists, antagonists, activators, and inhibitors; lysates; and multiplex assays. Its research products are used in the areas of cancer, cardiovascular, cell biology, developmental biology, epigenetics, nuclear signaling, immunology, metabolism, microbiology, neuroscience, signal transduction, and stem cells. Further, the company offers diagnostic and therapeutic solutions. The company also sells its products online. Abcam plc was founded in 1998 and is headquartered in Cambridge, the United Kingdom.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "FRA",
        "market": "dr_market",
        "country": "United Kingdom",
        "city": "Cambridge"
    },
    "ABC.L": {
        "short_name": "ABCAM PLC ORD 0.2P",
        "long_name": "Abcam plc",
        "summary": "Abcam plc, a life sciences company, researches, develops, and distributes biological reagents and tools for research, drug discovery, and diagnostics in the United States, China, Japan, Europe, the Middle East, Africa, and rest of Asia Pacific. The company offers various research products, including primary and secondary antibodies; ELISA and matched antibody pairs; cell and tissue imaging tools; cellular and biochemical assays; proteins and peptides; proteomics tools; agonists, antagonists, activators, and inhibitors; lysates; and multiplex assays. Its research products are used in the areas of cancer, cardiovascular, cell biology, developmental biology, epigenetics, nuclear signaling, immunology, metabolism, microbiology, neuroscience, signal transduction, and stem cells. Further, the company offers diagnostic and therapeutic solutions. The company also sells its products online. Abcam plc was founded in 1998 and is headquartered in Cambridge, the United Kingdom.",
        "currency": "GBp",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "LSE",
        "market": "gb_market",
        "country": "United Kingdom",
        "city": "Cambridge"
    },
    "ABCM": {
        "short_name": "Abcam plc",
        "long_name": "Abcam plc",
        "summary": "Abcam plc, a life sciences company, researches, develops, and distributes biological reagents and tools for research, drug discovery, and diagnostics in the United States, China, Japan, Europe, the Middle East, Africa, and rest of Asia Pacific. The company offers various research products, including primary and secondary antibodies; ELISA and matched antibody pairs; cell and tissue imaging tools; cellular and biochemical assays; proteins and peptides; proteomics tools; agonists, antagonists, activators, and inhibitors; lysates; and multiplex assays. Its research products are used in the areas of cancer, cardiovascular, cell biology, developmental biology, epigenetics, nuclear signaling, immunology, metabolism, microbiology, neuroscience, signal transduction, and stem cells. Further, the company offers diagnostic and therapeutic solutions. The company also sells its products online. Abcam plc was founded in 1998 and is headquartered in Cambridge, the United Kingdom.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "NMS",
        "market": "us_market",
        "country": "United Kingdom",
        "city": "Cambridge"
    },
    "ABCZF": {
        "short_name": "ABCAM PLC",
        "long_name": "Abcam plc",
        "summary": "Abcam plc, a life sciences company, researches, develops, and distributes biological reagents and tools for research, drug discovery, and diagnostics in the United States, China, Japan, Europe, the Middle East, Africa, and rest of Asia Pacific. The company offers various research products, including primary and secondary antibodies; ELISA and matched antibody pairs; cell and tissue imaging tools; cellular and biochemical assays; proteins and peptides; proteomics tools; agonists, antagonists, activators, and inhibitors; lysates; and multiplex assays. Its research products are used in the areas of cancer, cardiovascular, cell biology, developmental biology, epigenetics, nuclear signaling, immunology, metabolism, microbiology, neuroscience, signal transduction, and stem cells. Further, the company offers diagnostic and therapeutic solutions. The company also sells its products online. Abcam plc was founded in 1998 and is headquartered in Cambridge, the United Kingdom.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "PNK",
        "market": "us_market",
        "country": "United Kingdom",
        "city": "Cambridge"
    },
    "ABDX.L": {
        "short_name": "ABINGDON HEALTH PLC ORD 0.025P",
        "long_name": "Abingdon Health Plc",
        "summary": "Abingdon Health Plc, a technology-enabled lateral flow diagnostics company, develops, manufactures, and markets medical diagnostics worldwide. The company offers AbC-19 Rapid Test, a COVID-19 neutralizing antibody test; nucleic acid lateral flow immunoassays; and Seralite, a rapid lateral flow test for the quantitative measurement of kappa and lambda immunoglobulin free light chains in serum. It also provides lateral flow development, manufacturing, and reader customization services. The company was founded in 2008 and is headquartered in York, the United Kingdom.",
        "currency": "GBp",
        "sector": "Healthcare",
        "industry": "Diagnostics & Research",
        "exchange": "LSE",
        "market": "gb_market",
        "country": "United Kingdom",
        "city": "York"
    },
    "ACPH.BR": {
        "short_name": "ACACIA PHARMA",
        "long_name": "Acacia Pharma Group plc",
        "summary": "Acacia Pharma Group plc, a hospital pharmaceutical company, discovers, develops, and commercializes pharmaceutical products for the patients undergoing surgery, other invasive procedures, or cancer chemotherapy treatments in the United States and internationally. The company's lead product is BAREMSIS, an intravenous amisulpride for the treatment and prophylaxis of post-operative nausea and vomiting. Its products also comprise APD403, an intravenous and oral amisulpride that has completed Phase II clinical trials for the chemotherapy-induced nausea and vomiting treatment; and BYFAVO, an ultra-short-acting and reversible intravenous benzodiazepine sedative/anesthetic, which has completed Phase III clinical trials for the use in invasive medical procedures, such as colonoscopy and bronchoscopy. The company's products are primarily serves anesthesiologists and oncologists. Acacia Pharma Group plc was founded in 2007 and is based in Cambridge, the United Kingdom.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "BRU",
        "market": "be_market",
        "country": "United Kingdom",
        "city": "Cambridge"
    },
    "ADAP": {
        "short_name": "Adaptimmune Therapeutics plc",
        "long_name": "Adaptimmune Therapeutics plc",
        "summary": "Adaptimmune Therapeutics plc, a clinical-stage biopharmaceutical company, focuses on providing novel cell therapies primarily to patients with solid tumors in the United States. The company's specific peptide enhanced affinity receptor (SPEAR) T-cell platform enables it to identify cancer targets. It also develops ADP-A2M4 that is in phase I clinical trial for solid tumor indication that include urothelial, melanoma, head and neck, ovarian, non-small cell lung cancer (NSCLC), esophageal, gastric, synovial sarcoma, and myxoid round cell liposarcoma cancers; ADP-A2AFP that is in phase I clinical trial for hepatocellular carcinoma; ADP-A2M4CD8, which is in phase I clinical trial for SPEAR T-cell; and ADP-A2M10 that is in the phase I clinical trials for the treatment of NSCLC, as well as urothelial, melanoma, and head and neck cancers. The company has a strategic collaboration and license agreement with GSK to research, develop, and commercialize NY-ESO T-cell therapy; and collaboration agreement with Noile-Immune Biotech Inc. to develop SPEAR T-cells in combination with Noile-Immune's PRIME technology. It also has a co-development and co-commercialization agreement with Universal Cells, Inc to targets co-developing T-cell therapy. Adaptimmune Therapeutics plc was founded in 2008 and is headquartered in Abingdon, the United Kingdom.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "NMS",
        "market": "us_market",
        "country": "United Kingdom",
        "city": "Abingdon"
    },
    "AGL.L": {
        "short_name": "ANGLE PLC ORD 10P",
        "long_name": "ANGLE plc",
        "summary": "ANGLE plc, a medical diagnostic company, engages in developing cancer diagnostics products. It develops and commercializes Parsortix cell separation system, which captures and harvests circulating tumor cells in cancer patient blood; and Ziplex multiplex analysis system that is used with the ovarian cancer clinical application. The company was founded in 1994 and is based in Guildford, the United Kingdom.",
        "currency": "GBp",
        "sector": "Healthcare",
        "industry": "Diagnostics & Research",
        "exchange": "LSE",
        "market": "gb_market",
        "country": "United Kingdom",
        "city": "Guildford"
    },
    "AGY.L": {
        "short_name": "ALLERGY THERAPEUTICS PLC ORD 0.",
        "long_name": "Allergy Therapeutics plc",
        "summary": "Allergy Therapeutics plc engages in the research and development of allergy treatments. The company sells injectable and sublingual allergen-specific immunotherapies; and offers prescription for the treatment of pollen-related allergies, particularly to grasses, weeds, and trees, as well as diagnostics. Its products include Pollinex, Pollinex Quattro, Oralvac, Acarovac Plus, Acarovac MPL, Venomil, Synbiotics, Penicillin Diagnostics, and Peanut. The company also develops allergy vaccines for grass, tree, and house dust mite, as well as peanut allergy vaccines. It operates in Central Europe, Southern Europe, the United Kingdom, and internationally. Allergy Therapeutics plc was incorporated in 2004 and is headquartered in Worthing, the United Kingdom.",
        "currency": "GBp",
        "sector": "Healthcare",
        "industry": "Drug Manufacturers\u2014Specialty & Generic",
        "exchange": "LSE",
        "market": "gb_market",
        "country": "United Kingdom",
        "city": "Worthing"
    },
    "AGYTF": {
        "short_name": "ALLERGY THERAPEUTICS",
        "long_name": "Allergy Therapeutics plc",
        "summary": "Allergy Therapeutics plc engages in the research and development of allergy treatments. The company sells injectable and sublingual allergen-specific immunotherapies; and offers prescription for the treatment of pollen-related allergies, particularly to grasses, weeds, and trees, as well as diagnostics. Its products include Pollinex, Pollinex Quattro, Oralvac, Acarovac Plus, Acarovac MPL, Venomil, Synbiotics, Penicillin Diagnostics, and Peanut. The company also develops allergy vaccines for grass, tree, and house dust mite, as well as peanut allergy vaccines. It operates in Central Europe, Southern Europe, the United Kingdom, and internationally. Allergy Therapeutics plc was incorporated in 2004 and is headquartered in Worthing, the United Kingdom.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Drug Manufacturers\u2014Specialty & Generic",
        "exchange": "PNK",
        "market": "us_market",
        "country": "United Kingdom",
        "city": "Worthing"
    },
    "AKTX": {
        "short_name": "Akari Therapeutics Plc",
        "long_name": "Akari Therapeutics, Plc",
        "summary": "Akari Therapeutics, Plc, a clinical-stage biopharmaceutical company, focuses on the development and commercialization of treatments for a range of rare and orphan autoimmune and inflammatory diseases. Its lead product candidate is Coversin, a second-generation complement inhibitor that is in Phase II clinical trial for the treatment of autoimmune and inflammatory diseases, including paroxysmal nocturnal hemoglobinuria, guillain barr\u00c3\u00a9 syndrome, and atypical hemolytic uremic syndrome. Akari Therapeutics, Plc is based in London, the United Kingdom.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "NMS",
        "market": "us_market",
        "country": "United Kingdom",
        "city": "London"
    },
    "ALIMM.BR": {
        "short_name": "IMMUPHARMA",
        "long_name": "ImmuPharma plc",
        "summary": "ImmuPharma plc, a biopharmaceutical company, discovers and develops peptide-based therapeutics. Its peptide-based therapeutics are used in the therapy areas of autoimmunity, anti-infectives, metabolism, and cancer. The company's lead product candidate is the Lupuzor, an autophagy immunomodulator, which is in Phase III clinical trial for the treatment of lupus, an autoimmune chronic inflammatory disease. Its other product candidate includes IPP-204106, a peptide to modulate angiogenesis with application in cancer and ophthalmology; and BioGlucagon a therapy for low sugar events in diabetes. ImmuPharma plc has a collaboration arrangement with Centre National de la Recherche Scientifique for the development of a peptide technology platform for treating diabetes with glucagon-like peptide -1 agonists, as well as development of peptides as glucagon antagonists to treat type I and type II diabetes; and license and development agreement with Avion Pharmaceuticals LLC. The company was founded in 1999 and is headquartered in London, the United Kingdom.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "BRU",
        "market": "be_market",
        "country": "United Kingdom",
        "city": "London"
    },
    "ALNOV.PA": {
        "short_name": "NOVACYT",
        "long_name": "Novacyt S.A.",
        "summary": "Novacyt S.A., together with its subsidiaries, engages in the development, manufacture, and commercialization of clinical diagnostic products for cancer and infectious diseases in Africa, Europe, the Asia Pacific, the United States, and the Middle East. The company operates through Corporate and Diagnostics, and Molecular Products segments. The Corporate and Diagnostics segment manufactures and distributes reagents and kits for bacterial and blood tests. The Molecular Products segment designs, manufactures, and distributes test kits for various diseases in humans, animals, and food products. The company's diagnostic products are used in oncology, microbiology, haematology, and serology testing. It also develops, manufactures, and distributes diagnostic products for food laboratories; and manufactures and supplies reagents and tests for in vitro diagnostic tests and blood grouping applications under the Plasmatec and Biotec brand names. The company has collaboration with AstraZeneca, GSK, and the University of Cambridge to support increase testing for COVID-19. It serves universities, hospitals, clinics, and testing laboratories. Novacyt S.A. was founded in 2006 and is headquartered in Camberley, the United Kingdom.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Diagnostics & Research",
        "exchange": "PAR",
        "market": "fr_market",
        "country": "United Kingdom",
        "city": "Camberley"
    },
    "AMYT": {
        "short_name": "Amryt Pharma plc",
        "long_name": "Amryt Pharma plc",
        "summary": "Amryt Pharma plc, a biopharmaceutical company, develops and commercializes therapeutics to treat patients suffering from serious and life-threatening rare diseases. The company offers Lomitapide for the treatment of homozygous familial hypercholesterolemia; and Metreleptin for the treatment of generalized and partial lipodystrophy. It also develops FILSUVEZ drug candidate for the treatment of severe epidermolysis bullosa (EB), a rare and genetic skin disease; and AP103 for the treatment of patients with recessive dystrophic EB, a subset of EB. The company sells its products in the Americas, Europe, and the Middle East. Amryt Pharma plc was founded in 2015 and is based in London, the United Kingdom.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Drug Manufacturers\u2014Specialty & Generic",
        "exchange": "NMS",
        "market": "us_market",
        "country": "United Kingdom",
        "city": "London"
    },
    "AMYT.L": {
        "short_name": "AMRYT PHARMA PLC ORD 6P",
        "long_name": "Amryt Pharma plc",
        "summary": "Amryt Pharma plc, a biopharmaceutical company, develops and commercializes therapeutics to treat patients suffering from serious and life-threatening rare diseases. The company offers Lomitapide for the treatment of homozygous familial hypercholesterolemia; and Metreleptin for the treatment of generalized and partial lipodystrophy. It also develops FILSUVEZ drug candidate for the treatment of severe epidermolysis bullosa (EB), a rare and genetic skin disease; and AP103 for the treatment of patients with recessive dystrophic EB, a subset of EB. The company sells its products in the Americas, Europe, and the Middle East. Amryt Pharma plc was founded in 2015 and is based in London, the United Kingdom.",
        "currency": "GBp",
        "sector": "Healthcare",
        "industry": "Drug Manufacturers\u2014Specialty & Generic",
        "exchange": "LSE",
        "market": "gb_market",
        "country": "United Kingdom",
        "city": "London"
    },
    "ANCR.L": {
        "short_name": "ANIMALCARE GROUP PLC ORD 20P",
        "long_name": "Animalcare Group plc",
        "summary": "Animalcare Group plc engages in the development, sale, and distribution of licensed veterinary pharmaceuticals; and identification of products and services to companion animal veterinary markets in Spain, Portugal, Germany, Italy, other European Union, Asia, the Middle East, Africa, the United Kingdom, Belgium, the Netherlands, and internationally. It is also involved in the marketing of veterinary pharmaceuticals. Animalcare Group plc was founded in 1972 and is based in York, the United Kingdom.",
        "currency": "GBp",
        "sector": "Healthcare",
        "industry": "Medical Care Facilities",
        "exchange": "LSE",
        "market": "gb_market",
        "country": "United Kingdom",
        "city": "York"
    },
    "ANPCY": {
        "short_name": "ANGLE",
        "long_name": "ANGLE plc",
        "summary": "ANGLE plc, a medical diagnostic company, engages in developing cancer diagnostics products. It develops and commercializes Parsortix cell separation system, which captures and harvests circulating tumor cells in cancer patient blood; and Ziplex multiplex analysis system that is used with the ovarian cancer clinical application. The company was founded in 1994 and is based in Guildford, the United Kingdom.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Diagnostics & Research",
        "exchange": "PNK",
        "market": "us_market",
        "country": "United Kingdom",
        "city": "Guildford"
    },
    "AOHA.F": {
        "short_name": "RUA LIFE SCIENCES  LS0,05",
        "long_name": "Rua Life Sciences Plc",
        "summary": "Rua Life Sciences Plc, together with its subsidiaries, provides polymers, services, and products to the medical device industry in Europe, the United States, and internationally. The company operates as a contract developer and manufacturer of medical devices; and licensor of Elast-Eon and ECSil implantable co-polymers that are used in cardiology and urological applications, including pacing leads, cardiac cannulae, and stent devices, as well as reaction injection molding technology for use in high-precision medical device components. It also develops bore polymer sealed grafts and soft tissue patches; and tri leaflet polymeric heart valves. The company was formerly known as AorTech International plc and changed its name to Rua Life Sciences Plc in June 2020. Rua Life Sciences Plc was incorporated in 1996 and is headquartered in Irvine, the United Kingdom.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Medical Devices",
        "exchange": "FRA",
        "market": "dr_market",
        "country": "United Kingdom",
        "city": "Irvine"
    },
    "APM": {
        "short_name": "Aptorum Group Limited",
        "long_name": "Aptorum Group Limited",
        "summary": "Aptorum Group Limited, a pharmaceutical company, engages in the discovery, development, and commercialization of therapeutic assets to treat diseases with unmet medical needs, particularly infectious diseases and cancers. Its pipeline through the establishment of drug discovery platforms enable the discovery of new therapeutics assets, such as systematic screening of existing approved drug molecules, and microbiome-based research platform for treatments of metabolic diseases. The company is also pursuing therapeutic and diagnostic projects in neurology, gastroenterology, metabolic disorders, women's health, and other disease areas. It also has projects focused on surgical robotics and natural supplement for women undergoing menopause and experiencing related symptoms. Aptorum Group Limited was incorporated in 2010 and is headquartered in London, the United Kingdom.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "NMS",
        "market": "us_market",
        "country": "United Kingdom",
        "city": "London"
    },
    "APM.PA": {
        "short_name": "APTORUM GROUP CL A",
        "long_name": "Aptorum Group Limited",
        "summary": "Aptorum Group Limited, a pharmaceutical company, engages in the discovery, development, and commercialization of therapeutic assets to treat diseases with unmet medical needs, particularly infectious diseases and cancers. Its pipeline through the establishment of drug discovery platforms enable the discovery of new therapeutics assets, such as systematic screening of existing approved drug molecules, and microbiome-based research platform for treatments of metabolic diseases. The company is also pursuing therapeutic and diagnostic projects in neurology, gastroenterology, metabolic disorders, women's health, and other disease areas. It also has projects focused on surgical robotics and natural supplement for women undergoing menopause and experiencing related symptoms. Aptorum Group Limited was incorporated in 2010 and is headquartered in London, the United Kingdom.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "PAR",
        "market": "fr_market",
        "country": "United Kingdom",
        "city": "London"
    },
    "AQA.F": {
        "short_name": "ADVANCED MED.SO.GRP LS-05",
        "long_name": "Advanced Medical Solutions Group plc",
        "summary": "Advanced Medical Solutions Group plc, together with its subsidiaries, designs, develops, manufactures, and distributes products for the wound care, surgical, and wound closure markets in the United Kingdom, Germany, Europe, the United States, and internationally. It operates in two segments, Surgical and Woundcare. The Surgical segment offers topical tissue adhesives for wound closure and sealing under the LiquiBand; sutures and collagen based products for the surgical and dental markets under the RESORBA; collagens; and laparoscopic device which reduces surgical complications under the LiquiBand Fix8 brands. The Woundcare segment provides wound care platform technologies, which include alginates, foams, films, fibres, hydrogels, antimicrobial dressings, and hydrocolloids, as well as wound care products under the ActivHeal. It also sells its products under the Seal-G and Biomatlante brand names, such as Moldable Bone Graft Substitute, a biphasic calcium phosphate synthetic bone graft substitute that includes Syringes, Inserts, and In'Oss; EZ Cure, a collagen membranes; and Osteotwin, a Biocompatible Interference Resorbable Screw. The company was founded in 1991 and is headquartered in Winsford, the United Kingdom.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Medical Instruments & Supplies",
        "exchange": "FRA",
        "market": "dr_market",
        "country": "United Kingdom",
        "city": "Winsford"
    },
    "ARIX.L": {
        "short_name": "ARIX BIOSCIENCE PLC ORD 0.001P",
        "long_name": "Arix Bioscience plc",
        "summary": "Arix Bioscience plc is a venture capital firm specializing in all stages of growth, seed stage, preclinical and clinical stage assets, startup, early stage, mid venture, late stage, growth capital investments as well as private and public equity. The firm seeks to invest in biotech companies, novel therapeutics, innovative technologies, medical innovation comprising healthcare and life sciences. It seeks to invest globally. The firm employs an evergreen approach to funding. It primarily makes investments from its own balance sheet. The firm prefers to take board seat. The firm exit when the optimum value has been reached. Arix Bioscience plc is formerly known as Perceptive Bioscience Investments Limited. Arix Bioscience plc was founded in 2015 and is based in London, United Kingdom.",
        "currency": "GBp",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "LSE",
        "market": "gb_market",
        "country": "United Kingdom",
        "city": "London"
    },
    "AUTL": {
        "short_name": "Autolus Therapeutics plc",
        "long_name": "Autolus Therapeutics plc",
        "summary": "Autolus Therapeutics plc, a clinical-stage biopharmaceutical company, develops T cell therapies for the treatment of hematological malignancies and solid tumors. The company is developing AUTO1 and AUTO3 for B cell malignancies; AUTO2 for the treatment of multiple myeloma; AUTO4 and AUTO 5 for T cell lymphoma; and AUTO6 and AUTO7 to treat solid tumors. The company was founded in 2014 and is headquartered in London, the United Kingdom.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "NMS",
        "market": "us_market",
        "country": "United Kingdom",
        "city": "London"
    },
    "AVCT.L": {
        "short_name": "AVACTA GROUP PLC ORD 10P",
        "long_name": "Avacta Group Plc",
        "summary": "Avacta Group Plc offers reagents and therapeutics based on Affimer technology for diagnostic and research applications in the United Kingdom, North America, Asia, and rest of Europe. It operates in Diagnostics, Therapeutics, and Animal Health segments. The company develops custom Affimer proteins for customer products and in-house diagnostic assays. It also develops novel cancer immunotherapies combining proprietary platforms; and provides tools and contract services to assist diagnosis of conditions in animals to enable faster treatment for veterinarians. The company has a research partnership with Moderna Therapeutics; research collaboration with pre|CISION technology incorporates a substrate that is sensitive to cleavage by fibroblast activation protein; co-development partnership agreement with Bach Biosciences LLP to develop Affimer drug conjugate therapies; drug development collaboration with LG Chem Life Sciences; a partnership with Selexis to develop cell line for clinical manufacturing, and with Tufts University School of Medicine for developing Affimer drug conjugate therapies; a collaboration with Cytiva to develop and manufacture an Affimer-based point-of-care rapid test; and a collaboration with Adeptrix to develop Affimer-based COVID-19 antigen tests. Avacta Group Plc was incorporated in 2003 and is based in Wetherby, the United Kingdom.",
        "currency": "GBp",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "LSE",
        "market": "gb_market",
        "country": "United Kingdom",
        "city": "Wetherby"
    },
    "AVO.L": {
        "short_name": "ADVANCED ONCOTHERAPY PLC ORD 25",
        "long_name": "Advanced Oncotherapy plc",
        "summary": "Advanced Oncotherapy plc, together with its subsidiaries, engages in designing, assembling, selling, and maintaining proton-based radiotherapy systems for treatment of cancer. It is developing Linac Image Guided Hadron Technology, a proton therapy system for treating cancer. It has operations in the United Kingdom, Switzerland, and the United States. The company was formerly known as CareCapital Group plc and changed its name to Advanced Oncotherapy PLC in September 2012. Advanced Oncotherapy plc was founded in 1994 and is headquartered in London, the United Kingdom.",
        "currency": "GBp",
        "sector": "Healthcare",
        "industry": "Medical Devices",
        "exchange": "LSE",
        "market": "gb_market",
        "country": "United Kingdom",
        "city": "London"
    },
    "AZN": {
        "short_name": "Astrazeneca PLC",
        "long_name": "AstraZeneca PLC",
        "summary": "AstraZeneca PLC discovers, develops, and commercializes prescription medicines in the areas of oncology, cardiovascular, renal and metabolism, respiratory, autoimmunity, infection, neuroscience, and gastroenterology worldwide. Its marketed products include Arimidex, Casodex/Cosudex, Calquence, Faslodex, Imfinzi, Iressa, Lynparza, Nolvadex, Tagrisso, and Zoladex for oncology diseases; Atacand/Atacand HCT/Atacand Plus, Brilinta/Brilique, Crestor, Plendil, Seloken/Toprol-XL, Tenormin, and Zestril for cardiovascular diseases; and Bydureon, Byetta, Farxiga/Forxiga, Kombiglyze XR/Komboglyze, Onglyza, Qtern, Symlin, Xigduo/Xigduo XR for metabolic diseases. The company's marketed products also comprise Accolate, Bevespi Aerosphere, Bricanyl Respules, Bricanyl Turbuhaler, Daliresp/Daxas, Duaklir Genuair, Tudorza/Eklira, Fasenra, Oxis Turbuhaler, Pulmicort Turbuhaler/Pulmicort Flexhaler, Pulmicort Respules, Symbicort pMDI, and Symbicort Turbuhaler for respiratory diseases; Fluenz Tetra/FluMist Quadrivalen and Synagis for infection diseases; Movantik/Moventig, Seroquel IR/Seroquel XR, and Vimovo for neuroscience diseases; and Losec/Prilosec and Nexium for gastrointestinal diseases. The company serves primary care and specialty care physicians through distributors and local representative offices. It has a collaboration agreement with Arcus Biosciences, Inc. to evaluate domvanalimab (AB154), an investigational anti-TIGIT antibody in combination with Imfinzi (durvalumab); Fusion Pharmaceuticals Inc. to develop and commercialize next-generation alpha-emitting radiopharmaceuticals and combination therapies for the treatment of cancer; and Recombinetics Inc. The company was formerly known as Zeneca Group PLC and changed its name to AstraZeneca PLC in April 1999. AstraZeneca PLC was founded in 1992 and is headquartered in Cambridge, the United Kingdom.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Drug Manufacturers\u2014General",
        "exchange": "NMS",
        "market": "us_market",
        "country": "United Kingdom",
        "city": "Cambridge"
    },
    "AZN.L": {
        "short_name": "ASTRAZENECA PLC ORD SHS $0.25",
        "long_name": "AstraZeneca PLC",
        "summary": "AstraZeneca PLC discovers, develops, and commercializes prescription medicines in the areas of oncology, cardiovascular, renal and metabolism, respiratory, autoimmunity, infection, neuroscience, and gastroenterology worldwide. Its marketed products include Arimidex, Casodex/Cosudex, Calquence, Faslodex, Imfinzi, Iressa, Lynparza, Nolvadex, Tagrisso, and Zoladex for oncology diseases; Atacand/Atacand HCT/Atacand Plus, Brilinta/Brilique, Crestor, Plendil, Seloken/Toprol-XL, Tenormin, and Zestril for cardiovascular diseases; and Bydureon, Byetta, Farxiga/Forxiga, Kombiglyze XR/Komboglyze, Onglyza, Qtern, Symlin, Xigduo/Xigduo XR for metabolic diseases. The company's marketed products also comprise Accolate, Bevespi Aerosphere, Bricanyl Respules, Bricanyl Turbuhaler, Daliresp/Daxas, Duaklir Genuair, Tudorza/Eklira, Fasenra, Oxis Turbuhaler, Pulmicort Turbuhaler/Pulmicort Flexhaler, Pulmicort Respules, Symbicort pMDI, and Symbicort Turbuhaler for respiratory diseases; Fluenz Tetra/FluMist Quadrivalen and Synagis for infection diseases; Movantik/Moventig, Seroquel IR/Seroquel XR, and Vimovo for neuroscience diseases; and Losec/Prilosec and Nexium for gastrointestinal diseases. The company serves primary care and specialty care physicians through distributors and local representative offices. It has a collaboration agreement with Arcus Biosciences, Inc. to evaluate domvanalimab (AB154), an investigational anti-TIGIT antibody in combination with Imfinzi (durvalumab); Fusion Pharmaceuticals Inc. to develop and commercialize next-generation alpha-emitting radiopharmaceuticals and combination therapies for the treatment of cancer; and Recombinetics Inc. The company was formerly known as Zeneca Group PLC and changed its name to AstraZeneca PLC in April 1999. AstraZeneca PLC was founded in 1992 and is headquartered in Cambridge, the United Kingdom.",
        "currency": "GBp",
        "sector": "Healthcare",
        "industry": "Drug Manufacturers\u2014General",
        "exchange": "LSE",
        "market": "gb_market",
        "country": "United Kingdom",
        "city": "Cambridge"
    },
    "AZN.ST": {
        "short_name": "AstraZeneca PLC",
        "long_name": "AstraZeneca PLC",
        "summary": "AstraZeneca PLC discovers, develops, and commercializes prescription medicines in the areas of oncology, cardiovascular, renal and metabolism, respiratory, autoimmunity, infection, neuroscience, and gastroenterology worldwide. Its marketed products include Arimidex, Casodex/Cosudex, Calquence, Faslodex, Imfinzi, Iressa, Lynparza, Nolvadex, Tagrisso, and Zoladex for oncology diseases; Atacand/Atacand HCT/Atacand Plus, Brilinta/Brilique, Crestor, Plendil, Seloken/Toprol-XL, Tenormin, and Zestril for cardiovascular diseases; and Bydureon, Byetta, Farxiga/Forxiga, Kombiglyze XR/Komboglyze, Onglyza, Qtern, Symlin, Xigduo/Xigduo XR for metabolic diseases. The company's marketed products also comprise Accolate, Bevespi Aerosphere, Bricanyl Respules, Bricanyl Turbuhaler, Daliresp/Daxas, Duaklir Genuair, Tudorza/Eklira, Fasenra, Oxis Turbuhaler, Pulmicort Turbuhaler/Pulmicort Flexhaler, Pulmicort Respules, Symbicort pMDI, and Symbicort Turbuhaler for respiratory diseases; Fluenz Tetra/FluMist Quadrivalen and Synagis for infection diseases; Movantik/Moventig, Seroquel IR/Seroquel XR, and Vimovo for neuroscience diseases; and Losec/Prilosec and Nexium for gastrointestinal diseases. The company serves primary care and specialty care physicians through distributors and local representative offices. It has a collaboration agreement with Arcus Biosciences, Inc. to evaluate domvanalimab (AB154), an investigational anti-TIGIT antibody in combination with Imfinzi (durvalumab); Fusion Pharmaceuticals Inc. to develop and commercialize next-generation alpha-emitting radiopharmaceuticals and combination therapies for the treatment of cancer; and Recombinetics Inc. The company was formerly known as Zeneca Group PLC and changed its name to AstraZeneca PLC in April 1999. AstraZeneca PLC was founded in 1992 and is headquartered in Cambridge, the United Kingdom.",
        "currency": "SEK",
        "sector": "Healthcare",
        "industry": "Drug Manufacturers\u2014General",
        "exchange": "STO",
        "market": "se_market",
        "country": "United Kingdom",
        "city": "Cambridge"
    },
    "AZNCF": {
        "short_name": "ASTRAZENECA",
        "long_name": "AstraZeneca PLC",
        "summary": "AstraZeneca PLC discovers, develops, and commercializes prescription medicines in the areas of oncology, cardiovascular, renal and metabolism, respiratory, autoimmunity, infection, neuroscience, and gastroenterology worldwide. Its marketed products include Arimidex, Casodex/Cosudex, Calquence, Faslodex, Imfinzi, Iressa, Lynparza, Nolvadex, Tagrisso, and Zoladex for oncology diseases; Atacand/Atacand HCT/Atacand Plus, Brilinta/Brilique, Crestor, Plendil, Seloken/Toprol-XL, Tenormin, and Zestril for cardiovascular diseases; and Bydureon, Byetta, Farxiga/Forxiga, Kombiglyze XR/Komboglyze, Onglyza, Qtern, Symlin, Xigduo/Xigduo XR for metabolic diseases. The company's marketed products also comprise Accolate, Bevespi Aerosphere, Bricanyl Respules, Bricanyl Turbuhaler, Daliresp/Daxas, Duaklir Genuair, Tudorza/Eklira, Fasenra, Oxis Turbuhaler, Pulmicort Turbuhaler/Pulmicort Flexhaler, Pulmicort Respules, Symbicort pMDI, and Symbicort Turbuhaler for respiratory diseases; Fluenz Tetra/FluMist Quadrivalen and Synagis for infection diseases; Movantik/Moventig, Seroquel IR/Seroquel XR, and Vimovo for neuroscience diseases; and Losec/Prilosec and Nexium for gastrointestinal diseases. The company serves primary care and specialty care physicians through distributors and local representative offices. It has a collaboration agreement with Arcus Biosciences, Inc. to evaluate domvanalimab (AB154), an investigational anti-TIGIT antibody in combination with Imfinzi (durvalumab); Fusion Pharmaceuticals Inc. to develop and commercialize next-generation alpha-emitting radiopharmaceuticals and combination therapies for the treatment of cancer; and Recombinetics Inc. The company was formerly known as Zeneca Group PLC and changed its name to AstraZeneca PLC in April 1999. AstraZeneca PLC was founded in 1992 and is headquartered in Cambridge, the United Kingdom.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Drug Manufacturers\u2014General",
        "exchange": "PNK",
        "market": "us_market",
        "country": "United Kingdom",
        "city": "Cambridge"
    },
    "AZNN.MX": {
        "short_name": "ASTRAZENECA",
        "long_name": "AstraZeneca PLC",
        "summary": "AstraZeneca PLC discovers, develops, and commercializes prescription medicines in the areas of oncology, cardiovascular, renal and metabolism, respiratory, autoimmunity, infection, neuroscience, and gastroenterology worldwide. Its marketed products include Arimidex, Casodex/Cosudex, Calquence, Faslodex, Imfinzi, Iressa, Lynparza, Nolvadex, Tagrisso, and Zoladex for oncology diseases; Atacand/Atacand HCT/Atacand Plus, Brilinta/Brilique, Crestor, Plendil, Seloken/Toprol-XL, Tenormin, and Zestril for cardiovascular diseases; and Bydureon, Byetta, Farxiga/Forxiga, Kombiglyze XR/Komboglyze, Onglyza, Qtern, Symlin, Xigduo/Xigduo XR for metabolic diseases. The company's marketed products also comprise Accolate, Bevespi Aerosphere, Bricanyl Respules, Bricanyl Turbuhaler, Daliresp/Daxas, Duaklir Genuair, Tudorza/Eklira, Fasenra, Oxis Turbuhaler, Pulmicort Turbuhaler/Pulmicort Flexhaler, Pulmicort Respules, Symbicort pMDI, and Symbicort Turbuhaler for respiratory diseases; Fluenz Tetra/FluMist Quadrivalen and Synagis for infection diseases; Movantik/Moventig, Seroquel IR/Seroquel XR, and Vimovo for neuroscience diseases; and Losec/Prilosec and Nexium for gastrointestinal diseases. The company serves primary care and specialty care physicians through distributors and local representative offices. It has a collaboration agreement with Arcus Biosciences, Inc. to evaluate domvanalimab (AB154), an investigational anti-TIGIT antibody in combination with Imfinzi (durvalumab); Fusion Pharmaceuticals Inc. to develop and commercialize next-generation alpha-emitting radiopharmaceuticals and combination therapies for the treatment of cancer; and Recombinetics Inc. The company was formerly known as Zeneca Group PLC and changed its name to AstraZeneca PLC in April 1999. AstraZeneca PLC was founded in 1992 and is headquartered in Cambridge, the United Kingdom.",
        "currency": "MXN",
        "sector": "Healthcare",
        "industry": "Drug Manufacturers\u2014General",
        "exchange": "MEX",
        "market": "mx_market",
        "country": "United Kingdom",
        "city": "Cambridge"
    },
    "BCYC": {
        "short_name": "Bicycle Therapeutics plc",
        "long_name": "Bicycle Therapeutics plc",
        "summary": "Bicycle Therapeutics plc, a clinical-stage biopharmaceutical company, develops a class of medicines for diseases that are underserved by existing therapeutics. Its lead product candidate is BT1718, a bicycle toxin conjugate (BTC), which is in Phase I/IIa clinical trials targeting tumors that express Membrane Type 1 matrix metalloprotease. The company's oncology product candidates also comprise BT5528, a BTC that is in a Phase I/IIa clinical trial targeting EphA2; BT8009, which is in preclinical studies targeting Nectin-4; and CD137, an immune cell co-stimulatory molecule that is in preclinical stage. In addition, it is developing THR-149, a plasma kallikrein inhibitor that completed Phase I clinical trials for the treatment of diabetic macular edema. Further, the company collaborates with biopharmaceutical companies and organizations to develop programs in therapeutic areas, such as anti-infective, cardiovascular, ophthalmology, and respiratory indications. Bicycle Therapeutics plc has a clinical trial and license agreement with the Cancer Research Technology Limited and CRUK; research collaboration agreements with AstraZeneca, Sanofi, Oxurion, and the Dementia Discovery Fund; and discovery collaboration and license agreement with Genentech for the discovery and development of Bicycle peptides for multiple immuno-oncology targets. The company was incorporated in 2009 and is headquartered in Cambridge, the United Kingdom.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "NMS",
        "market": "us_market",
        "country": "United Kingdom",
        "city": "Cambridge"
    },
    "BHCCF": {
        "short_name": "BENCHMARK HLDGS PLC",
        "long_name": "Benchmark Holdings plc",
        "summary": "Benchmark Holdings plc, together with its subsidiaries, provides technical services, products, and specialist knowledge that support the development of food and farming industries worldwide. The company operates through Genetics, Advanced Nutrition, and Health segments. The Genetics segment offers salmon breeding technologies and production facilities to the harnesses industry to provide a range of genetic merit ova. The Advanced Nutrition segment manufactures and offers nutrition and health products to the aquaculture industry. The Health segment provides health products to aquaculture market. Benchmark Holdings plc was founded in 2000 and is based in Sheffield, the United Kingdom.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Drug Manufacturers\u2014Specialty & Generic",
        "exchange": "PNK",
        "market": "us_market",
        "country": "United Kingdom",
        "city": "Sheffield"
    },
    "BMK.L": {
        "short_name": "BENCHMARK HOLDINGS PLC ORD 0.1P",
        "long_name": "Benchmark Holdings plc",
        "summary": "Benchmark Holdings plc, together with its subsidiaries, provides technical services, products, and specialist knowledge that support the development of food and farming industries worldwide. The company operates through Genetics, Advanced Nutrition, and Health segments. The Genetics segment offers salmon breeding technologies and production facilities to the harnesses industry to provide a range of genetic merit ova. The Advanced Nutrition segment manufactures and offers nutrition and health products to the aquaculture industry. The Health segment provides health products to aquaculture market. Benchmark Holdings plc was founded in 2000 and is based in Sheffield, the United Kingdom.",
        "currency": "GBp",
        "sector": "Healthcare",
        "industry": "Drug Manufacturers\u2014Specialty & Generic",
        "exchange": "LSE",
        "market": "gb_market",
        "country": "United Kingdom",
        "city": "Sheffield"
    },
    "BQB1.F": {
        "short_name": "YOURGENE HEALTH  LS 0,001",
        "long_name": "Yourgene Health Plc",
        "summary": "Yourgene Health Plc, a molecular diagnostic company, researches, develops, and commercializes gene analysis techniques for prenatal screening and other applications in the United Kingdom, Europe, and internationally. The company develops the IONA Test, an in vitro diagnostic non-invasive pre-natal test (NIPT) screening for pregnant women to estimate Down's syndrome and other genetic disorders. The IONA test enables clinical laboratories to perform their own NIPT screening service. It also offers Cystic Fibrosis screening test; genetic disease screening products; and reproductive health products that include polymerase chain reaction -based screening tests for male factor infertility, recurrent pregnancy loss, and thrombosis. The company was formerly known as Premaitha Health PLC and changed its name to Yourgene Health Plc in November 2018. The company was incorporated in 2000 and is headquartered in Manchester, the United Kingdom.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Diagnostics & Research",
        "exchange": "FRA",
        "market": "dr_market",
        "country": "United Kingdom",
        "city": "Manchester"
    },
    "BVXP.L": {
        "short_name": "BIOVENTIX PLC ORD 5P",
        "long_name": "Bioventix PLC",
        "summary": "Bioventix PLC creates, manufactures, and supplies sheep monoclonal antibodies (SMAs) for diagnostic applications worldwide. The company offers a portfolio of purified SMAs for thyroid, vitamin D, cardiac, drugs of abuse, fertility, infectious disease, oncology, and miscellaneous indications. It also provides contract SMAs and recombinant services. The company was founded in 2003 and is based in London, the United Kingdom.",
        "currency": "GBp",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "LSE",
        "market": "gb_market",
        "country": "United Kingdom",
        "city": "London"
    },
    "C5P.F": {
        "short_name": "CARETECH HLDGS  LS -,005",
        "long_name": "CareTech Holdings PLC",
        "summary": "CareTech Holdings PLC provides social care and support services for children and adults in the United Kingdom. It operates in three segments: Adults Services, Children's Services, and Foster Care. The Adults Services segment offers learning disabilities, mental health, autism and aspergers, physical disabilities, and brain injury rehabilitation services. The Children's Services segment provides learning disabilities, mental health, autism spectrum conditions, complex social, emotional and behavioural difficulties, education and therapeutic support, and young people in crisis. The Fostering segment offers therapeutic foster placement, challenging and complex behavior, and learning disabilities. CareTech Holdings PLC was founded in 1993 and is headquartered in Potters Bar, the United Kingdom.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Medical Care Facilities",
        "exchange": "FRA",
        "market": "dr_market",
        "country": "United Kingdom",
        "city": "Potters Bar"
    },
    "CIR.L": {
        "short_name": "CIRCASSIA GROUP PLC ORD 0.08P",
        "long_name": "Circassia Group Plc",
        "summary": "Circassia Group Plc, a specialty pharmaceutical company, focuses on the development and commercialization of respiratory products. It operates through three segments: NIOX, Chronic Obstructive Pulmonary Disease (COPD), and LungFit. The company markets NIOX and NIOX VERO for use in asthma diagnosis and management; Tudorza for the treatment of COPD; and Duaklir, a fixed-dose combination of the long-acting muscarinic antagonist aclidinium bromide and long-acting beta agonist formoterol fumarate, which is administered twice-daily through the breath actuated Pressair inhaler for the maintenance treatment of COPD. It is also developing LungFit, a portable ventilator-compatible system that utilizes an electric voltage to produce precise quantities of nitric oxide from the nitrogen and oxygen in air. The company markets its products directly to specialists in the United States, the United Kingdom, China, Italy, and Germany, as well as through a network of partners internationally. Circassia Group Plc has a collaboration agreement with AstraZeneca to promote Tudorza and Duaklir for COPD treatment; and the United States and Chinese commercial rights to LungFit. The company was formerly known as Circassia Pharmaceuticals plc and changed its name to Circassia Group Plc in May 2020. Circassia Group Plc was founded in 2006 and is headquartered in Oxford, the United Kingdom.",
        "currency": "GBp",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "LSE",
        "market": "gb_market",
        "country": "United Kingdom",
        "city": "Oxford"
    },
    "CLIN.L": {
        "short_name": "CLINIGEN GROUP PLC ORD 0.1P",
        "long_name": "Clinigen Group plc",
        "summary": "Clinigen Group plc operates as a pharmaceutical and services company in the United Kingdom, rest of Europe, the United States, South Africa, Australia, and internationally. It operates through three segments: Commercial Medicines, Unlicensed Medicines, and Clinical Services. The Commercial Medicines segment acquires and licenses commercial medicines and then revitalises them, as well as provides access to licensed and branded generic medicines. The Unlicensed Medicines segment is involved in sourcing and supplying unlicensed medicines to hospital pharmacists and physicians for patients with a high unmet medical need. The Clinical Services segment packages, supplies, distributes, and manages comparator medicines and services to clinical trials and investigator initiated trials. It offers Cardioxane that protects the heart against the cardiotoxic effects of anthracyclines; Ethyol, which protect against the harmful effects of chemotherapy medications and radiation treatment; Proleukin for the treatment of kidney cancer; Imukin that is used in chronic granulomatous disease; Totect, a dexrazoxane product; Foscavir, an anti-virals which work by stopping viruses from multiplying in number; AZEDR for the treatment of adult and pediatric patients; and Savene, which is indicated in adults for the treatment of anthracycline extravasation. The company was incorporated in 2008 and is headquartered in Burton-on-Trent, the United Kingdom.",
        "currency": "GBp",
        "sector": "Healthcare",
        "industry": "Medical Distribution",
        "exchange": "LSE",
        "market": "gb_market",
        "country": "United Kingdom",
        "city": "Burton-on-Trent"
    },
    "CMPS": {
        "short_name": "COMPASS Pathways Plc - American",
        "long_name": "COMPASS Pathways plc",
        "summary": "COMPASS Pathways plc operates as a mental health care company in the United Kingdom and the United States. It develops COMP360, a psilocybin formulation, which is in Phase IIb clinical trial to treat patients with treatment-resistant depression. The company was formerly known as COMPASS Rx Limited and changed its name to COMPASS Pathways plc in August 2020. COMPASS Pathways plc was incorporated in 2020 and is based in Cheshire, the United Kingdom.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Medical Care Facilities",
        "exchange": "NMS",
        "market": "us_market",
        "country": "United Kingdom",
        "city": "Altrincham"
    },
    "CNVVY": {
        "short_name": "CONVATEC GROUP PLC",
        "long_name": "Convatec Group Plc",
        "summary": "ConvaTec Group Plc develops, manufactures, and markets medical products and technologies worldwide. It offers advanced wound dressings and skin care products for the management of chronic wounds resulting from various conditions, such as diabetes, immobility, and venous disease, as well as from traumatic injury, burns, invasive surgery, and other causes. The company also provides devices, accessories, and services for people with a stoma resulting from colorectal cancer, inflammatory bowel disease, bladder cancer, obesity, and other causes. In addition, it offers continence and critical care products, including intermittent urinary catheters; and products for people with urinary continence issues related to spinal cord injuries, multiple sclerosis, spina bifida, and urological disorders, as well as devices and products use in intensive care units and hospital settings. Further, the company provides advanced systems for managing acute fecal incontinence, as well as for monitoring urine production output and intra-abdominal pressure; and various disposable medical devices, such as wound drainage systems, urine collection bags and catheters, airway management and oxygen/aerosol therapy devices, suction handles and tubes, gastroenterology tubes, and securement devices. Additionally, it offers disposable infusion sets to the manufacturers of insulin pumps for diabetes, as well as similar pumps that are used in continuous infusion treatments for other conditions; and various products to hospitals and the home healthcare sector. The company sells its products to pharmacies, hospitals, and other acute and post-acute healthcare service providers directly or through distributors and wholesalers. It serves a range of customers, including healthcare providers, patients, and manufacturers. ConvaTec Group Plc was incorporated in 2016 and is headquartered in Reading, the United Kingdom.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Medical Instruments & Supplies",
        "exchange": "PNK",
        "market": "us_market",
        "country": "United Kingdom",
        "city": "Reading"
    },
    "CREO.L": {
        "short_name": "CREO MEDICAL GROUP PLC ORD GBP0",
        "long_name": "Creo Medical Limited",
        "summary": "Creo Medical Limited engages in the research and development of electrosurgical medical devices relating to the field of surgical endoscopy in the United Kingdom. It is developing Speedboat RS2, a medical instrument through a combination of bipolar radiofrequency and microwave energy in a single platform for tissue dissection, resection, ablation, and coagulation. Creo Medical Limited was formerly known as MicroOncology Ltd. The company was founded in 2003 and is headquartered in Chepstow, the United Kingdom. Creo Medical Limited is a subsidiary of Creo Medical Group plc.",
        "currency": "GBp",
        "sector": "Healthcare",
        "industry": "Medical Devices",
        "exchange": "LSE",
        "market": "gb_market",
        "country": "United Kingdom",
        "city": "Chepstow"
    },
    "CRO.F": {
        "short_name": "OPEN ORPHAN PLC  LS-,001",
        "long_name": "Open Orphan plc",
        "summary": "Open Orphan plc operates as a clinical research organization pharmaceutical services company with a focus on virology, vaccine studies, and orphan drugs in the United Kingdom, Ireland, France, the Netherlands, Germany, and Singapore. It operates a virtual rep, a pharmaceutical commercialization platform for rare/orphan disease space; and develops Genomic Health Data platform, a collection of infectious disease progression data. The company also provides consulting and clinical trial services to pharmaceutical, biotechnology, and medical device organizations. In addition, it offers hVIVO COVID Clear Test, an antibody test for employers in the United Kingdom and Ireland. The company is headquartered in London, the United Kingdom.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "FRA",
        "market": "dr_market",
        "country": "United Kingdom",
        "city": "London"
    },
    "CRW.L": {
        "short_name": "CRANEWARE PLC ORD 1P",
        "long_name": "Craneware plc",
        "summary": "Craneware plc, together with its subsidiaries, develops, licenses, and supports computer software for the healthcare industry in the United States. The company provides solutions, such as Chargemaster Toolkit, an automated software-as-a-service (SaaS) chargemaster management solution for capturing optimal legitimate reimbursement for providers; Trisus Supply, a solution that utilizes data to identify data gaps between the systems; Physician Revenue Toolkit, a SaaS solution for managing physician group KPIs, charges, codes, RVUs, fee schedules, and related information; Reference Plus, a SaaS solution to perform chargemaster analysis; Pharmacy ChargeLink, a solution to enhance charge capture, pricing, and cost management; interface scripting module, a software that automatically uploads chargemaster changes to the patient billing system for accurate billing; Trisus Pricing Analyzer, a SaaS solution that simplifies the price modelling process; and Online Reference Toolkit and supplies assistant solutions. It also offers InSight Medical Necessity, a SaaS solution that provides medical necessity validation for the United States payors and advance beneficiary notice creation; Trisus Claims Informatics, a software that automates claim and coding reviews; and InSight Audit, a web-based audit management application for healthcare organizations to manage government and commercial audits. In addition, the company provides Trisus Healthcare Intelligence, a cost analytics and resource efficiency platform; Patient Charge Estimator to simplify the process of providing patient bill estimates for inpatient and outpatient services; InSight Denials to analyze, track, trend, and report on denial data; and appeals services. Further, it offers consulting and professional services; and sales and marketing, product development, and software development services. Craneware plc was founded in 1999 and is headquartered in Edinburgh, the United Kingdom.",
        "currency": "GBp",
        "sector": "Healthcare",
        "industry": "Health Information Services",
        "exchange": "LSE",
        "market": "gb_market",
        "country": "United Kingdom",
        "city": "Edinburgh"
    },
    "CTEC.L": {
        "short_name": "CONVATEC GROUP PLC ORD 10P",
        "long_name": "Convatec Group Plc",
        "summary": "ConvaTec Group Plc develops, manufactures, and markets medical products and technologies worldwide. It offers advanced wound dressings and skin care products for the management of chronic wounds resulting from various conditions, such as diabetes, immobility, and venous disease, as well as from traumatic injury, burns, invasive surgery, and other causes. The company also provides devices, accessories, and services for people with a stoma resulting from colorectal cancer, inflammatory bowel disease, bladder cancer, obesity, and other causes. In addition, it offers continence and critical care products, including intermittent urinary catheters; and products for people with urinary continence issues related to spinal cord injuries, multiple sclerosis, spina bifida, and urological disorders, as well as devices and products use in intensive care units and hospital settings. Further, the company provides advanced systems for managing acute fecal incontinence, as well as for monitoring urine production output and intra-abdominal pressure; and various disposable medical devices, such as wound drainage systems, urine collection bags and catheters, airway management and oxygen/aerosol therapy devices, suction handles and tubes, gastroenterology tubes, and securement devices. Additionally, it offers disposable infusion sets to the manufacturers of insulin pumps for diabetes, as well as similar pumps that are used in continuous infusion treatments for other conditions; and various products to hospitals and the home healthcare sector. The company sells its products to pharmacies, hospitals, and other acute and post-acute healthcare service providers directly or through distributors and wholesalers. It serves a range of customers, including healthcare providers, patients, and manufacturers. ConvaTec Group Plc was incorporated in 2016 and is headquartered in Reading, the United Kingdom.",
        "currency": "GBp",
        "sector": "Healthcare",
        "industry": "Medical Instruments & Supplies",
        "exchange": "LSE",
        "market": "gb_market",
        "country": "United Kingdom",
        "city": "Reading"
    },
    "CTH.L": {
        "short_name": "CARETECH HOLDINGS PLC ORD 0.5P",
        "long_name": "CareTech Holdings PLC",
        "summary": "CareTech Holdings PLC provides social care and support services for children and adults in the United Kingdom. It operates in three segments: Adults Services, Children's Services, and Foster Care. The Adults Services segment offers learning disabilities, mental health, autism and aspergers, physical disabilities, and brain injury rehabilitation services. The Children's Services segment provides learning disabilities, mental health, autism spectrum conditions, complex social, emotional and behavioural difficulties, education and therapeutic support, and young people in crisis. The Fostering segment offers therapeutic foster placement, challenging and complex behavior, and learning disabilities. CareTech Holdings PLC was founded in 1993 and is headquartered in Potters Bar, the United Kingdom.",
        "currency": "GBp",
        "sector": "Healthcare",
        "industry": "Medical Care Facilities",
        "exchange": "LSE",
        "market": "gb_market",
        "country": "United Kingdom",
        "city": "Potters Bar"
    },
    "CXRXF": {
        "short_name": "ADVANZ PHARMA CORP LTD (JY)",
        "long_name": "ADVANZ PHARMA Corp. Limited",
        "summary": "ADVANZ PHARMA Corp., a specialty pharmaceutical company, through its subsidiaries, owns or licenses a portfolio of branded and generic prescription products. The company operates in two segments, ADVANZ PHARMA International and ADVANZ PHARMA North America. The ADVANZ PHARMA International segment owns or licenses a portfolio of branded and generic prescription products to wholesalers, hospitals, and pharmacies. This segment's products include Macrobid/Macrodantin to treat bladder infections, such as cystitis and urinary tract infections; Eltroxin, levothyroxine sodium that treats patients with an underactive thyroid gland; Fucithalmic, a topical gel treatment for patients suffering with a bacterial infection of the surface lining of the front of the eye; Zapain, a combination of codeine phosphate and paracetamol for severe pain reliefs, such as back pain, toothache, severe sprains and strains, and pain after operations. The ADVANZ PHARMA North America segment provides Donnatal, which is used as adjunctive therapy for irritable bowel syndrome; Zonegran, an anti-seizure drug indicated for adjunctive therapy in the treatment of partial seizures in adults with epilepsy; Nilandron for the treatment of metastatic prostate cancer; Plaquenil for the treatment of lupus and rheumatoid arthritis; and Photofrin for the treatment of certain types of cancer. The company sells its products through direct sales and local distribution relationships. The company was formerly known as Concordia International Corp. and changed its name to ADVANZ PHARMA Corp. in November 2018. ADVANZ PHARMA Corp. is headquartered in London, the United Kingdom.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Drug Manufacturers\u2014Specialty & Generic",
        "exchange": "PNK",
        "market": "us_market",
        "country": "United Kingdom",
        "city": "London"
    },
    "D6M.F": {
        "short_name": "GENEDRIVE PLC  LS -,015",
        "long_name": "genedrive plc",
        "summary": "genedrive plc, a molecular diagnostics company, engages in developing and commercializing point of need diagnostics platform for infectious diseases, genotyping, pathogen detection, and other indications. The company provides Genedrive, a patented small molecular diagnostic platform, which enables rapid nucleic acid amplification and detection from various sample types, including plasma, sputum, and buccal swabs. Its Genedrive platform offers Genedrive HCV ID Kit, a qualitative molecular solution for Hepatitis C Virus testing; and Genedrive Connect app, an android-based mobile app that allows added data management flexibility and results transmission. The company serves biotechnology and pharmaceutical industries in the United Kingdom, Europe, the United States, and internationally. It has a collaboration agreement with Beckman Coulter Life Sciences to automate the laboratory PCR testing process for COVID-19. The company was formerly known as Epistem Holdings Plc and changed its name to genedrive plc in July 2016. genedrive plc was founded in 2000 and is headquartered in Manchester, the United Kingdom.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Diagnostics & Research",
        "exchange": "FRA",
        "market": "dr_market",
        "country": "United Kingdom",
        "city": "Manchester"
    },
    "DDDD.L": {
        "short_name": "4D PHARMA PLC ORD 0.25P",
        "long_name": "4D pharma plc",
        "summary": "4D pharma plc, together with its subsidiaries, engages in the research, development, and production of live biotherapeutic products. The company's development programs include Blautix for irritable bowel syndrome and Thetanix for paediatric crohn's disease. It also develops immuno-oncology products comprising MRx0518, MRx0573, and MRx1299 for solid tumors, and MRx0518 for pancreatic cancer; respiratory products, such as MRx-4DP0004 for asthma and COVID-19; central nervous system products, including MRx0005 and MRx0029 for neurodegeneration; and platform products comprising vaccines and autoimmune. 4D pharma plc has a collaboration agreement with Merck & Co., Inc. to conduct a clinical trial evaluating the combination of Keytruda and MRx0518 in patients with solid tumours. The company was formerly known as Schosween 18 Limited. 4D pharma plc was founded in 2014 and is headquartered in Leeds, the United Kingdom.",
        "currency": "GBp",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "LSE",
        "market": "gb_market",
        "country": "United Kingdom",
        "city": "Leeds"
    },
    "DEMG.L": {
        "short_name": "DELTEX MEDICAL GROUP PLC ORD 1P",
        "long_name": "Deltex Medical Group plc",
        "summary": "Deltex Medical Group plc, together with its subsidiaries, manufactures, markets, and sells oesophageal doppler haemodynamic monitoring systems under the TrueVue name in the United Kingdom, the United States, Spain, Canada, and internationally. It offers Doppler Probes that is used to measure a patient's blood flow and fluid status directly from the descending aorta during surgery and critical care; Loops plots aortic blood flow velocity and aortic blood pressure monitoring throughout every heartbeat; High Definition Impedance Cardiography, a non-invasive cardiac function and fluid status monitoring system for awake patients; and PressureWave, a pulse pressure wave algorithm for deriving haemodynamic parameters. The company's products are used in Covid-19 critical care; sepsis; major abdominal, laparoscopic, and spinal surgeries; cardiac, trauma, and transplant procedures; and post-operative acute kidney injury monitoring. Deltex Medical Group plc was incorporated in 2000 and is headquartered in Chichester, the United Kingdom.",
        "currency": "GBp",
        "sector": "Healthcare",
        "industry": "Medical Devices",
        "exchange": "LSE",
        "market": "gb_market",
        "country": "United Kingdom",
        "city": "Chichester"
    },
    "DNL.L": {
        "short_name": "DIURNAL GROUP PLC ORD GBP0.05",
        "long_name": "Diurnal Group plc",
        "summary": "Diurnal Group plc operates as a specialty pharma company worldwide. The company develops hormone therapeutics for the treatment of chronic endocrine conditions, including congenital adrenal hyperplasia, adrenal insufficiency, hypogonadism, and hypothyroidism. The company offers Alkindi, a replacement therapy for paediatric adrenal insufficiency in Europe. It also develops Chronocort, which completed Phase III clinical trials targeting congenital adrenal hyperplasia and adrenal insufficiency. The company's early stage pipeline products comprise Native Oral Testosterone, a replacement treatment for patients suffering from hypogonadism; siRNA, a short interfering RNA oligonucleotide therapy for patients suffering from adrenocorticotropin-dependent Cushing's syndrome; and T3 modified, a modified-release preparation of T3 (levothyroxine) hormone for patients suffering from hypothyroidism. Diurnal Group plc was incorporated in 2015 and is headquartered in Cardiff, the United Kingdom.",
        "currency": "GBp",
        "sector": "Healthcare",
        "industry": "Drug Manufacturers\u2014Specialty & Generic",
        "exchange": "LSE",
        "market": "gb_market",
        "country": "United Kingdom",
        "city": "Cardiff"
    },
    "DOC.AX": {
        "short_name": "DOCTORCARE CDI 1:1",
        "long_name": "Doctor Care Anywhere Group PLC",
        "summary": "Doctor Care Anywhere Group PLC operates as a doctor-founded digital healthcare company. It offers services in the areas of appointments, patient records, prescriptions, referrals and fit notes, and service improvements. The company provides treatments for allergies, bites and stings, cold and flu conditions, headaches and migraines, joint pains, lifestyle support, mental health conditions, sexual health problems, skin conditions, and stomach and digestive problems. It serves corporate, and small and medium-sized enterprise clients in the United Kingdom. The company was founded in 2013 and is based in London, United Kingdom.",
        "currency": "AUD",
        "sector": "Healthcare",
        "industry": "Health Information Services",
        "exchange": "ASX",
        "market": "au_market",
        "country": "United Kingdom",
        "city": "London"
    },
    "DPH.L": {
        "short_name": "DECHRA PHARMACEUTICALS PLC ORD ",
        "long_name": "Dechra Pharmaceuticals PLC",
        "summary": "Dechra Pharmaceuticals PLC develops, manufactures, regulates, markets, and sells veterinary pharmaceuticals and related products for veterinarians worldwide. It operates through three segments: European Pharmaceuticals, North American Pharmaceuticals, and Pharmaceuticals Research and Development. The company offers various endocrinology, dermatology, analgesia and anesthesia, cardiovascular, and critical care products for dogs and cats; water soluble antibiotics, poultry vaccines, and pain management for poultry, pigs, and cattle; and lameness and pain management products for horses and ponies. It also provides pet nutrition products for supporting cats and dogs with various therapeutic conditions, such as allergies, obesity, heart, and kidney diseases. In addition, the company distributes veterinary pharmaceuticals and equipment; offers financial services; markets pet diets; and develops, regulates, manufactures, and markets crop protection. It markets its products through wholesaler and distributor networks. Dechra Pharmaceuticals PLC was incorporated in 1997 and is headquartered in Northwich, the United Kingdom.",
        "currency": "GBp",
        "sector": "Healthcare",
        "industry": "Drug Manufacturers\u2014General",
        "exchange": "LSE",
        "market": "gb_market",
        "country": "United Kingdom",
        "city": "Northwich"
    },
    "DPHN.MX": {
        "short_name": "DECHRA PHARMACEUTICALS",
        "long_name": "Dechra Pharmaceuticals PLC",
        "summary": "Dechra Pharmaceuticals PLC develops, manufactures, regulates, markets, and sells veterinary pharmaceuticals and related products for veterinarians worldwide. It operates through three segments: European Pharmaceuticals, North American Pharmaceuticals, and Pharmaceuticals Research and Development. The company offers various endocrinology, dermatology, analgesia and anesthesia, cardiovascular, and critical care products for dogs and cats; water soluble antibiotics, poultry vaccines, and pain management for poultry, pigs, and cattle; and lameness and pain management products for horses and ponies. It also provides pet nutrition products for supporting cats and dogs with various therapeutic conditions, such as allergies, obesity, heart, and kidney diseases. In addition, the company distributes veterinary pharmaceuticals and equipment; offers financial services; markets pet diets; and develops, regulates, manufactures, and markets crop protection. It markets its products through wholesaler and distributor networks. Dechra Pharmaceuticals PLC was incorporated in 1997 and is headquartered in Northwich, the United Kingdom.",
        "currency": "MXN",
        "sector": "Healthcare",
        "industry": "Drug Manufacturers - Major",
        "exchange": "MEX",
        "market": "mx_market",
        "country": "United Kingdom",
        "city": "Northwich"
    },
    "DSH.F": {
        "short_name": "SENSYNE HEALTH LT  LS-,1",
        "long_name": "Sensyne Health plc",
        "summary": "Sensyne Health plc, a healthcare technology company, develops software products that connects healthcare professionals with patients in the United Kingdom and the United States. Its products include CVm-Health, a web-based application for coronavirus self-monitoring; DBm-Health, which helps individuals monitor their blood glucose levels and share their readings with health care professionals; GDm-Health, a prescribed digital therapeutic for remote management of diabetes in pregnancy; and BPm-Health that allows pregnant women to self-monitor blood pressure during pregnancy. The company's products also include SEND, an early warning system for monitoring patient vital signs in hospital; EDGE, a prescribed digital therapeutic for monitoring chronic obstructive pulmonary disease at home; CleanSpace, a system for monitoring personal exposure to air pollution; and Support-HF, a prescribed digital therapeutic for monitoring heart failure at home. Sensyne Health has strategic research alliance with Bayer to develop new treatments using clinical artificial intelligence; research collaboration agreement with Bristol Myers Squibb to apply machine learning for rare blood disease research; and strategic research agreement with Milton Keynes University Hospital NHS Foundation Trust to enable the ethical application of clinical artificial intelligence research to improve patient care and research into new medicines; collaboration agreement with Bristol Myers Squibb to apply machine learning for rare blood disease research; and strategic research agreement with Hampshire Hospitals NHS Foundation Trust. Sensyne Health plc was incorporated in 2018 and is based in Oxford, the United Kingdom.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Health Information Services",
        "exchange": "FRA",
        "market": "dr_market",
        "country": "United Kingdom",
        "city": "Oxford"
    },
    "DWV.F": {
        "short_name": "ANGLE PLC  LS-,10",
        "long_name": "ANGLE plc",
        "summary": "ANGLE plc, a medical diagnostic company, engages in developing cancer diagnostics products. It develops and commercializes Parsortix cell separation system, which captures and harvests circulating tumor cells in cancer patient blood; and Ziplex multiplex analysis system that is used with the ovarian cancer clinical application. The company was founded in 1994 and is based in Guildford, the United Kingdom.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Diagnostics & Research",
        "exchange": "FRA",
        "market": "dr_market",
        "country": "United Kingdom",
        "city": "Guildford"
    },
    "DXRX.L": {
        "short_name": "DIACEUTICS PLC ORD GBP0.002",
        "long_name": "Diaceutics PLC",
        "summary": "Diaceutics Plc provides data, data analytics, and implementation services for pharmaceutical companies worldwide. It offers diagnostic landscape services, such as patient journey, lab mapping, diagnostic regulation, turnaround time, and sample availability analysis services; diagnostic tracking services, including lab tracking, patient insights, and physician segmentation services; and diagnostic payers research, diagnostic clinical landscape, integrated mapping research, buying process research, and testers/non-testers research services. The company also provides diagnostic planning services consisting of strategic and tactical planning, launch planning, diagnostic partner selection, and financial forecast services; commercialization services comprising content creation; LabEd/workshops, diagnostic adboards, conference support, and proficiency testing services; and Diagnostic reimbursement services. Diaceutics Plc was founded in 2005 and is headquartered in Belfast, the United Kingdom.",
        "currency": "GBp",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "LSE",
        "market": "gb_market",
        "country": "United Kingdom",
        "city": "Belfast"
    },
    "EAH.L": {
        "short_name": "ECO ANIMAL HEALTH GROUP PLC ORD",
        "long_name": "ECO Animal Health Group plc",
        "summary": "ECO Animal Health Group plc develops and markets pharmaceutical products for animals worldwide. The company offers Aivlosin, a macrolide antibiotic for the treatment of respiratory and enteric diseases in pigs and poultry. It also provides generic drugs, such as Ecomectin, Ecoheart, Ecotraz, and Ecomintic, which are endectocides and other antiparasitics for the treatment and prevention of parasites in cattle, sheep, pigs, horses, and dogs; and Chlortetracycline and Oxytetracycline for treatment of bacterial infections in pigs, poultry, and cattle. The company was founded in 1972 and is headquartered in New Malden, the United Kingdom.",
        "currency": "GBp",
        "sector": "Healthcare",
        "industry": "Drug Manufacturers\u2014Specialty & Generic",
        "exchange": "LSE",
        "market": "gb_market",
        "country": "United Kingdom",
        "city": "New Malden"
    },
    "EAJF.F": {
        "short_name": "VALIRX PLC  LS-,001",
        "long_name": "ValiRx plc",
        "summary": "ValiRx plc, a biotechnology oncology focused company, engages in developing novel therapeutics and associated biomarkers for cancer in the United Kingdom. The company's lead drug candidates include VAL201, an anti-cancer therapeutic that is in Phase I/II trials for the treatment of prostate cancer and other indications of hormone induced unregulated growth, including endometriosis; VAL301, a reformulation of VAL201, which is in pre-clinical development for the treatment of women with endometriosis; and VAL401, a reformulation of generic drug Risperidone, which has completed Phase II clinical trial for the treatment of non-small cell lung cancer. Its drug candidates also comprise VAL101, a candidate produced by GeneICE technology platform to modulate BCl2 expression \u00c2\u0096 implicated in cancers. ValiRx plc has collaboration agreement with Oncolytika Limited and Black Cat Bio Limited to develop and evaluate BC201 for patients suffering a hyperimmune response to Coronavirus SARS-CoV2 infection. The company was incorporated in 2000 and is based in Hatfield, the United Kingdom.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "FRA",
        "market": "dr_market",
        "country": "United Kingdom",
        "city": "Hatfield"
    },
    "EKF.L": {
        "short_name": "EKF DIAGNOSTICS HOLDINGS PLC OR",
        "long_name": "EKF Diagnostics Holdings plc",
        "summary": "EKF Diagnostics Holdings plc designs, develops, manufactures, and sells diagnostic instruments, reagents, and other ancillary products in Europe, the Middle East, the Americas, Asia, and Africa. It offers DiaSpect and DiaSpect T hemoglobin analyzers; DiaSpect Hemoglobin T Low to determine low levels of hemoglobin in plasma and serum specimens, aqueous solutions, or stored or banked erythrocytes; Hemo Control, a point-of-care hemoglobin analyzer that provides quantitative and lab quality hemoglobin results; and HemataStat II, a microhematocrit centrifuge that provides a quantitative hematocrit reading for six blood samples. The company also provides glucose and lactate analyzers, such as Biosen C-Line GP+ and C-Line Clinic; Quo-Lab A1c, a desktop point-of-care analyzer for measuring glycated hemoglobin; Quo-Test A1c for the monitoring and management of diabetes in a point-of-care setting; and STAT-Site M Beta-hydroxybutyrate analyzer. In addition, it offers Creamatocrit Plus, an analyzer for detecting the lipid concentration and calorific density in mothers' milk; QuPID and True20 pregnancy tests; and Lactate Scout 4, a lactate analyzer. Further, the company offers Altair 240, a chemistry analyzer; Excel, a semi-automated chemistry analyzer; Micro 12, a micro centrifuge for clinical, molecular, and bacteriological applications; sTNFRr1, a predictive marker of end stage renal disease; Hema-Screen Serology, an analyzer dependent for early detection of colorectal cancer; Uri-Trak 120 urine analyzer; and RaPET Serology immunoassay kits, as well as reagents, calibrators, standards, and controls. Additionally, it provides contract manufacturing services, as well as services and distributes third party company's products. It sells its products directly to hospitals, laboratories, and government agencies, as well as through a network of distributors. EKF Diagnostics Holdings plc was founded in 1990 and is headquartered in Cardiff, the United Kingdom.",
        "currency": "GBp",
        "sector": "Healthcare",
        "industry": "Diagnostics & Research",
        "exchange": "LSE",
        "market": "gb_market",
        "country": "United Kingdom",
        "city": "Cardiff"
    },
    "EMIS.L": {
        "short_name": "EMIS GROUP PLC ORD 1P",
        "long_name": "EMIS Group plc",
        "summary": "EMIS Group plc, through its subsidiaries, provides healthcare software, information technology, and related services for healthcare professionals in the United Kingdom. It operates in two segments: EMIS Health and EMIS Enterprise. The EMIS Health segment supplies integrated care technology to NHS markets, including primary, community, acute, and social care. The EMIS Enterprise segment focuses on B2B technology sector in the healthcare market, such as management of medicines, partner businesses, patient-facing services, and healthcare block chain. The company also supplies technologies; provides patient-centric medical and wellbeing information and related transactional services under the patient brand; offers specialist ICT infrastructure, hardware, and engineering services, as well as non-clinical software under the egton brand; and operates Patient.info, an online health platform that provides personalized online patient-facing services and healthcare content and Patient Access, which enables people to book appointments for healthcare services. The company was founded in 1987 and is headquartered in Leeds, the United Kingdom.",
        "currency": "GBp",
        "sector": "Healthcare",
        "industry": "Health Information Services",
        "exchange": "LSE",
        "market": "gb_market",
        "country": "United Kingdom",
        "city": "Leeds"
    },
    "EMMLF": {
        "short_name": "OKYO PHARMA LTD",
        "long_name": "OKYO Pharma Limited",
        "summary": "OKYO Pharma Limited operates as a life sciences and biopharmaceutical company in the United Kingdom. Its pre-clinical development program includes Chemerin for the treatment of ocular inflammation, dry eye disease, and ocular neuropathic pain; and BAM8, a non-opioid analgesic. OKYO Pharma Limited is headquartered in London, the United Kingdom.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "PNK",
        "market": "us_market",
        "country": "United Kingdom",
        "city": "London"
    },
    "ERGO.L": {
        "short_name": "ERGOMED PLC ORD 1P",
        "long_name": "Ergomed plc",
        "summary": "Ergomed plc, together with its subsidiaries, provides clinical trial planning, management, and monitoring; and drug safety and medical information services in the United Kingdom and Rest of Europe, the Middle East, Africa, North America, Asia, and Australia. It operates through two segments, Clinical Research Outsourcing and Pharmacovigilance. The company provides and manages clinical development, trial management, and pharmacovigilance services for pharmaceutical and generics companies, as well as small and mid-sized drug development companies. It focuses on various therapeutic areas, including oncology, haematology, allergy, respiratory, neurology, and CNS, as well as develops orphan drugs. The company also provides site support services. Ergomed plc was formerly known as Ergomed Clinical Research Limited and changed its name to Ergomed plc in June 2014. Ergomed plc was founded in 1997 and is headquartered in Guildford, the United Kingdom.",
        "currency": "GBp",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "LSE",
        "market": "gb_market",
        "country": "United Kingdom",
        "city": "Guildford"
    },
    "ETX.L": {
        "short_name": "E-THERAPEUTICS PLC ORD 0.1P",
        "long_name": "e-therapeutics plc",
        "summary": "e-Therapeutics plc engages in the discovery of drugs through its proprietary network-driven drug discovery platform in the United Kingdom. It is developing two NDD-derived immuno-oncology programs, including tryptophan catabolism and immune checkpoint modulation. The company, through its subsidiary, Searchbolt Limited, develops search engine technology. The company has collaborations with C4X Holdings PLC, Intellegens, Biorelate, Novo Nordisk, and Galapagos NV. e-Therapeutics plc was founded in 2001 and is based in Long Hanborough, the United Kingdom.",
        "currency": "GBp",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "LSE",
        "market": "gb_market",
        "country": "United Kingdom",
        "city": "Long Hanborough"
    },
    "EVARF": {
        "short_name": "LOMBARD MED INC",
        "long_name": "Lombard Medical, Inc.",
        "summary": "Lombard Medical, Inc., a medical technology company, develops, manufactures, and markets endovascular stent-grafts for the repair of aortic aneurysms in the United States, the United Kingdom, Germany, Japan, and internationally. The company's principal product is Aorfix, which is an endovascular stent-graft for the treatment of abdominal aortic aneurysms (AAAs) with angulation at the neck of the aneurysm of up to 90 degrees. Its products also include Altura endovascular stent graft system for the treatment of standard AAA anatomies; Aorflex delivery system for accurate placement of Aorfix in the abdominal aorta; and IntelliFlex LP delivery system that enhances the precision and control of Aorfix deployment and placement. Lombard Medical, Inc. sells its products directly through its direct sales force and distributors to state-or-government-owned hospitals. The company was founded in 2000 and is headquartered in Didcot, the United Kingdom.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Medical Devices",
        "exchange": "PNK",
        "market": "us_market",
        "country": "United Kingdom",
        "city": "Didcot"
    },
    "EVG.L": {
        "short_name": "EVGEN PHARMA PLC ORD 0.25P",
        "long_name": "Evgen Pharma plc",
        "summary": "Evgen Pharma plc, a clinical stage drug development company, engages in developing sulforaphane based medicines for the treatment of multiple diseases. Its core technology is Sulforadex, which include synthetic and stabilized analogues of the naturally occurring compound sulforaphane. The company's lead product is SFX-01, a synthetic version of sulforaphane stabilised that is in Phase II clinical trials for the treatment of metastatic breast cancer and subarachnoid haemorrhage, as well as in preclinical stage for multiple sclerosis and clinical stage to treat prostate cancer, autism, non-alcoholic steatohepatitis, and chronic kidney diseases. Evgen Pharma plc was founded in 2007 and is headquartered in Wilmslow, the United Kingdom.",
        "currency": "GBp",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "LSE",
        "market": "gb_market",
        "country": "United Kingdom",
        "city": "Wilmslow"
    },
    "FAB.L": {
        "short_name": "FUSION ANTIBODIES PLC ORD 4P",
        "long_name": "Fusion Antibodies plc",
        "summary": "Fusion Antibodies plc, a contract research organization, engages in the research, development, and manufacture of recombinant proteins and antibodies primarily for cancer and infectious diseases in the United Kingdom, the rest of Europe, North America, and internationally. The company offers monoclonal antibody discovery and development services; and a range of antibody engineering services for various stages of therapeutic and diagnostic antibody development. It also engages in the humanization of antibodies, antibody developability, affinity maturation, and antibody reformatting activities. In addition, the company provides antibody sequencing services; custom expression and purification of recombinant proteins; transient protein expression; and cell line development services, as well as antibody analysis services. It serves pharmaceuticals, biotech, and diagnostic companies. The company has a collaboration partnership with Celonic AG for the development of high yield stable cell lines. Fusion Antibodies plc was incorporated in 2000 and is headquartered in Belfast, the United Kingdom.",
        "currency": "GBp",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "LSE",
        "market": "gb_market",
        "country": "United Kingdom",
        "city": "Belfast"
    },
    "FDBK.L": {
        "short_name": "FEEDBACK PLC ORD 0.25P",
        "long_name": "Feedback plc",
        "summary": "Feedback plc, a medical imaging technology company, provides software and systems to those working in the field of medical imaging. Its products include TexRAD, a software tool, which extracts and quantifies texture features in radiological images, assisting research into all tumor types, as well as uncovers biomarkers in medical images; and TexRAD Lung for the analysis of lung cancer for clinical use in the European Union. The company also offers Cadran image platform that provides hospitals and research institutes with a comprehensive picture archiving communication system for medical images, as well as equips users with a platform for image handling from all imaging modalities, such as CT and PET scanners; and Bleepa, which combines secure instant messaging with the ability to see clinical grade medical images, including X-rays, and CT and MRI scans using portable devices, such as smartphones or tablets. Feedback plc was founded in 1958 and is headquartered in London, the United Kingdom.",
        "currency": "GBp",
        "sector": "Healthcare",
        "industry": "Health Information Services",
        "exchange": "LSE",
        "market": "gb_market",
        "country": "United Kingdom",
        "city": "London"
    },
    "FRLN": {
        "short_name": "Freeline Therapeutics Holdings ",
        "long_name": "Freeline Therapeutics Holdings plc",
        "summary": "Freeline Therapeutics Holdings plc operates as a clinical-stage systemic adeno-associated virus (AAV)-based gene therapy company. Its advanced product candidate is FLT180a, a gene therapy product candidate that is being evaluated in a Phase 1/2 dose-finding clinical trials in adult males for the treatment of patients with moderate or severe hemophilia B. The company's products also include FLT190, which is in dose-escalating Phase 1/2 clinical trials for the treatment of Fabry disease; FLT201, a liver-directed gene therapy product candidate to treat type 1 Gaucher disease; and FLT210, a liver-directed gene therapy product candidate for the treatment of hemophilia A. In addition, it has research programs in various indications for systemic gene therapy. The company was founded in 2015 and is headquartered in Stevenage, the United Kingdom.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "NMS",
        "market": "us_market",
        "country": "United Kingdom",
        "city": "Stevenage"
    },
    "FRPRF": {
        "short_name": "4D PHARMA PLC",
        "long_name": "4D pharma plc",
        "summary": "4D pharma plc, together with its subsidiaries, engages in the research, development, and production of live biotherapeutic products. The company's development programs include Blautix for irritable bowel syndrome and Thetanix for paediatric crohn's disease. It also develops immuno-oncology products comprising MRx0518, MRx0573, and MRx1299 for solid tumors, and MRx0518 for pancreatic cancer; respiratory products, such as MRx-4DP0004 for asthma and COVID-19; central nervous system products, including MRx0005 and MRx0029 for neurodegeneration; and platform products comprising vaccines and autoimmune. 4D pharma plc has a collaboration agreement with Merck & Co., Inc. to conduct a clinical trial evaluating the combination of Keytruda and MRx0518 in patients with solid tumours. The company was formerly known as Schosween 18 Limited. 4D pharma plc was founded in 2014 and is headquartered in Leeds, the United Kingdom.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "PNK",
        "market": "us_market",
        "country": "United Kingdom",
        "city": "Leeds"
    },
    "FSTX": {
        "short_name": "F-star Therapeutics, Inc.",
        "long_name": "F-star Therapeutics, Inc.",
        "summary": "F-star Therapeutics, Inc., a clinical-stage biopharmaceutical company develops tetravalent bispecific antibodies for cancer therapy. Its medicines used in immuno-oncology treatments. The company plans for the initiation of a Phase I, open label, first-in-human clinical study of FS222, a bispecific antibody targeting CD137 (4-1BB) and PD-L1. The company is based in Cambridge, the United Kingdom.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "NMS",
        "market": "us_market",
        "country": "United Kingdom",
        "city": "Cambridge"
    },
    "GBE.F": {
        "short_name": "GENUS PLC  LS-,1",
        "long_name": "Genus plc",
        "summary": "Genus plc operates as an animal genetics company in North America, Latin America, the United Kingdom, rest of Europe, the Middle East, Russia, Africa, and Asia. The company operates through three segments: Genus PIC, Genus ABS, and Research and Development. It sells sows, boars, and semen to breed pigs with various characteristics for pork production under the PIC brand. The company also sells bull semen and embryos to breed calves with various characteristics for milk and beef production under the ABS, Genus, and Bovec brands. In addition, it offers semen sexing, in vitro fertilization, reproductive, and other technical services to farmers. Genus plc has a strategic porcine collaboration with Beijing Capital Agribusiness Co. Ltd to research, develop, register, and market porcine reproductive and respiratory syndrome virus resistant pigs. The company was incorporated in 1994 and is based in Basingstoke, the United Kingdom.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "FRA",
        "market": "dr_market",
        "country": "United Kingdom",
        "city": "Basingstoke"
    },
    "GDR.L": {
        "short_name": "GENEDRIVE PLC ORD 1.5P",
        "long_name": "genedrive plc",
        "summary": "genedrive plc, a molecular diagnostics company, engages in developing and commercializing point of need diagnostics platform for infectious diseases, genotyping, pathogen detection, and other indications. The company provides Genedrive, a patented small molecular diagnostic platform, which enables rapid nucleic acid amplification and detection from various sample types, including plasma, sputum, and buccal swabs. Its Genedrive platform offers Genedrive HCV ID Kit, a qualitative molecular solution for Hepatitis C Virus testing; and Genedrive Connect app, an android-based mobile app that allows added data management flexibility and results transmission. The company serves biotechnology and pharmaceutical industries in the United Kingdom, Europe, the United States, and internationally. It has a collaboration agreement with Beckman Coulter Life Sciences to automate the laboratory PCR testing process for COVID-19. The company was formerly known as Epistem Holdings Plc and changed its name to genedrive plc in July 2016. genedrive plc was founded in 2000 and is headquartered in Manchester, the United Kingdom.",
        "currency": "GBp",
        "sector": "Healthcare",
        "industry": "Diagnostics & Research",
        "exchange": "LSE",
        "market": "gb_market",
        "country": "United Kingdom",
        "city": "Manchester"
    },
    "GENSF": {
        "short_name": "GENUS",
        "long_name": "Genus plc",
        "summary": "Genus plc operates as an animal genetics company in North America, Latin America, the United Kingdom, rest of Europe, the Middle East, Russia, Africa, and Asia. The company operates through three segments: Genus PIC, Genus ABS, and Research and Development. It sells sows, boars, and semen to breed pigs with various characteristics for pork production under the PIC brand. The company also sells bull semen and embryos to breed calves with various characteristics for milk and beef production under the ABS, Genus, and Bovec brands. In addition, it offers semen sexing, in vitro fertilization, reproductive, and other technical services to farmers. Genus plc has a strategic porcine collaboration with Beijing Capital Agribusiness Co. Ltd to research, develop, register, and market porcine reproductive and respiratory syndrome virus resistant pigs. The company was incorporated in 1994 and is based in Basingstoke, the United Kingdom.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "PNK",
        "market": "us_market",
        "country": "United Kingdom",
        "city": "Basingstoke"
    },
    "GLAXF": {
        "short_name": "GLAXOSMITHKLINE",
        "long_name": "GlaxoSmithKline plc",
        "summary": "GlaxoSmithKline plc engages in the creation, discovery, development, manufacture, and marketing of pharmaceutical products, vaccines, over-the-counter medicines, and health-related consumer products in the United Kingdom, the United States, and internationally. It operates through four segments: Pharmaceuticals, Pharmaceuticals R&D, Vaccines, and Consumer Healthcare. The company offers pharmaceutical products comprising medicines in the therapeutic areas, such as respiratory, HIV, immuno-inflammation, oncology, anti-viral, central nervous system, cardiovascular and urogenital, metabolic, anti-bacterial, and dermatology. It also provides consumer healthcare products in wellness, oral health, nutrition, and skin health categories. The company offers its consumer healthcare products in the form of nasal sprays, tablets, syrups, lozenges, gum and trans-dermal patches, caplets, infant syrup drops, liquid filled suspension, wipes, gels, effervescents, toothpastes, toothbrushes, mouthwashes, denture adhesives and cleansers, topical creams and non-medicated patches, lip balm, gummies, and soft chews. It has collaboration agreements with 23andMe; Merck KGaA; Lyell Immunopharma; CEPI; Innovax and Xiamen University; VBI; Viome; Sanofi SA; CureVac; and research collaboration with Sengenics focusing on immunology. GlaxoSmithKline plc was founded in 1715 and is headquartered in Brentford, the United Kingdom.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Drug Manufacturers\u2014General",
        "exchange": "PNK",
        "market": "us_market",
        "country": "United Kingdom",
        "city": "Brentford"
    },
    "GNS.L": {
        "short_name": "GENUS PLC ORD 10P",
        "long_name": "Genus plc",
        "summary": "Genus plc operates as an animal genetics company in North America, Latin America, the United Kingdom, rest of Europe, the Middle East, Russia, Africa, and Asia. The company operates through three segments: Genus PIC, Genus ABS, and Research and Development. It sells sows, boars, and semen to breed pigs with various characteristics for pork production under the PIC brand. The company also sells bull semen and embryos to breed calves with various characteristics for milk and beef production under the ABS, Genus, and Bovec brands. In addition, it offers semen sexing, in vitro fertilization, reproductive, and other technical services to farmers. Genus plc has a strategic porcine collaboration with Beijing Capital Agribusiness Co. Ltd to research, develop, register, and market porcine reproductive and respiratory syndrome virus resistant pigs. The company was incorporated in 1994 and is based in Basingstoke, the United Kingdom.",
        "currency": "GBp",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "LSE",
        "market": "gb_market",
        "country": "United Kingdom",
        "city": "Basingstoke"
    },
    "GS7.DE": {
        "short_name": "GLAXOSMITHKLINE  LS-,25",
        "long_name": "GlaxoSmithKline plc",
        "summary": "GlaxoSmithKline plc engages in the creation, discovery, development, manufacture, and marketing of pharmaceutical products, vaccines, over-the-counter medicines, and health-related consumer products in the United Kingdom, the United States, and internationally. It operates through four segments: Pharmaceuticals, Pharmaceuticals R&D, Vaccines, and Consumer Healthcare. The company offers pharmaceutical products comprising medicines in the therapeutic areas, such as respiratory, HIV, immuno-inflammation, oncology, anti-viral, central nervous system, cardiovascular and urogenital, metabolic, anti-bacterial, and dermatology. It also provides consumer healthcare products in wellness, oral health, nutrition, and skin health categories. The company offers its consumer healthcare products in the form of nasal sprays, tablets, syrups, lozenges, gum and trans-dermal patches, caplets, infant syrup drops, liquid filled suspension, wipes, gels, effervescents, toothpastes, toothbrushes, mouthwashes, denture adhesives and cleansers, topical creams and non-medicated patches, lip balm, gummies, and soft chews. It has collaboration agreements with 23andMe; Merck KGaA; Lyell Immunopharma; CEPI; Innovax and Xiamen University; VBI; Viome; Sanofi SA; CureVac; and research collaboration with Sengenics focusing on immunology. GlaxoSmithKline plc was founded in 1715 and is headquartered in Brentford, the United Kingdom.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Drug Manufacturers\u2014General",
        "exchange": "GER",
        "market": "de_market",
        "country": "United Kingdom",
        "city": "Brentford"
    },
    "GSK": {
        "short_name": "GlaxoSmithKline PLC",
        "long_name": "GlaxoSmithKline plc",
        "summary": "GlaxoSmithKline plc engages in the creation, discovery, development, manufacture, and marketing of pharmaceutical products, vaccines, over-the-counter medicines, and health-related consumer products in the United Kingdom, the United States, and internationally. It operates through four segments: Pharmaceuticals, Pharmaceuticals R&D, Vaccines, and Consumer Healthcare. The company offers pharmaceutical products comprising medicines in the therapeutic areas, such as respiratory, HIV, immuno-inflammation, oncology, anti-viral, central nervous system, cardiovascular and urogenital, metabolic, anti-bacterial, and dermatology. It also provides consumer healthcare products in wellness, oral health, nutrition, and skin health categories. The company offers its consumer healthcare products in the form of nasal sprays, tablets, syrups, lozenges, gum and trans-dermal patches, caplets, infant syrup drops, liquid filled suspension, wipes, gels, effervescents, toothpastes, toothbrushes, mouthwashes, denture adhesives and cleansers, topical creams and non-medicated patches, lip balm, gummies, and soft chews. It has collaboration agreements with 23andMe; Merck KGaA; Lyell Immunopharma; CEPI; Innovax and Xiamen University; VBI; Viome; Sanofi SA; CureVac; and research collaboration with Sengenics focusing on immunology. GlaxoSmithKline plc was founded in 1715 and is headquartered in Brentford, the United Kingdom.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Drug Manufacturers\u2014General",
        "exchange": "NYQ",
        "market": "us_market",
        "country": "United Kingdom",
        "city": "Brentford"
    },
    "GSK.L": {
        "short_name": "GLAXOSMITHKLINE PLC ORD 25P",
        "long_name": "GlaxoSmithKline plc",
        "summary": "GlaxoSmithKline plc engages in the creation, discovery, development, manufacture, and marketing of pharmaceutical products, vaccines, over-the-counter medicines, and health-related consumer products in the United Kingdom, the United States, and internationally. It operates through four segments: Pharmaceuticals, Pharmaceuticals R&D, Vaccines, and Consumer Healthcare. The company offers pharmaceutical products comprising medicines in the therapeutic areas, such as respiratory, HIV, immuno-inflammation, oncology, anti-viral, central nervous system, cardiovascular and urogenital, metabolic, anti-bacterial, and dermatology. It also provides consumer healthcare products in wellness, oral health, nutrition, and skin health categories. The company offers its consumer healthcare products in the form of nasal sprays, tablets, syrups, lozenges, gum and trans-dermal patches, caplets, infant syrup drops, liquid filled suspension, wipes, gels, effervescents, toothpastes, toothbrushes, mouthwashes, denture adhesives and cleansers, topical creams and non-medicated patches, lip balm, gummies, and soft chews. It has collaboration agreements with 23andMe; Merck KGaA; Lyell Immunopharma; CEPI; Innovax and Xiamen University; VBI; Viome; Sanofi SA; CureVac; and research collaboration with Sengenics focusing on immunology. GlaxoSmithKline plc was founded in 1715 and is headquartered in Brentford, the United Kingdom.",
        "currency": "GBp",
        "sector": "Healthcare",
        "industry": "Drug Manufacturers\u2014General",
        "exchange": "LSE",
        "market": "gb_market",
        "country": "United Kingdom",
        "city": "Brentford"
    },
    "GSKN.MX": {
        "short_name": "GLAXOSMITHKLINE",
        "long_name": "GlaxoSmithKline plc",
        "summary": "GlaxoSmithKline plc engages in the creation, discovery, development, manufacture, and marketing of pharmaceutical products, vaccines, over-the-counter medicines, and health-related consumer products in the United Kingdom, the United States, and internationally. It operates through four segments: Pharmaceuticals, Pharmaceuticals R&D, Vaccines, and Consumer Healthcare. The company offers pharmaceutical products comprising medicines in the therapeutic areas, such as respiratory, HIV, immuno-inflammation, oncology, anti-viral, central nervous system, cardiovascular and urogenital, metabolic, anti-bacterial, and dermatology. It also provides consumer healthcare products in wellness, oral health, nutrition, and skin health categories. The company offers its consumer healthcare products in the form of nasal sprays, tablets, syrups, lozenges, gum and trans-dermal patches, caplets, infant syrup drops, liquid filled suspension, wipes, gels, effervescents, toothpastes, toothbrushes, mouthwashes, denture adhesives and cleansers, topical creams and non-medicated patches, lip balm, gummies, and soft chews. It has collaboration agreements with 23andMe; Merck KGaA; Lyell Immunopharma; CEPI; Innovax and Xiamen University; VBI; Viome; Sanofi SA; CureVac; and research collaboration with Sengenics focusing on immunology. GlaxoSmithKline plc was founded in 1715 and is headquartered in Brentford, the United Kingdom.",
        "currency": "MXN",
        "sector": "Healthcare",
        "industry": "Drug Manufacturers\u2014General",
        "exchange": "MEX",
        "market": "mx_market",
        "country": "United Kingdom",
        "city": "Brentford"
    },
    "GWPH": {
        "short_name": "GW Pharmaceuticals Plc",
        "long_name": "GW Pharmaceuticals plc",
        "summary": "GW Pharmaceuticals plc, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics from its proprietary cannabinoid product platform. Its lead product is Epidiolex, an oral medicine for the treatment of refractory childhood epilepsies, Dravet syndrome, and Lennox-Gastaut syndrome, as well as in phase III clinical trials for the treatment of tuberous sclerosis complex. The company also develops and markets Sativex for the treatment of spasticity due to multiple sclerosis. In addition, it develops various product candidates for the treatment of for schizophrenia, autism spectrum disorder, and neonatal hypoxic ischemic encephalopathy. It primarily operates in Europe, the United Kingdom, the United States, and internationally. GW Pharmaceuticals plc was founded in 1998 and is based in Cambridge, the United Kingdom.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Drug Manufacturers\u2014General",
        "exchange": "NMS",
        "market": "us_market",
        "country": "United Kingdom",
        "city": "Cambridge"
    },
    "GWPRF": {
        "short_name": "GW PHARMACEUTICALS",
        "long_name": "GW Pharmaceuticals plc",
        "summary": "GW Pharmaceuticals plc, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics from its proprietary cannabinoid product platform. Its lead product is Epidiolex, an oral medicine for the treatment of refractory childhood epilepsies, Dravet syndrome, and Lennox-Gastaut syndrome, as well as in phase III clinical trials for the treatment of tuberous sclerosis complex. The company also develops and markets Sativex for the treatment of spasticity due to multiple sclerosis. In addition, it develops various product candidates for the treatment of for schizophrenia, autism spectrum disorder, and neonatal hypoxic ischemic encephalopathy. It primarily operates in Europe, the United Kingdom, the United States, and internationally. GW Pharmaceuticals plc was founded in 1998 and is based in Cambridge, the United Kingdom.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Drug Manufacturers\u2014General",
        "exchange": "PNK",
        "market": "us_market",
        "country": "United Kingdom",
        "city": "Cambridge"
    },
    "GYX.F": {
        "short_name": "FUTURA MEDICAL  LS-,002",
        "long_name": "Futura Medical plc",
        "summary": "Futura Medical plc, a pharmaceutical company, researches and develops pharmaceutical drugs and medical devices for the consumer healthcare markets focusing on sexual health and pain relief management. The company offers CSD500, a condom that contains erectogenic gel. It is also developing MED3000, a topical gel for the treatment of erectile dysfunction that has completed Phase III clinical trials. In addition, the company develops pain relief products, including TPR100, a topical diclofenac pain relief gel; CBD100, a topical cannabidiol formulation; and TIB200, a topical ibuprofen pain relief gel. Futura Medical plc was incorporated in 2001 and is headquartered in Guildford, the United Kingdom.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "FRA",
        "market": "dr_market",
        "country": "United Kingdom",
        "city": "Guildford"
    },
    "H5P.F": {
        "short_name": "HIKMA PHARMACEUTIC.LS-,10",
        "long_name": "Hikma Pharmaceuticals PLC",
        "summary": "Hikma Pharmaceuticals PLC develops, manufactures, and markets a range of generic, branded, and in-licensed pharmaceutical products. The company offers its products in solid, semi-solid, liquid, and injectable final dosage forms. It operates through three segments: Injectables, Generics, and Branded. The Injectables segment develops, manufactures, and sells generic injectable products primarily for use in hospitals. The Generics segment develops and manufactures oral and other non-injectable generic products for the retail market. The Branded segment develops, manufactures, markets, and sells branded generics and in-licensed products to retail and hospital markets. The company offers its products in various therapeutic areas, including anti-infective, cardiovascular, central nervous system, diabetes, oncology, pain management, and respiratory. It operates in the United Kingdom, the United States, the Middle East, North Africa, Europe, and internationally. The company was founded in 1978 and is based in London, the United Kingdom.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Drug Manufacturers\u2014Specialty & Generic",
        "exchange": "FRA",
        "market": "dr_market",
        "country": "United Kingdom",
        "city": "London"
    },
    "HEMO.L": {
        "short_name": "HEMOGENYX PHARMACEUTICALS PLC O",
        "long_name": "Hemogenyx Pharmaceuticals Plc",
        "summary": "Hemogenyx Pharmaceuticals Plc, a preclinical-stage biotechnology company, focuses on the discovery, development, and commercialization of novel therapies and treatments for blood diseases. It is developing products for bone marrow/hematopoietic stem cell BM/HSC transplant market, including CDX bi-specific antibody and CAR-T therapy for eliminating relapsed and/or refractory acute myeloid leukaemia, acute lymphoblastic leukaemia, and myelodysplastic syndrome; and Human Postnatal Hemogenic Endothelial Cells, a cell therapy product for BM/HSC transplants. Hemogenyx Pharmaceuticals Plc has collaboration with GlobalCo. Hemogenyx Pharmaceuticals Plc was founded in 2013 and is headquartered in London, the United Kingdom.",
        "currency": "GBp",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "LSE",
        "market": "gb_market",
        "country": "United Kingdom",
        "city": "London"
    },
    "HIK.L": {
        "short_name": "HIKMA PHARMACEUTICALS PLC ORD S",
        "long_name": "Hikma Pharmaceuticals PLC",
        "summary": "Hikma Pharmaceuticals PLC develops, manufactures, and markets a range of generic, branded, and in-licensed pharmaceutical products. The company offers its products in solid, semi-solid, liquid, and injectable final dosage forms. It operates through three segments: Injectables, Generics, and Branded. The Injectables segment develops, manufactures, and sells generic injectable products primarily for use in hospitals. The Generics segment develops and manufactures oral and other non-injectable generic products for the retail market. The Branded segment develops, manufactures, markets, and sells branded generics and in-licensed products to retail and hospital markets. The company offers its products in various therapeutic areas, including anti-infective, cardiovascular, central nervous system, diabetes, oncology, pain management, and respiratory. It operates in the United Kingdom, the United States, the Middle East, North Africa, Europe, and internationally. The company was founded in 1978 and is based in London, the United Kingdom.",
        "currency": "GBp",
        "sector": "Healthcare",
        "industry": "Drug Manufacturers\u2014Specialty & Generic",
        "exchange": "LSE",
        "market": "gb_market",
        "country": "United Kingdom",
        "city": "London"
    },
    "HKMPF": {
        "short_name": "HIKMA PHARMACEUTICALS",
        "long_name": "Hikma Pharmaceuticals PLC",
        "summary": "Hikma Pharmaceuticals PLC develops, manufactures, and markets a range of generic, branded, and in-licensed pharmaceutical products. The company offers its products in solid, semi-solid, liquid, and injectable final dosage forms. It operates through three segments: Injectables, Generics, and Branded. The Injectables segment develops, manufactures, and sells generic injectable products primarily for use in hospitals. The Generics segment develops and manufactures oral and other non-injectable generic products for the retail market. The Branded segment develops, manufactures, markets, and sells branded generics and in-licensed products to retail and hospital markets. The company offers its products in various therapeutic areas, including anti-infective, cardiovascular, central nervous system, diabetes, oncology, pain management, and respiratory. It operates in the United Kingdom, the United States, the Middle East, North Africa, Europe, and internationally. The company was founded in 1978 and is based in London, the United Kingdom.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Drug Manufacturers\u2014Specialty & Generic",
        "exchange": "PNK",
        "market": "us_market",
        "country": "United Kingdom",
        "city": "London"
    },
    "HKMPY": {
        "short_name": "HIKMA PHARMACEUTICALS",
        "long_name": "Hikma Pharmaceuticals PLC",
        "summary": "Hikma Pharmaceuticals PLC develops, manufactures, and markets a range of generic, branded, and in-licensed pharmaceutical products. The company offers its products in solid, semi-solid, liquid, and injectable final dosage forms. It operates through three segments: Injectables, Generics, and Branded. The Injectables segment develops, manufactures, and sells generic injectable products primarily for use in hospitals. The Generics segment develops and manufactures oral and other non-injectable generic products for the retail market. The Branded segment develops, manufactures, markets, and sells branded generics and in-licensed products to retail and hospital markets. The company offers its products in various therapeutic areas, including anti-infective, cardiovascular, central nervous system, diabetes, oncology, pain management, and respiratory. It operates in the United Kingdom, the United States, the Middle East, North Africa, Europe, and internationally. The company was founded in 1978 and is based in London, the United Kingdom.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Drug Manufacturers\u2014Specialty & Generic",
        "exchange": "PNK",
        "market": "us_market",
        "country": "United Kingdom",
        "city": "London"
    },
    "HOPHF": {
        "short_name": "HEMOGENYX PHARMACEUTICALS PLC",
        "long_name": "Hemogenyx Pharmaceuticals Plc",
        "summary": "Hemogenyx Pharmaceuticals Plc, a preclinical-stage biotechnology company, focuses on the discovery, development, and commercialization of novel therapies and treatments for blood diseases. It is developing products for bone marrow/hematopoietic stem cell BM/HSC transplant market, including CDX bi-specific antibody and CAR-T therapy for eliminating relapsed and/or refractory acute myeloid leukaemia, acute lymphoblastic leukaemia, and myelodysplastic syndrome; and Human Postnatal Hemogenic Endothelial Cells, a cell therapy product for BM/HSC transplants. Hemogenyx Pharmaceuticals Plc has collaboration with GlobalCo. Hemogenyx Pharmaceuticals Plc was founded in 2013 and is headquartered in London, the United Kingdom.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "PNK",
        "market": "us_market",
        "country": "United Kingdom",
        "city": "London"
    },
    "I9SA.F": {
        "short_name": "VERONA PHARMA SP.ADR 8",
        "long_name": "Verona Pharma plc",
        "summary": "Verona Pharma plc, a clinical stage biopharmaceutical company, focuses on develops and commercializes therapies for the treatment of respiratory diseases with unmet medical needs. Its product candidate, ensifentrine (RPL554), is an inhaled, dual inhibitor of the enzymes phosphodiesterase 3 and 4 that acts as both a bronchodilator and an anti-inflammatory agent in a single compound. The formulations of ensifentrine are under development for the treatment chronic obstructive pulmonary disease (COPD): nebulized ensifentrine is in Phase 2b clinical development for the maintenance treatment of COPD; and a dry powder inhaler and a pressurized metered-dose inhaler. The company also focuses on developing ensifentrine for the treatment of cystic fibrosis and asthma. Verona Pharma plc was founded in 2005 and is headquartered in London, the United Kingdom.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "FRA",
        "market": "dr_market",
        "country": "United Kingdom",
        "city": "London"
    },
    "IHC.L": {
        "short_name": "INSPIRATION HEALTHCARE GROUP PL",
        "long_name": "Inspiration Healthcare Group plc",
        "summary": "Inspiration Healthcare Group plc, together with its subsidiaries, provides medical devices for use in critical care, operating theatre, and home healthcare applications worldwide. The company offers neonatal intensive care products, such as Unique+ CFM, a wireless electroencephalography monitoring device; a nasal continuous positive airway pressure (nCPAP) device for treating infants, as well as a range of breathing circuits under the Inspire nCPAP name; inspiration air/oxygen blenders; and Tecotherm Neo, a servo control device for total body cooling and warming used in initial stabilization of preterm infants. Its neonatal intensive care products also include LifeStart, a neonatal bedside resuscitation unit; and Inspire rPAP, a 2-piece non-invasive system for the initial stabilization and resuscitation of infants. In addition, the company provides adult intensive care products; AlphaCore5, a patient warming system for prevention of inadvertent hypothermia; and CosyTherm2, a patient warming system for management of body temperature in neonates. Inspiration Healthcare Group plc was founded in 1998 and is headquartered in Crawley, the United Kingdom.",
        "currency": "GBp",
        "sector": "Healthcare",
        "industry": "Medical Devices",
        "exchange": "LSE",
        "market": "gb_market",
        "country": "United Kingdom",
        "city": "Crawley"
    },
    "IMM.L": {
        "short_name": "IMMUPHARMA PLC ORD 10P",
        "long_name": "ImmuPharma plc",
        "summary": "ImmuPharma plc, a biopharmaceutical company, discovers and develops peptide-based therapeutics. Its peptide-based therapeutics are used in the therapy areas of autoimmunity, anti-infectives, metabolism, and cancer. The company's lead product candidate is the Lupuzor, an autophagy immunomodulator, which is in Phase III clinical trial for the treatment of lupus, an autoimmune chronic inflammatory disease. Its other product candidate includes IPP-204106, a peptide to modulate angiogenesis with application in cancer and ophthalmology; and BioGlucagon a therapy for low sugar events in diabetes. ImmuPharma plc has a collaboration arrangement with Centre National de la Recherche Scientifique for the development of a peptide technology platform for treating diabetes with glucagon-like peptide -1 agonists, as well as development of peptides as glucagon antagonists to treat type I and type II diabetes; and license and development agreement with Avion Pharmaceuticals LLC. The company was founded in 1999 and is headquartered in London, the United Kingdom.",
        "currency": "GBp",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "LSE",
        "market": "gb_market",
        "country": "United Kingdom",
        "city": "London"
    },
    "INHC.L": {
        "short_name": "INDUCTION HEALTHCARE GROUP PLC ",
        "long_name": "Induction Healthcare Group PLC",
        "summary": "Induction Healthcare Group PLC provides software to healthcare professionals in the United Kingdom, rest of Europe, the United States, and internationally. It offers Induction Switch, a communication and sharing platform that enables healthcare professionals to connect and collaborate securely with the people they need within a complex clinical environment; MicroGuide, a platform to create, edit, and publish structured and governance-controlled guidance and policies; Zesty, a digital platform that allows patients to book appointments, read appointment and clinical letters, store a local copy of clinical record, and provide data to care teams remotely; and HealthStream that reads and writes demographic, appointment, and clinical record data. The company was incorporated in 2019 and is based in London, the United Kingdom.",
        "currency": "GBp",
        "sector": "Healthcare",
        "industry": "Health Information Services",
        "exchange": "LSE",
        "market": "gb_market",
        "country": "United Kingdom",
        "city": "London"
    },
    "INS.L": {
        "short_name": "INSTEM PLC ORD 10P",
        "long_name": "Instem plc",
        "summary": "Instem plc, together with its subsidiaries, provides information technology applications to the life sciences healthcare market worldwide. The company offers solutions for data collection, management, and analysis to meet the needs of life science and healthcare organizations for data-driven decision making. Its solutions include ALPHADAS, an eSource EDC system for early phase clinical trials; Ames Study Manager, an integrated suite of software for conducting the Bacterial Reverse Mutation Test; Toxicology Resource Planning, a toxicology solution; Comet Assay IV, a live video imaging system for reproducible comet slide scoring; Cyto Study Manager, a data acquisition and reporting solution; lead scope for computational toxicology; Logbook, a repository for information; NOTOCORD-hem software platforms to acquire, display, and analyze physiological signals; and Provantis, a Windows-based system for organizations and universities that are engaged in non-clinical evaluation studies. The company also provides Samarind RMS to manage medical product information; Sorcerer Colony Counter for automatic plate counter; SEND Explorer, a web-based application with optional data warehousing capabilities; submit platform that provides a suite of integrated tools and services for the creation and management of SEND datasets and associated documents for contract research organizations and sponsors; and SENDTrial, a full Web based solution that can be accessed through a subscription. In addition, it offers data management, cloud, safety assessment, regulatory information management, solution deployment, and validation services. Further, the company provides software solutions for extracting intelligence from research and development related healthcare data; and develops, manufactures, and supplies software and hardware products for in vitro study data collection and study management. Instem plc was founded in 1969 and is headquartered in Stone, the United Kingdom.",
        "currency": "GBp",
        "sector": "Healthcare",
        "industry": "Health Information Services",
        "exchange": "LSE",
        "market": "gb_market",
        "country": "United Kingdom",
        "city": "Stone"
    },
    "IXI.L": {
        "short_name": "IXICO PLC ORD 1P",
        "long_name": "IXICO plc",
        "summary": "IXICO plc provides data analytics services to the biopharmaceutical industry in the United States, the United Kingdom, Europe, and internationally. It provides collection, analysis, management, and reporting services on data generated in the course of a clinical study. The company's technologies include Assessa, a secure online digital platform that provides clinical decision support for patient selection and post-marketing surveillance; and TrialTracker, a platform that delivers imaging services designed to manage the complex imaging workflow from image upload, QC, and reading/analysis to reporting and data transfer. The company offers end-to-end imaging services, primarily in the fields of Alzheimer's, Parkinson's, Huntington's, multiple sclerosis, cerebrovascular, and progressive supranuclear palsy diseases; and engages in the data collection and analysis of neurological diseases. Its services are used to select patients for clinical trials, assess the safety and efficacy of new drugs in development, and in post marketing surveillance. The company was incorporated in 1995 and is based in London, the United Kingdom.",
        "currency": "GBp",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "LSE",
        "market": "gb_market",
        "country": "United Kingdom",
        "city": "London"
    },
    "KMK.L": {
        "short_name": "KROMEK GROUP PLC ORD 1P",
        "long_name": "Kromek Group plc",
        "summary": "Kromek Group plc, together with its subsidiaries, develops, manufactures, and sells radiation detection products for medical imaging, nuclear detection, and security screening markets in the United Kingdom, North America, Asia, Europe, and Australasia. Its solutions provide high-resolution information on material composition and structure to enable the identification of cancerous tissues and hazardous materials, as well as for the analysis of radioactive materials. The company also provides a range of radiation detectors that use cadmium zinc telluride (CZT) or scintillator technology, such as handheld rugged gamma detectors, thermal neutron detectors, gamma-ray detector spectrometers, scintillator detectors, preamplifiers for radiation detectors and detector electronics, and EV-CPG compact gamma ray detectors, as well as quant GR1 shielded gamma detectors, multichannel analyzers, CZT-based gamma ray imagers, quant air, scalable x-ray CZR linear array, gamma-ray spectroscopy software, gamma ray radionuclide detectors, and voltage to frequency converters. In addition, it offers medical imaging products, including CZT gamma detector for SPECT imaging, CZT bone mineral densitometry detectors, and photon-counting spectral CT. Further, the company provides security products, such as D3 PRD high accuracy, D3M, and D3S PRD personal radiation detectors; D3S wearable RIID gamma neutron detectors; D3S NET networked radiation detectors and static node; static radiation detector; vehicle mounted radiation detectors; UAV radiation mapping drone and AARM system; liquid explosive detection algorithm; and Identifier liquid explosive detectors. Additionally, it engages in scientific research and development activities. The company sells its products through distributors, OEM, and direct sales. Kromek Group plc was incorporated in 2013 and is headquartered in Sedgefield, the United Kingdom.",
        "currency": "GBp",
        "sector": "Healthcare",
        "industry": "Medical Devices",
        "exchange": "LSE",
        "market": "gb_market",
        "country": "United Kingdom",
        "city": "Sedgefield"
    },
    "LIA.F": {
        "short_name": "LIVANOVA PLC  DL -,01",
        "long_name": "LivaNova PLC",
        "summary": "LivaNova PLC, a medical device company, designs, develops, manufactures, and sells therapeutic solutions worldwide. It operates in two segments, Cardiovascular (CV\u00c2\u0094) and Neuromodulation (NM). The CV segment develops, produces, and sells cardiopulmonary products, including heart-lung machines, oxygenators, perfusion tubing sets, cannulae, and accessories, as well as related equipment and disposables for autotransfusion and autologous blood washing for neonatal, pediatric, and adult patients. It also provides surgical tissue and mechanical valve replacements, and repair products for damaged or diseased heart valves, such as self-anchoring tissue heart, tissue heart, and mechanical heart valves, as well as heart valve repair products; and temporary extracorporeal cardiopulmonary life support solutions for critically ill patients. The NM segment designs, develops, and markets VNS Therapy System, an implantable device that delivers vagus nerve stimulation (VNS) therapy for the treatment of drug-resistant epilepsy, treatment-resistant depression, and obstructive sleep apnea. It is also involved in the development and clinical testing of the VITARIA System for treating heart failure through VNS. The company serves perfusionists, neurologists, neurosurgeons, and other physicians, as well as hospitals, other medical institutions, and healthcare providers. It sells its products through direct sales representatives and independent distributors. LivaNova PLC has a research collaboration with Verily to gain insights into Vagus nerve stimulation impact on difficult-to-treat depression. The company was founded in 1987 and is headquartered in London, the United Kingdom.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Medical Devices",
        "exchange": "FRA",
        "market": "dr_market",
        "country": "United Kingdom",
        "city": "London"
    },
    "LIVN": {
        "short_name": "LivaNova PLC",
        "long_name": "LivaNova PLC",
        "summary": "LivaNova PLC, a medical device company, designs, develops, manufactures, and sells therapeutic solutions worldwide. It operates in two segments, Cardiovascular (CV\u00c2\u0094) and Neuromodulation (NM). The CV segment develops, produces, and sells cardiopulmonary products, including heart-lung machines, oxygenators, perfusion tubing sets, cannulae, and accessories, as well as related equipment and disposables for autotransfusion and autologous blood washing for neonatal, pediatric, and adult patients. It also provides surgical tissue and mechanical valve replacements, and repair products for damaged or diseased heart valves, such as self-anchoring tissue heart, tissue heart, and mechanical heart valves, as well as heart valve repair products; and temporary extracorporeal cardiopulmonary life support solutions for critically ill patients. The NM segment designs, develops, and markets VNS Therapy System, an implantable device that delivers vagus nerve stimulation (VNS) therapy for the treatment of drug-resistant epilepsy, treatment-resistant depression, and obstructive sleep apnea. It is also involved in the development and clinical testing of the VITARIA System for treating heart failure through VNS. The company serves perfusionists, neurologists, neurosurgeons, and other physicians, as well as hospitals, other medical institutions, and healthcare providers. It sells its products through direct sales representatives and independent distributors. LivaNova PLC has a research collaboration with Verily to gain insights into Vagus nerve stimulation impact on difficult-to-treat depression. The company was founded in 1987 and is headquartered in London, the United Kingdom.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Medical Devices",
        "exchange": "NMS",
        "market": "us_market",
        "country": "United Kingdom",
        "city": "London"
    },
    "LRSV": {
        "short_name": "LINK RESERVATIONS INC",
        "long_name": "Link Reservations Inc.",
        "summary": "Link Reservations Inc., through its subsidiary, produces cannabidiol-based (CBD) products primarily for pets in Europe and the United States. It develops and markets hemp-based CBD products for cats, dogs, and horses. The company was formerly known as Vendum Batteries, Inc. and changed its name to Link Reservations Inc. in May 2015. Link Reservations Inc. was incorporated in 2006 and is based in Kington, the United Kingdom.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Drug Manufacturers\u2014Specialty & Generic",
        "exchange": "PNK",
        "market": "us_market",
        "country": "United Kingdom",
        "city": "Kington"
    },
    "LWA.F": {
        "short_name": "ECO ANIMAL HLTH GR.LS-,05",
        "long_name": "ECO Animal Health Group plc",
        "summary": "ECO Animal Health Group plc develops and markets pharmaceutical products for animals worldwide. The company offers Aivlosin, a macrolide antibiotic for the treatment of respiratory and enteric diseases in pigs and poultry. It also provides generic drugs, such as Ecomectin, Ecoheart, Ecotraz, and Ecomintic, which are endectocides and other antiparasitics for the treatment and prevention of parasites in cattle, sheep, pigs, horses, and dogs; and Chlortetracycline and Oxytetracycline for treatment of bacterial infections in pigs, poultry, and cattle. The company was founded in 1972 and is headquartered in New Malden, the United Kingdom.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Drug Manufacturers\u2014Specialty & Generic",
        "exchange": "FRA",
        "market": "dr_market",
        "country": "United Kingdom",
        "city": "New Malden"
    },
    "LWX.F": {
        "short_name": "IMMUNODIAGNOSTIC  LS -,02",
        "long_name": "Immunodiagnostic Systems Holdings PLC",
        "summary": "Immunodiagnostic Systems Holdings PLC develops, manufactures, and sells in-vitro diagnostic tests to the clinical laboratory market in the United Kingdom, the United States, Germany, France, and internationally. It develops, manufactures, and markets immunoassays and automated immunoanalyser technologies to provide diagnostic outcomes for patients. It offers IDS-iSYS multi-discipline automated systems, which is based on chemiluminescence and absorbency technology is used for immunoassay testing. The company provides its products and services for diagnosis of bone metabolism, calcium metabolism, hypertension, chronic kidney disease mineral bone disorder, growth, fertility, autoimmunity, infectious disease, sarcoidosis, and allergy. Immunodiagnostic Systems Holdings PLC was founded in 1977 and is headquartered in Boldon, the United Kingdom.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Medical Devices",
        "exchange": "FRA",
        "market": "dr_market",
        "country": "United Kingdom",
        "city": "Boldon"
    },
    "MAH0.F": {
        "short_name": "MEREO BIOPH. ADR  LS-,003",
        "long_name": "Mereo BioPharma Group plc",
        "summary": "Mereo BioPharma Group plc, a biopharmaceutical company, acquires, develops, and commercializes therapeutics for the treatment of oncology and rare diseases. Its lead product candidate, etigilimab (OMP-313M32), an antibody T-cell immunoreceptor with Ig and ITIM domains, which is in Phase 1b clinical trial for the treatment of tumor. The company also develops Navicixizumab (OMP-305B83) that is in Phase 1a clinical trial for the treatment of the late line ovarian cancer; Acumapimod (BCT-197), a p38 MAP kinase inhibitor that has completed Phase II clinical trial to treat acute exacerbations of chronic obstructive pulmonary disease; and Leflutrozole (BGS-649), an oral aromatase inhibitor for the treatment of hypogonadotropic hypogonadism. In addition, it develops rare disease product candidates, including Setrusumab (BPS-804), a novel antibody, which is in Phase IIb clinical trial for the treatment of osteogenesis imperfect; and Alvelestat (MPH-966), an oral small molecule that is in Phase II clinical trial to treat Alpha-1 antitrypsin deficiency. Mereo BioPharma Group plc was founded in 2015 and is based in London, the United Kingdom.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "FRA",
        "market": "dr_market",
        "country": "United Kingdom",
        "city": "London"
    },
    "MAH0.SG": {
        "short_name": "Mereo Biopharma Group Ltd. Reg.",
        "long_name": "Mereo BioPharma Group plc",
        "summary": "Mereo BioPharma Group plc, a biopharmaceutical company, acquires, develops, and commercializes therapeutics for the treatment of oncology and rare diseases. Its lead product candidate, etigilimab (OMP-313M32), an antibody T-cell immunoreceptor with Ig and ITIM domains, which is in Phase 1b clinical trial for the treatment of tumor. The company also develops Navicixizumab (OMP-305B83) that is in Phase 1a clinical trial for the treatment of the late line ovarian cancer; Acumapimod (BCT-197), a p38 MAP kinase inhibitor that has completed Phase II clinical trial to treat acute exacerbations of chronic obstructive pulmonary disease; and Leflutrozole (BGS-649), an oral aromatase inhibitor for the treatment of hypogonadotropic hypogonadism. In addition, it develops rare disease product candidates, including Setrusumab (BPS-804), a novel antibody, which is in Phase IIb clinical trial for the treatment of osteogenesis imperfect; and Alvelestat (MPH-966), an oral small molecule that is in Phase II clinical trial to treat Alpha-1 antitrypsin deficiency. Mereo BioPharma Group plc was founded in 2015 and is based in London, the United Kingdom.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "STU",
        "market": "dr_market",
        "country": "United Kingdom",
        "city": "London"
    },
    "MDVI.TA": {
        "short_name": "MEDIVIE THERP-M",
        "long_name": "Medivie Therapeutic Ltd",
        "summary": "Medivie Therapeutic Limited develops and markets dental devices. It offers Laboraide, a dental device that is placed between the woman's lower and upper jaw during birth, which allows the relaxation of the jaw, neck, and head muscles through the flow of oxygen to the muscles. The company also develops modular pacifiers that enables development of mouth structure and prevent future damage to the child's gingival structure and teeth. Its product has applications in the areas of birth, migraines, chronic pains, and improving concentration and cognitive activity. The company markets and distributes its products through a network of distributors, as well as online in the Asia, Latin America, the United States, Europe, and Canada. Medivie Therapeutic Limited was founded in 2012 and is based in Hemel Hempstead, the United Kingdom.",
        "currency": "ILA",
        "sector": "Healthcare",
        "industry": "Medical Instruments & Supplies",
        "exchange": "TLV",
        "market": "il_market",
        "country": "United Kingdom",
        "city": "Hemel Hempstead"
    },
    "MHC.L": {
        "short_name": "MYHEALTHCHECKED PLC ORD 0.1P",
        "long_name": "MyHealthChecked Plc",
        "summary": "MyHealthChecked Plc, a women's healthcare company, develops and commercializes mobile health diagnostics medical devices in the United Kingdom. Its products help women with unexplained infertility to concieve. The company offers myLotus, a dual purpose monitoring system that allows both ovulation (LH) and pregnancy (hCG) testing. The company was formerly known as Concepta PLC and changed its name to MyHealthChecked Plc in December 2020. MyHealthChecked Plc was incorporated in 2008 and is based in Cardiff, the United Kingdom.",
        "currency": "GBp",
        "sector": "Healthcare",
        "industry": "Medical Devices",
        "exchange": "LSE",
        "market": "gb_market",
        "country": "United Kingdom",
        "city": "Cardiff"
    },
    "MREO": {
        "short_name": "Mereo BioPharma Group plc",
        "long_name": "Mereo BioPharma Group plc",
        "summary": "Mereo BioPharma Group plc, a biopharmaceutical company, acquires, develops, and commercializes therapeutics for the treatment of oncology and rare diseases. Its lead product candidate, etigilimab (OMP-313M32), an antibody T-cell immunoreceptor with Ig and ITIM domains, which is in Phase 1b clinical trial for the treatment of tumor. The company also develops Navicixizumab (OMP-305B83) that is in Phase 1a clinical trial for the treatment of the late line ovarian cancer; Acumapimod (BCT-197), a p38 MAP kinase inhibitor that has completed Phase II clinical trial to treat acute exacerbations of chronic obstructive pulmonary disease; and Leflutrozole (BGS-649), an oral aromatase inhibitor for the treatment of hypogonadotropic hypogonadism. In addition, it develops rare disease product candidates, including Setrusumab (BPS-804), a novel antibody, which is in Phase IIb clinical trial for the treatment of osteogenesis imperfect; and Alvelestat (MPH-966), an oral small molecule that is in Phase II clinical trial to treat Alpha-1 antitrypsin deficiency. Mereo BioPharma Group plc was founded in 2015 and is based in London, the United Kingdom.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "NGM",
        "market": "us_market",
        "country": "United Kingdom",
        "city": "London"
    },
    "MTP": {
        "short_name": "Midatech Pharma PLC",
        "long_name": "Midatech Pharma plc",
        "summary": "Midatech Pharma plc focuses on the research and development of oncology and rare disease products in the United Kingdom, rest of Europe, and internationally. The company is developing MTD201, a long acting dose of Octreotide for the treatment of acromegaly and neuroendocrine tumors; and MTX110, a direct delivery treatment for diffuse intrinsic pontine glioma. It also offers drug delivery platforms, such as Q-Sphera, a microencapsulation and polymer-depot sustained release drug delivery platform; MidaSolve, an oligosaccharide nanotechnology used to solubilize drugs so that they can be administered in liquid form directly and locally into tumors; and MidaCore, a gold nanoparticle used for targeting sites of disease by using chemotherapeutic agents or immunotherapeutic agents. Midatech Pharma plc was founded in 2000 and is headquartered in Cardiff, the United Kingdom.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "NCM",
        "market": "us_market",
        "country": "United Kingdom",
        "city": "Cardiff"
    },
    "MTPH.L": {
        "short_name": "MIDATECH PHARMA PLC ORD 0.1P",
        "long_name": "Midatech Pharma plc",
        "summary": "Midatech Pharma plc focuses on the research and development of oncology and rare disease products in the United Kingdom, rest of Europe, and internationally. The company is developing MTD201, a long acting dose of Octreotide for the treatment of acromegaly and neuroendocrine tumors; and MTX110, a direct delivery treatment for diffuse intrinsic pontine glioma. It also offers drug delivery platforms, such as Q-Sphera, a microencapsulation and polymer-depot sustained release drug delivery platform; MidaSolve, an oligosaccharide nanotechnology used to solubilize drugs so that they can be administered in liquid form directly and locally into tumors; and MidaCore, a gold nanoparticle used for targeting sites of disease by using chemotherapeutic agents or immunotherapeutic agents. Midatech Pharma plc was founded in 2000 and is headquartered in Cardiff, the United Kingdom.",
        "currency": "GBp",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "LSE",
        "market": "gb_market",
        "country": "United Kingdom",
        "city": "Cardiff"
    },
    "MYOV": {
        "short_name": "Myovant Sciences Ltd.",
        "long_name": "Myovant Sciences Ltd.",
        "summary": "Myovant Sciences Ltd., a clinical-stage biopharmaceutical company, focuses on developing and commercializing therapies for women's health and endocrine diseases. The company's lead product is relugolix, an oral, once-daily, small molecule that acts as a gonadotropin-releasing hormone receptor antagonist for the treatment of heavy menstrual bleeding related with uterine fibroids, endometriosis-associated pain, and advanced prostate cancer. It is also developing MVT-602, an oligopeptide kisspeptin agonist, for the treatment of female infertility as part of assisted reproduction. Myovant Sciences Ltd. has collaboration with Pfizer Inc. to develop and commercialize relugolix in oncology and women's health. The company was formerly known as Roivant Endocrinology Ltd. and changed its name to Myovant Sciences Ltd. in May 2016. The company was founded in 2016 and is based in London, the United Kingdom. As of December 27, 2019, Myovant Sciences Ltd. operates as a subsidiary of Sumitovant Biopharma Ltd.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "NYQ",
        "market": "us_market",
        "country": "United Kingdom",
        "city": "London"
    },
    "N04A.F": {
        "short_name": "NUCANA  SP.ADR 1/ LS-,04",
        "long_name": "NuCana plc",
        "summary": "NuCana plc, a clinical-stage biopharmaceutical company, engages in the development of products for the treatment of cancer. The company develops its products based on its proprietary ProTide technology. Its lead product candidate includes Acelarin, which is in Phase Ib and Phase III clinical trials for the treatment of patients with biliary tract cancer; a Phase II clinical trial for the treatment of patients with platinum-resistant ovarian cancer; Phase Ib clinical trial for the treatment of patients with biliary cancer; and Phase III clinical trial for the treatment of patients with metastatic pancreatic cancer. The company is also developing NUC-3373, a ProTide transformation of the active anti-cancer metabolite of 5-fluorouracil, which is in Phase I clinical trial for the treatment of patients with advanced solid tumors; and NUC-7738, a nucleoside analog that is in Phase I clinical trial for the treatment of patients with advanced solid tumors and hematological tumors. NuCana plc has a research, collaboration, and license agreement with Cardiff University and University College Cardiff Consultants Ltd. for the design, synthesis, characterization, and evaluation of ProTides; and an assignment, license, and collaboration agreement with Cardiff ProTides Ltd. The company was formerly known as NuCana BioMed Limited and changed its name to NuCana plc in August 2017. NuCana plc was incorporated in 1997 and is headquartered in Edinburgh, the United Kingdom.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "FRA",
        "market": "dr_market",
        "country": "United Kingdom",
        "city": "Edinburgh"
    },
    "NCNA": {
        "short_name": "NuCana plc",
        "long_name": "NuCana plc",
        "summary": "NuCana plc, a clinical-stage biopharmaceutical company, engages in the development of products for the treatment of cancer. The company develops its products based on its proprietary ProTide technology. Its lead product candidate includes Acelarin, which is in Phase Ib and Phase III clinical trials for the treatment of patients with biliary tract cancer; a Phase II clinical trial for the treatment of patients with platinum-resistant ovarian cancer; Phase Ib clinical trial for the treatment of patients with biliary cancer; and Phase III clinical trial for the treatment of patients with metastatic pancreatic cancer. The company is also developing NUC-3373, a ProTide transformation of the active anti-cancer metabolite of 5-fluorouracil, which is in Phase I clinical trial for the treatment of patients with advanced solid tumors; and NUC-7738, a nucleoside analog that is in Phase I clinical trial for the treatment of patients with advanced solid tumors and hematological tumors. NuCana plc has a research, collaboration, and license agreement with Cardiff University and University College Cardiff Consultants Ltd. for the design, synthesis, characterization, and evaluation of ProTides; and an assignment, license, and collaboration agreement with Cardiff ProTides Ltd. The company was formerly known as NuCana BioMed Limited and changed its name to NuCana plc in August 2017. NuCana plc was incorporated in 1997 and is headquartered in Edinburgh, the United Kingdom.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "NMS",
        "market": "us_market",
        "country": "United Kingdom",
        "city": "Edinburgh"
    },
    "NCYT.L": {
        "short_name": "NOVACYT S.A. EUR1/15TH (CDI)",
        "long_name": "Novacyt S.A.",
        "summary": "Novacyt S.A., together with its subsidiaries, engages in the development, manufacture, and commercialization of clinical diagnostic products for cancer and infectious diseases in Africa, Europe, the Asia Pacific, the United States, and the Middle East. The company operates through Corporate and Diagnostics, and Molecular Products segments. The Corporate and Diagnostics segment manufactures and distributes reagents and kits for bacterial and blood tests. The Molecular Products segment designs, manufactures, and distributes test kits for various diseases in humans, animals, and food products. The company's diagnostic products are used in oncology, microbiology, haematology, and serology testing. It also develops, manufactures, and distributes diagnostic products for food laboratories; and manufactures and supplies reagents and tests for in vitro diagnostic tests and blood grouping applications under the Plasmatec and Biotec brand names. The company has collaboration with AstraZeneca, GSK, and the University of Cambridge to support increase testing for COVID-19. It serves universities, hospitals, clinics, and testing laboratories. Novacyt S.A. was founded in 2006 and is headquartered in Camberley, the United Kingdom.",
        "currency": "GBp",
        "sector": "Healthcare",
        "industry": "Diagnostics & Research",
        "exchange": "LSE",
        "market": "gb_market",
        "country": "United Kingdom",
        "city": "Camberley"
    },
    "NFX.L": {
        "short_name": "NUFORMIX PLC ORD 0.1P",
        "long_name": "Nuformix plc",
        "summary": "Nuformix plc, a pharmaceutical development company, develops drugs using cocrystal technology in the United Kingdom. Its lead programs include NXP001, which is used for oncology supportive care; and NXP002 for use in the treatment of fibrosis. The company is also developing NXP004, which is under the pre-clinical stage for the treatment of multiple forms of fibrosis in various human tissues. It has an agreement with VistaGen Therapeutics, Inc. to develop co-crystal-based formulations of AV-101 for the treatment of various central nervous system conditions. The company also has an option agreement with Oxilio Ltd. to provide consultancy services for developing and exploiting NXP001 for the treatment of cancer. Nuformix plc was founded in 2008 and is headquartered in Cambridge, the United Kingdom.",
        "currency": "GBp",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "LSE",
        "market": "gb_market",
        "country": "United Kingdom",
        "city": "Cambridge"
    },
    "NMHLY": {
        "short_name": "NMC HEALTH PLC",
        "long_name": "NMC Health Plc",
        "summary": "NMC Health Plc provides healthcare services in the United Arab Emirates, the United Kingdom, Spain, and internationally. The company operates through two segments, Healthcare, and Distribution & Services. It owns and manages approximately 200 healthcare facilities, including hospitals, medical centers, long term care facilities, day surgery centers, fertility clinics, and home health services providers. The company offers medical services comprising diagnostic, and in and outpatient services, as well as research and medical services in the field of gynecology, obstetrics, and human reproduction; and management services in respect of hospitals, as well as retails pharmaceutical goods. It also trades in pharmaceutical goods, medical equipment, cosmetics, and food products. NMC Health Plc was founded in 1975 and is based in London, the United Kingdom.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Medical Care Facilities",
        "exchange": "PNK",
        "market": "us_market",
        "country": "United Kingdom",
        "city": "London"
    },
    "NPW1.F": {
        "short_name": "SMITH + NEP.  DL -,20",
        "long_name": "Smith & Nephew plc",
        "summary": "Smith & Nephew plc develops, manufactures, and sells medical devices worldwide. The company offers knee implant products for specialized knee replacement procedures; hip implants for the reconstruction of hip joints; and trauma and extremities products that include internal and external devices used in the stabilization of severe fractures and deformity correction procedures. It also provides sports medicine joint repair products for surgeons, including an array of instruments, technologies, and implants necessary to perform minimally invasive surgery of the joints, such as the repair of soft tissue injuries and degenerative conditions of the knee, hip, and shoulder, as well as meniscal repair systems. In addition, the company offers arthroscopic enabling technologies comprising fluid management equipment for surgical access, high definition cameras, digital image capture, scopes, light sources, and monitors to assist with visualization inside the joints, radio frequency, electromechanical and mechanical tissue resection devices, and hand instruments for removing damaged tissue; and ear, nose, and throat solutions. Further, it provides advanced wound care products for the treatment and prevention of acute and chronic wounds, which comprise leg, diabetic and pressure ulcers, burns, and post-operative wounds; advanced wound bioactives, including biologics and other bioactive technologies for debridement and dermal repair/regeneration, as well as regenerative medicine products including skin, bone graft, and articular cartilage substitutes; and advanced wound devices, such as traditional and single-use negative pressure wound therapy, and hydrosurgery systems. It primarily serves the healthcare providers. Smith & Nephew plc was founded in 1856 and is headquartered in Watford, the United Kingdom.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Medical Devices",
        "exchange": "FRA",
        "market": "dr_market",
        "country": "United Kingdom",
        "city": "Watford"
    },
    "NPWA.F": {
        "short_name": "SMITH+NEPHEW ADR5 DL-20/2",
        "long_name": "Smith & Nephew plc",
        "summary": "Smith & Nephew plc develops, manufactures, and sells medical devices worldwide. The company offers knee implant products for specialized knee replacement procedures; hip implants for the reconstruction of hip joints; and trauma and extremities products that include internal and external devices used in the stabilization of severe fractures and deformity correction procedures. It also provides sports medicine joint repair products for surgeons, including an array of instruments, technologies, and implants necessary to perform minimally invasive surgery of the joints, such as the repair of soft tissue injuries and degenerative conditions of the knee, hip, and shoulder, as well as meniscal repair systems. In addition, the company offers arthroscopic enabling technologies comprising fluid management equipment for surgical access, high definition cameras, digital image capture, scopes, light sources, and monitors to assist with visualization inside the joints, radio frequency, electromechanical and mechanical tissue resection devices, and hand instruments for removing damaged tissue; and ear, nose, and throat solutions. Further, it provides advanced wound care products for the treatment and prevention of acute and chronic wounds, which comprise leg, diabetic and pressure ulcers, burns, and post-operative wounds; advanced wound bioactives, including biologics and other bioactive technologies for debridement and dermal repair/regeneration, as well as regenerative medicine products including skin, bone graft, and articular cartilage substitutes; and advanced wound devices, such as traditional and single-use negative pressure wound therapy, and hydrosurgery systems. It primarily serves the healthcare providers. Smith & Nephew plc was founded in 1856 and is headquartered in Watford, the United Kingdom.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Medical Devices",
        "exchange": "FRA",
        "market": "dr_market",
        "country": "United Kingdom",
        "city": "Watford"
    },
    "NSCI.L": {
        "short_name": "NETSCIENTIFIC PLC ORD 5P",
        "long_name": "NetScientific plc",
        "summary": "NetScientific plc is a venture capital firm specializing in seed, early and mid stage investments. The firm focuses to invest in transformative biomedical and healthcare technologies focusing on digital health, diagnostics, and therapeutics sectors. It also prefers to invest in companies that significantly improve the health and well-being of people with chronic diseases. Within digital health it focuses on data analytics, wearable technologies, and devices. The firm seeks to invest in companies based in European developed markets and in the United States. It typically invests up to $15 million, but may consider larger amounts. It prefers to hold a controlling interest in all principal subsidiaries. The firm prefers to invest through its balance sheet investments. NetScientific plc was founded in 2008 and is based in London, United Kingdom.",
        "currency": "GBp",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "LSE",
        "market": "gb_market",
        "country": "United Kingdom",
        "city": "London"
    },
    "NVYTF": {
        "short_name": "NOVACYT",
        "long_name": "Novacyt S.A.",
        "summary": "Novacyt S.A., together with its subsidiaries, engages in the development, manufacture, and commercialization of clinical diagnostic products for cancer and infectious diseases in Africa, Europe, the Asia Pacific, the United States, and the Middle East. The company operates through Corporate and Diagnostics, and Molecular Products segments. The Corporate and Diagnostics segment manufactures and distributes reagents and kits for bacterial and blood tests. The Molecular Products segment designs, manufactures, and distributes test kits for various diseases in humans, animals, and food products. The company's diagnostic products are used in oncology, microbiology, haematology, and serology testing. It also develops, manufactures, and distributes diagnostic products for food laboratories; and manufactures and supplies reagents and tests for in vitro diagnostic tests and blood grouping applications under the Plasmatec and Biotec brand names. The company has collaboration with AstraZeneca, GSK, and the University of Cambridge to support increase testing for COVID-19. It serves universities, hospitals, clinics, and testing laboratories. Novacyt S.A. was founded in 2006 and is headquartered in Camberley, the United Kingdom.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Diagnostics & Research",
        "exchange": "PNK",
        "market": "us_market",
        "country": "United Kingdom",
        "city": "Camberley"
    },
    "NYZ.F": {
        "short_name": "NOVACYT  EO-,0667",
        "long_name": "Novacyt S.A.",
        "summary": "Novacyt S.A., together with its subsidiaries, engages in the development, manufacture, and commercialization of clinical diagnostic products for cancer and infectious diseases in Africa, Europe, the Asia Pacific, the United States, and the Middle East. The company operates through Corporate and Diagnostics, and Molecular Products segments. The Corporate and Diagnostics segment manufactures and distributes reagents and kits for bacterial and blood tests. The Molecular Products segment designs, manufactures, and distributes test kits for various diseases in humans, animals, and food products. The company's diagnostic products are used in oncology, microbiology, haematology, and serology testing. It also develops, manufactures, and distributes diagnostic products for food laboratories; and manufactures and supplies reagents and tests for in vitro diagnostic tests and blood grouping applications under the Plasmatec and Biotec brand names. The company has collaboration with AstraZeneca, GSK, and the University of Cambridge to support increase testing for COVID-19. It serves universities, hospitals, clinics, and testing laboratories. Novacyt S.A. was founded in 2006 and is headquartered in Camberley, the United Kingdom.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Diagnostics & Research",
        "exchange": "FRA",
        "market": "dr_market",
        "country": "United Kingdom",
        "city": "Camberley"
    },
    "NZCA.F": {
        "short_name": "PROVEXIS PLC  LS-,001",
        "long_name": "Provexis plc",
        "summary": "Provexis plc, together with its subsidiaries, develops, licenses, and markets functional foods, medical foods, and dietary supplements worldwide. Its products include Fruitflow, a tomato extract that reduces the propensity for aberrant blood clotting typically associated with cardiovascular diseases, such as heart attack and stroke. The company's syrup and powder versions of Fruitflow are used in foods, beverages, and dietary supplement formats. It also offers Fruitflow + Omega-3, a supplement in capsule form that supports healthy blood flow and normal heart function. Provexis plc has a collaboration agreement with By-Health Co., Ltd. The company offers its products through retail stores, as well as online. Provexis plc was founded in 1999 and is based in Reading, the United Kingdom.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Drug Manufacturers\u2014Specialty & Generic",
        "exchange": "FRA",
        "market": "dr_market",
        "country": "United Kingdom",
        "city": "Reading"
    },
    "OB3.F": {
        "short_name": "OPTIBIOTIX HLTH PLC LS-02",
        "long_name": "OptiBiotix Health Plc",
        "summary": "Optibiotix Health Plc, a life sciences company, engages in the research and development of microbiome modulators primarily in the United Kingdom. The company identifies and develops microbial strains, compounds, and formulations for use in food ingredients, supplements, and active compounds that impacts human physiology deriving potential health benefits. Its products include Slimbiome, a natural ingredient, which offers a healthy and hunger-free weight management system; CholBiome, a food supplement for maintaining healthy levels of cholesterol; Lactobacillus plantarum LPLDL, a probiotic that aids elements of cardiovascular and wellbeing; LPGOS, a galactooligosaccharid that ID used in food products and applications, which helps in reducing cardiovascular risk factors and enhancing health; and Sweetbiotix, a sweetener for use in food products and beverages. The company's products prevents and manages chronic lifestyle diseases, including obesity, hypercholesterolemia and lipid profiles, and diabetes. Optibiotix Health Plc has an agreement with Fondazione Edmund Mach - Centro Ricerca e Innovazione to jointly fund and carry out a research project examining the role of its microbiome products to improve sleep, stress, and anxiety. The company was founded in 2012 and is headquartered in York, the United Kingdom.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "FRA",
        "market": "dr_market",
        "country": "United Kingdom",
        "city": "York"
    },
    "OBD.L": {
        "short_name": "OXFORD BIODYNAMICS PLC ORD GBP0",
        "long_name": "Oxford BioDynamics Plc",
        "summary": "Oxford BioDynamics Plc, a biotechnology company, discovers and develops biomarkers for use within the pharmaceutical and biotechnology industry primarily in the United Kingdom and Malaysia. The company provides EpiSwitch, a proprietary technology platform for the discovery, evaluation, validation, and monitoring of epigenetic biomarkers known as chromosome conformation signatures. It has collaboration agreements with Holos Life Sciences Pte. Ltd. to develop non-invasive epigenetic biomarkers associated with sports-related concussions; and Casa Sollievo della Sofferenza to identify EpiSwitch biomarkers for the blood-based diagnosis of Autism Spectrum Disorder. The company also has a strategic partnership with Boca Biolistics LLC to provide a range of blood samples from COVID-19 patients with clinical information on disease severity. Oxford BioDynamics Plc was founded in 2007 and is headquartered in Oxford, the United Kingdom.",
        "currency": "GBp",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "LSE",
        "market": "gb_market",
        "country": "United Kingdom",
        "city": "Oxford"
    },
    "OCY.SG": {
        "short_name": "Oncimmune Holdings PLC Register",
        "long_name": "Oncimmune Holdings plc",
        "summary": "Oncimmune Holdings plc develops and commercializes technologies that enable cancer diagnosis in the United Kingdom, North America, Europe, and internationally. It offers EarlyCDT-Lung, a blood test for early detection of lung cancer. The company also develops SeroTag, a platform that is used to discover and validate biomarkers that can help stratify patients in multiple cancer indications, infectious diseases, and with various autoimmune diseases; and NavigAID disease-specific stratification panels. Oncimmune Holdings plc was incorporated in 2015 and is based in Nottingham, the United Kingdom.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "STU",
        "market": "dr_market",
        "country": "United Kingdom",
        "city": "Nottingham"
    },
    "ODX.L": {
        "short_name": "OMEGA DIAGNOSTICS GROUP PLC ORD",
        "long_name": "Omega Diagnostics Group PLC",
        "summary": "Omega Diagnostics Group PLC, through its subsidiaries, develops, manufactures, and distributes medical diagnostics products in the United Kingdom, rest of Europe, North America, South/Central America, India, other Asian countries, Africa, and the Middle East. The company operates in three segments: Allergy and Autoimmune, Food Intolerance, and Infectious Diseases and Other. The Allergy and Autoimmune segment engages in the research, development, production, and marketing of in-vitro allergy and autoimmune tests used by doctors to diagnose patients with allergies and autoimmune diseases. This segment's product includes 69 CE-marked allergens. The Food Intolerance segment engages in the research, development, and production of kits to aid the detection of immune reactions to food under the Foodprint name. This segment also provides CNS laboratory services that offer clinical analysis to the general public, clinics, and health professionals, as well as supplies Food Detective, a consumer food test. The Infectious Diseases and Other segment is involved in the research, development, production, and marketing of kits that are used in the diagnosis of infectious diseases. This segment's products include VISITECT CD4, an in-vitro diagnostic test, which is used in the management of patients with pre-diagnosed HIV infection, as well as develops and manufactures COVID-19 antibody and antigen tests. The company offers its products to hospitals, clinics, and laboratories through distributors in approximately 75 countries worldwide. Omega Diagnostics Group PLC was founded in 1987 and is headquartered in Alva, the United Kingdom.",
        "currency": "GBp",
        "sector": "Healthcare",
        "industry": "Medical Instruments & Supplies",
        "exchange": "LSE",
        "market": "gb_market",
        "country": "United Kingdom",
        "city": "Alva"
    },
    "OKYO.L": {
        "short_name": "OKYO PHARMA LIMITED ORD NPV",
        "long_name": "OKYO Pharma Limited",
        "summary": "OKYO Pharma Limited operates as a life sciences and biopharmaceutical company in the United Kingdom. Its pre-clinical development program includes Chemerin for the treatment of ocular inflammation, dry eye disease, and ocular neuropathic pain; and BAM8, a non-opioid analgesic. OKYO Pharma Limited is headquartered in London, the United Kingdom.",
        "currency": "GBp",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "LSE",
        "market": "gb_market",
        "country": "United Kingdom",
        "city": "London"
    },
    "OMY.SG": {
        "short_name": "Synairgen PLC Registered Shares",
        "long_name": "Synairgen plc",
        "summary": "Synairgen plc discovers and develops drugs for respiratory diseases. It develops inhaled interferon beta (IFN-\u00c3\u009f), which is in Phase-II clinical trials for the treatment of asthma caused by the common cold and flu; IFN-\u00c3\u009f that is in Phase-II clinical trial for the treatment or prevention of chronic obstructive pulmonary disease exacerbations caused by the common cold and flu; and LOXL2 inhibitor, which has completed Phase I clinical trial for the treatment of idiopathic pulmonary fibrosis (IPF) and non-alcoholic fatty liver diseases. The company has a licensing and collaboration agreement with Pharmaxis Ltd. to develop a LOXL2 inhibitor; and a strategic collaboration with Parexel Biotech on pivotal Phase III trial for the study of inhaled COVID-19 treatment. Synairgen plc was incorporated in 2004 and is headquartered in Southampton, the United Kingdom.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "STU",
        "market": "dr_market",
        "country": "United Kingdom",
        "city": "Southampton"
    },
    "ONC.L": {
        "short_name": "ONCIMMUNE HOLDINGS PLC ORD 1P",
        "long_name": "Oncimmune Holdings plc",
        "summary": "Oncimmune Holdings plc develops and commercializes technologies that enable cancer diagnosis in the United Kingdom, North America, Europe, and internationally. It offers EarlyCDT-Lung, a blood test for early detection of lung cancer. The company also develops SeroTag, a platform that is used to discover and validate biomarkers that can help stratify patients in multiple cancer indications, infectious diseases, and with various autoimmune diseases; and NavigAID disease-specific stratification panels. Oncimmune Holdings plc was incorporated in 2015 and is based in Nottingham, the United Kingdom.",
        "currency": "GBp",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "LSE",
        "market": "gb_market",
        "country": "United Kingdom",
        "city": "Nottingham"
    },
    "OPTI.L": {
        "short_name": "OPTIBIOTIX HEALTH PLC ORD 2P",
        "long_name": "OptiBiotix Health Plc",
        "summary": "Optibiotix Health Plc, a life sciences company, engages in the research and development of microbiome modulators primarily in the United Kingdom. The company identifies and develops microbial strains, compounds, and formulations for use in food ingredients, supplements, and active compounds that impacts human physiology deriving potential health benefits. Its products include Slimbiome, a natural ingredient, which offers a healthy and hunger-free weight management system; CholBiome, a food supplement for maintaining healthy levels of cholesterol; Lactobacillus plantarum LPLDL, a probiotic that aids elements of cardiovascular and wellbeing; LPGOS, a galactooligosaccharid that ID used in food products and applications, which helps in reducing cardiovascular risk factors and enhancing health; and Sweetbiotix, a sweetener for use in food products and beverages. The company's products prevents and manages chronic lifestyle diseases, including obesity, hypercholesterolemia and lipid profiles, and diabetes. Optibiotix Health Plc has an agreement with Fondazione Edmund Mach - Centro Ricerca e Innovazione to jointly fund and carry out a research project examining the role of its microbiome products to improve sleep, stress, and anxiety. The company was founded in 2012 and is headquartered in York, the United Kingdom.",
        "currency": "GBp",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "LSE",
        "market": "gb_market",
        "country": "United Kingdom",
        "city": "York"
    },
    "ORPH.L": {
        "short_name": "OPEN ORPHAN PLC ORD 0.1P",
        "long_name": "Open Orphan plc",
        "summary": "Open Orphan plc operates as a clinical research organization pharmaceutical services company with a focus on virology, vaccine studies, and orphan drugs in the United Kingdom, Ireland, France, the Netherlands, Germany, and Singapore. It operates a virtual rep, a pharmaceutical commercialization platform for rare/orphan disease space; and develops Genomic Health Data platform, a collection of infectious disease progression data. The company also provides consulting and clinical trial services to pharmaceutical, biotechnology, and medical device organizations. In addition, it offers hVIVO COVID Clear Test, an antibody test for employers in the United Kingdom and Ireland. The company is headquartered in London, the United Kingdom.",
        "currency": "GBp",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "LSE",
        "market": "gb_market",
        "country": "United Kingdom",
        "city": "London"
    },
    "ORTX": {
        "short_name": "Orchard Therapeutics plc",
        "long_name": "Orchard Therapeutics plc",
        "summary": "Orchard Therapeutics plc, a biopharmaceutical company, develops gene therapies for serious and life-threatening rare diseases in the United Kingdom, European Union, and the United States. The company's gene therapy approach seeks to transform a patient's hematopoietic stem cells into a gene-modified drug product to treat the patient's disease through a single administration. It provides Strimvelis, a gammaretroviral-based product for the treatment of adenosine deaminase-severe combined immunodeficiency (ADA-SCID). The company's clinical development products comprise OTL-101 for the treatment of ADA-SCID; OTL-200 to treat metachromatic leukodystrophy; OTL-103 for the treatment of Wiskott-Aldrich syndrome; OTL-102 for X-linked chronic granulomatous disease; and OTL-300 for transfusion-dependent beta-thalassemia. Its preclinical programs include OTL-203 for mucopolysaccharidosis type I, OTL-201 for mucopolysaccharidosis type MPS-IIIA, and OTL-202 for mucopolysaccharidosis type IIIB. The company was formerly known as Orchard Rx Limited. Orchard Therapeutics plc was founded in 2015 and is headquartered in London, the United Kingdom.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "NMS",
        "market": "us_market",
        "country": "United Kingdom",
        "city": "London"
    },
    "OT1A.F": {
        "short_name": "ORCHARD THERAP.SP.ADRS/1",
        "long_name": "Orchard Therapeutics plc",
        "summary": "Orchard Therapeutics plc, a biopharmaceutical company, develops gene therapies for serious and life-threatening rare diseases in the United Kingdom, European Union, and the United States. The company's gene therapy approach seeks to transform a patient's hematopoietic stem cells into a gene-modified drug product to treat the patient's disease through a single administration. It provides Strimvelis, a gammaretroviral-based product for the treatment of adenosine deaminase-severe combined immunodeficiency (ADA-SCID). The company's clinical development products comprise OTL-101 for the treatment of ADA-SCID; OTL-200 to treat metachromatic leukodystrophy; OTL-103 for the treatment of Wiskott-Aldrich syndrome; OTL-102 for X-linked chronic granulomatous disease; and OTL-300 for transfusion-dependent beta-thalassemia. Its preclinical programs include OTL-203 for mucopolysaccharidosis type I, OTL-201 for mucopolysaccharidosis type MPS-IIIA, and OTL-202 for mucopolysaccharidosis type IIIB. The company was formerly known as Orchard Rx Limited. Orchard Therapeutics plc was founded in 2015 and is headquartered in London, the United Kingdom.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "FRA",
        "market": "dr_market",
        "country": "United Kingdom",
        "city": "London"
    },
    "OXB.L": {
        "short_name": "OXFORD BIOMEDICA PLC ORD 50P",
        "long_name": "Oxford Biomedica plc",
        "summary": "Oxford Biomedica plc, a biopharmaceutical company, engages in the research, development, and bioprocessing of lentiviral vector and cell therapy products for the treatment of various diseases in Europe and internationally. The company operates in two segments, Platform and Product. Its LentiVector platform technology integrates genes into non-dividing cells, including neurons in the brain and retinal cells in the eye, as well as accommodates multiple therapeutic genes. The company's products under development stage include OXB-302 that targets haematological tumours with a CAR-T 5T4; OXB-203, which is in pre-clinical stage for the treatment of wet age-related macular degeneration; OXB-202 for the treatment of corneal graft rejection; OXB-204, a lentiviral-based therapy for the ocular disease Leber's congenital amaurosis variant 10; OXB-103 (ALS) for central nervous system; and OXB-401 for liver indication. Its partnered products in development stage comprise AXO-Lenti-PD that is in a Phase I/II trial preparation for the treatment of Parkinson's disease; SAR 422459, which is in a Phase II trial for the treatment of Stargardt disease; and SAR 421869 that is in Phase I/II trial for the treatment of Usher syndrome 1B. Oxford Biomedica plc has partnerships with Novartis, Bristol Myers Squibb, Sanofi, Axovant Gene Therapies, Orchard Therapeutics, Boehringer Ingelheim, the UK Cystic Fibrosis Gene Therapy Consortium, Imperial Innovations, Santen Pharmaceutical Co Ltd, Microsoft Research, and Vaccines Manufacturing and Innovation Centre. The company also has a research collaboration agreement with Papyrus Therapeutics, Inc. to assess the impact and therapeutic benefit of PYTX-002, a gene replacement therapy to confer cellular pharmacy properties on a CAR-T cell therapy. It has a discovery collaboration with PhoreMost Limited to develop CAR-T cell therapies. Oxford Biomedica plc was founded in 1995 and is headquartered in Oxford, the United Kingdom.",
        "currency": "GBp",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "LSE",
        "market": "gb_market",
        "country": "United Kingdom",
        "city": "Oxford"
    },
    "OXBDF": {
        "short_name": "OXFORD BIOMEDICA",
        "long_name": "Oxford Biomedica plc",
        "summary": "Oxford Biomedica plc, a biopharmaceutical company, engages in the research, development, and bioprocessing of lentiviral vector and cell therapy products for the treatment of various diseases in Europe and internationally. The company operates in two segments, Platform and Product. Its LentiVector platform technology integrates genes into non-dividing cells, including neurons in the brain and retinal cells in the eye, as well as accommodates multiple therapeutic genes. The company's products under development stage include OXB-302 that targets haematological tumours with a CAR-T 5T4; OXB-203, which is in pre-clinical stage for the treatment of wet age-related macular degeneration; OXB-202 for the treatment of corneal graft rejection; OXB-204, a lentiviral-based therapy for the ocular disease Leber's congenital amaurosis variant 10; OXB-103 (ALS) for central nervous system; and OXB-401 for liver indication. Its partnered products in development stage comprise AXO-Lenti-PD that is in a Phase I/II trial preparation for the treatment of Parkinson's disease; SAR 422459, which is in a Phase II trial for the treatment of Stargardt disease; and SAR 421869 that is in Phase I/II trial for the treatment of Usher syndrome 1B. Oxford Biomedica plc has partnerships with Novartis, Bristol Myers Squibb, Sanofi, Axovant Gene Therapies, Orchard Therapeutics, Boehringer Ingelheim, the UK Cystic Fibrosis Gene Therapy Consortium, Imperial Innovations, Santen Pharmaceutical Co Ltd, Microsoft Research, and Vaccines Manufacturing and Innovation Centre. The company also has a research collaboration agreement with Papyrus Therapeutics, Inc. to assess the impact and therapeutic benefit of PYTX-002, a gene replacement therapy to confer cellular pharmacy properties on a CAR-T cell therapy. It has a discovery collaboration with PhoreMost Limited to develop CAR-T cell therapies. Oxford Biomedica plc was founded in 1995 and is headquartered in Oxford, the United Kingdom.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "PNK",
        "market": "us_market",
        "country": "United Kingdom",
        "city": "Oxford"
    },
    "OXFD": {
        "short_name": "Oxford Immunotec Global PLC",
        "long_name": "Oxford Immunotec Global PLC",
        "summary": "Oxford Immunotec Global PLC, a diagnostics company, focuses on developing and commercializing proprietary tests for immunology and infectious diseases in the United States, Europe, Asia, and internationally. The company develops its products using its T-SPOT technology platform that measures marker-specific cellular (T cells) responses at a single cell level and inform the diagnosis, prognosis, and monitoring of patients with immune-regulated conditions. It develops and markets T-SPOT.TB test used to test for tuberculosis; and reagents and methods to purify white blood cells for use in immunology assays. In addition, the company offers T-SPOT.CMV, an immune monitoring test for cytomegalovirus (CMV) for the quantification of effector T cells that respond to stimulation by antigens specific for CMV, as well as for the monitoring of CMV-seropositive responses in transplant recipients at various time-points post-transplantation applications. It serves independent laboratories, hospital systems, and public and private institutions. Oxford Immunotec Global PLC was founded in 2002 and is headquartered in Abingdon, the United Kingdom.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Diagnostics & Research",
        "exchange": "NGM",
        "market": "us_market",
        "country": "United Kingdom",
        "city": "Abingdon"
    },
    "OXOA.F": {
        "short_name": "OXFORD BIOMEDICA  LS-,50",
        "long_name": "Oxford Biomedica plc",
        "summary": "Oxford Biomedica plc, a biopharmaceutical company, engages in the research, development, and bioprocessing of lentiviral vector and cell therapy products for the treatment of various diseases in Europe and internationally. The company operates in two segments, Platform and Product. Its LentiVector platform technology integrates genes into non-dividing cells, including neurons in the brain and retinal cells in the eye, as well as accommodates multiple therapeutic genes. The company's products under development stage include OXB-302 that targets haematological tumours with a CAR-T 5T4; OXB-203, which is in pre-clinical stage for the treatment of wet age-related macular degeneration; OXB-202 for the treatment of corneal graft rejection; OXB-204, a lentiviral-based therapy for the ocular disease Leber's congenital amaurosis variant 10; OXB-103 (ALS) for central nervous system; and OXB-401 for liver indication. Its partnered products in development stage comprise AXO-Lenti-PD that is in a Phase I/II trial preparation for the treatment of Parkinson's disease; SAR 422459, which is in a Phase II trial for the treatment of Stargardt disease; and SAR 421869 that is in Phase I/II trial for the treatment of Usher syndrome 1B. Oxford Biomedica plc has partnerships with Novartis, Bristol Myers Squibb, Sanofi, Axovant Gene Therapies, Orchard Therapeutics, Boehringer Ingelheim, the UK Cystic Fibrosis Gene Therapy Consortium, Imperial Innovations, Santen Pharmaceutical Co Ltd, Microsoft Research, and Vaccines Manufacturing and Innovation Centre. The company also has a research collaboration agreement with Papyrus Therapeutics, Inc. to assess the impact and therapeutic benefit of PYTX-002, a gene replacement therapy to confer cellular pharmacy properties on a CAR-T cell therapy. It has a discovery collaboration with PhoreMost Limited to develop CAR-T cell therapies. Oxford Biomedica plc was founded in 1995 and is headquartered in Oxford, the United Kingdom.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "FRA",
        "market": "dr_market",
        "country": "United Kingdom",
        "city": "Oxford"
    },
    "PLPL": {
        "short_name": "PLANDAI BIOTECHNOLOGY INC",
        "long_name": "Planda\u00ed Biotechnology, Inc.",
        "summary": "Planda\u00c3\u00ad Biotechnology, Inc. focuses on the production of proprietary botanical extracts for the nutriceutical and pharmaceutical industries. It is developing Phytofare Catechin Complex, a botanical extract derived from green tea harvested in the Senteeko Tea Estate in Mpumalanga, South Africa; and Phytofare citrus complex, a citrus extract, as well as extracts from tomato fruit, Artemisia, and cannabis. The company also produces and sells timber and agricultural products from its farm and tea estate holdings in South Africa. Planda\u00c3\u00ad Biotechnology, Inc. is based in London, the United Kingdom.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "PNK",
        "market": "us_market",
        "country": "United Kingdom",
        "city": "London"
    },
    "PMSNF": {
        "short_name": "PROTEOME SCIENCES",
        "long_name": "Proteome Sciences plc",
        "summary": "Proteome Sciences plc provides contract research services for the identification, validation, and application of protein biomarkers. The company develops the technology for isobaric tandem mass tag (TMT) and TMTpro, and manufacture small, protein-reactive chemical reagents; and Elayta, a small molecule inhibitor of beta-amyloid interaction with synaptic receptors that modifies downstream signaling and provides neuroprotective effects. It offers SysQuant and TMT MS3, a method for biomarker discovery in plasma and other complex samples where quantitative accuracy is the most important factor; TMT Calibrator ?combines protein and fluid proteomics to identify tissue proteins with evidenced availability for peripheral detection; PD biomarker discovery; and TMT SRM and Immuno Assay for CDx biomarker validation. The company primarily serves pharmaceutical and biotechnology companies, including academic research. Proteome Sciences plc was incorporated in 1993 and is headquartered in London, the United Kingdom.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Diagnostics & Research",
        "exchange": "PNK",
        "market": "us_market",
        "country": "United Kingdom",
        "city": "London"
    },
    "PXS.L": {
        "short_name": "PROVEXIS PLC ORD 0.1P",
        "long_name": "Provexis plc",
        "summary": "Provexis plc, together with its subsidiaries, develops, licenses, and markets functional foods, medical foods, and dietary supplements worldwide. Its products include Fruitflow, a tomato extract that reduces the propensity for aberrant blood clotting typically associated with cardiovascular diseases, such as heart attack and stroke. The company's syrup and powder versions of Fruitflow are used in foods, beverages, and dietary supplement formats. It also offers Fruitflow + Omega-3, a supplement in capsule form that supports healthy blood flow and normal heart function. Provexis plc has a collaboration agreement with By-Health Co., Ltd. The company offers its products through retail stores, as well as online. Provexis plc was founded in 1999 and is based in Reading, the United Kingdom.",
        "currency": "GBp",
        "sector": "Healthcare",
        "industry": "Drug Manufacturers\u2014Specialty & Generic",
        "exchange": "LSE",
        "market": "gb_market",
        "country": "United Kingdom",
        "city": "Reading"
    },
    "PYC.L": {
        "short_name": "PHYSIOMICS PLC ORD 0.4P",
        "long_name": "Physiomics Plc",
        "summary": "Physiomics Plc provides consulting services to pharmaceutical companies in the areas of outsourced quantitative pharmacology and computational biology in the United Kingdom, the European Union, and the United States. It offers modeling, simulation, and data analysis services covering various ranges of oncology research and development using its proprietary Virtual Tumour predictive software. The company also develops technology for use in the field of personalized medicine. Physiomics Plc was incorporated in 2001 and is based in Oxford, the United Kingdom.",
        "currency": "GBp",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "LSE",
        "market": "gb_market",
        "country": "United Kingdom",
        "city": "Oxford"
    },
    "PYPB.F": {
        "short_name": "IXICO PLC  LS -,01",
        "long_name": "IXICO plc",
        "summary": "IXICO plc provides data analytics services to the biopharmaceutical industry in the United States, the United Kingdom, Europe, and internationally. It provides collection, analysis, management, and reporting services on data generated in the course of a clinical study. The company's technologies include Assessa, a secure online digital platform that provides clinical decision support for patient selection and post-marketing surveillance; and TrialTracker, a platform that delivers imaging services designed to manage the complex imaging workflow from image upload, QC, and reading/analysis to reporting and data transfer. The company offers end-to-end imaging services, primarily in the fields of Alzheimer's, Parkinson's, Huntington's, multiple sclerosis, cerebrovascular, and progressive supranuclear palsy diseases; and engages in the data collection and analysis of neurological diseases. Its services are used to select patients for clinical trials, assess the safety and efficacy of new drugs in development, and in post marketing surveillance. The company was incorporated in 1995 and is based in London, the United Kingdom.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "FRA",
        "market": "dr_market",
        "country": "United Kingdom",
        "city": "London"
    },
    "R3I1.F": {
        "short_name": "ADVANCED ONCOTHER. LS-,25",
        "long_name": "Advanced Oncotherapy plc",
        "summary": "Advanced Oncotherapy plc, together with its subsidiaries, engages in designing, assembling, selling, and maintaining proton-based radiotherapy systems for treatment of cancer. It is developing Linac Image Guided Hadron Technology, a proton therapy system for treating cancer. It has operations in the United Kingdom, Switzerland, and the United States. The company was formerly known as CareCapital Group plc and changed its name to Advanced Oncotherapy PLC in September 2012. Advanced Oncotherapy plc was founded in 1994 and is headquartered in London, the United Kingdom.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Medical Devices",
        "exchange": "FRA",
        "market": "dr_market",
        "country": "United Kingdom",
        "city": "London"
    },
    "REDX.L": {
        "short_name": "REDX PHARMA PLC ORD 1P",
        "long_name": "Redx Pharma Plc",
        "summary": "Redx Pharma Plc engages in drug discovery, pre-clinical development, and licensing activities in the United Kingdom. It discovers and develops small molecule drugs for treating anti-cancer and fibrosis targets in the areas of unmet medical needs. The company is developing RXC004, a porcupine inhibitor, which has completed Phase I clinical development for the treatment of colorectal, pancreatic, biliary, and gastric cancers, as well as melanoma; ROCK inhibitor for treating inflammatory intestinal fibrosis; RXC007, a Rho-associated protein kinase 2 inhibitors for the treatment of orphan disease, idiopathic pulmonary fibrosis, non-alcoholic steatohepatitis, and other systemic fibrotic conditions; and Porcupine (RXC006), which is in Phase I for the treatment of lung fibrosis. Redx Pharma Plc has a research collaboration agreement with Jazz Pharmaceuticals plc to discover and develop drug candidates for two cancer targets in the Ras/Raf/MAP kinase pathway. The company was founded in 2010 and is based in Macclesfield, the United Kingdom.",
        "currency": "GBp",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "LSE",
        "market": "gb_market",
        "country": "United Kingdom",
        "city": "Macclesfield"
    },
    "RENE.L": {
        "short_name": "RENEURON GROUP PLC ORD 1P",
        "long_name": "ReNeuron Group plc",
        "summary": "ReNeuron Group plc develops and sells cell-based therapies in the United Kingdom. The company engages in the development of CTX stem cell therapy candidate that is in Phase IIb clinical trial for stroke disability; and human retinal progenitor cell therapy that is in Phase I/IIa clinical trial for treating retinitis pigmentosa, a blindness-causing disease. It also developing CTX-derived exosomes, which are Nano-sized packages of information released by CTX cells. ReNeuron Group plc has a research agreement with U.S. biotechnology company in the discovery and development of novel gene silencing-based therapeutics. The company was founded in 1997 and is headquartered in Pencoed, the United Kingdom.",
        "currency": "GBp",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "LSE",
        "market": "gb_market",
        "country": "United Kingdom",
        "city": "Pencoed"
    },
    "RENX.L": {
        "short_name": "RENALYTIX AI PLC ORD 0.25P",
        "long_name": "Renalytix AI plc",
        "summary": "Renalytix AI plc develops artificial intelligence-enabled in vitro diagnostic solutions for kidney diseases. The company offers KidneyIntelX, a diagnostic platform that employs an artificial intelligence-enabled algorithm that combines various data inputs, including validated blood-based biomarkers, inherited genetics and personalized patient data from electronic health record, and systems to generate a unique patient risk score. Renalytix AI plc has a license agreement with Mount Sinai Health System to develop and commercialize licensed products in connection with the application of artificial intelligence for the diagnosis of kidney disease; Joslin Diabetes Center, Inc. for developing and commercializing products for diagnosing and predicting kidney disease using biomarkers; and Kantaro Biosciences LLC for developing and commercializing laboratory tests for the detection of antibodies against SARS-CoV-2. Its products are used in kidney disease diagnosis and prognosis, clinical care, patient stratification for drug clinical trials, and drug target discovery. The company was founded in 2018 and is based in Cardiff, the United Kingdom.",
        "currency": "GBp",
        "sector": "Healthcare",
        "industry": "Diagnostics & Research",
        "exchange": "LSE",
        "market": "gb_market",
        "country": "United Kingdom",
        "city": "Cardiff"
    },
    "RNLX": {
        "short_name": "Renalytix AI plc",
        "long_name": "Renalytix AI plc",
        "summary": "Renalytix AI plc develops artificial intelligence-enabled in vitro diagnostic solutions for kidney diseases. The company offers KidneyIntelX, a diagnostic platform that employs an artificial intelligence-enabled algorithm that combines various data inputs, including validated blood-based biomarkers, inherited genetics and personalized patient data from electronic health record, and systems to generate a unique patient risk score. Renalytix AI plc has a license agreement with Mount Sinai Health System to develop and commercialize licensed products in connection with the application of artificial intelligence for the diagnosis of kidney disease; Joslin Diabetes Center, Inc. for developing and commercializing products for diagnosing and predicting kidney disease using biomarkers; and Kantaro Biosciences LLC for developing and commercializing laboratory tests for the detection of antibodies against SARS-CoV-2. Its products are used in kidney disease diagnosis and prognosis, clinical care, patient stratification for drug clinical trials, and drug target discovery. The company was founded in 2018 and is based in Cardiff, the United Kingdom.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Diagnostics & Research",
        "exchange": "NMS",
        "market": "us_market",
        "country": "United Kingdom",
        "city": "Cardiff"
    },
    "RNUGF": {
        "short_name": "RENEURON GROUP",
        "long_name": "ReNeuron Group plc",
        "summary": "ReNeuron Group plc develops and sells cell-based therapies in the United Kingdom. The company engages in the development of CTX stem cell therapy candidate that is in Phase IIb clinical trial for stroke disability; and human retinal progenitor cell therapy that is in Phase I/IIa clinical trial for treating retinitis pigmentosa, a blindness-causing disease. It also developing CTX-derived exosomes, which are Nano-sized packages of information released by CTX cells. ReNeuron Group plc has a research agreement with U.S. biotechnology company in the discovery and development of novel gene silencing-based therapeutics. The company was founded in 1997 and is headquartered in Pencoed, the United Kingdom.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "PNK",
        "market": "us_market",
        "country": "United Kingdom",
        "city": "Pencoed"
    },
    "RQE1.F": {
        "short_name": "RENEURON GRP PLC  LS-,01",
        "long_name": "ReNeuron Group plc",
        "summary": "ReNeuron Group plc develops and sells cell-based therapies in the United Kingdom. The company engages in the development of CTX stem cell therapy candidate that is in Phase IIb clinical trial for stroke disability; and human retinal progenitor cell therapy that is in Phase I/IIa clinical trial for treating retinitis pigmentosa, a blindness-causing disease. It also developing CTX-derived exosomes, which are Nano-sized packages of information released by CTX cells. ReNeuron Group plc has a research agreement with U.S. biotechnology company in the discovery and development of novel gene silencing-based therapeutics. The company was founded in 1997 and is headquartered in Pencoed, the United Kingdom.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "FRA",
        "market": "dr_market",
        "country": "United Kingdom",
        "city": "Pencoed"
    },
    "RTNXF": {
        "short_name": "RENALYTIX AI PLC",
        "long_name": "Renalytix AI plc",
        "summary": "Renalytix AI plc develops artificial intelligence-enabled in vitro diagnostic solutions for kidney diseases. The company offers KidneyIntelX, a diagnostic platform that employs an artificial intelligence-enabled algorithm that combines various data inputs, including validated blood-based biomarkers, inherited genetics and personalized patient data from electronic health record, and systems to generate a unique patient risk score. Renalytix AI plc has a license agreement with Mount Sinai Health System to develop and commercialize licensed products in connection with the application of artificial intelligence for the diagnosis of kidney disease; Joslin Diabetes Center, Inc. for developing and commercializing products for diagnosing and predicting kidney disease using biomarkers; and Kantaro Biosciences LLC for developing and commercializing laboratory tests for the detection of antibodies against SARS-CoV-2. Its products are used in kidney disease diagnosis and prognosis, clinical care, patient stratification for drug clinical trials, and drug target discovery. The company was founded in 2018 and is based in Cardiff, the United Kingdom.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Diagnostics & Research",
        "exchange": "PNK",
        "market": "us_market",
        "country": "United Kingdom",
        "city": "Cardiff"
    },
    "RTQ1.F": {
        "short_name": "AVACTA GROUP PLC  LS-,10",
        "long_name": "Avacta Group Plc",
        "summary": "Avacta Group Plc offers reagents and therapeutics based on Affimer technology for diagnostic and research applications in the United Kingdom, North America, Asia, and rest of Europe. It operates in Diagnostics, Therapeutics, and Animal Health segments. The company develops custom Affimer proteins for customer products and in-house diagnostic assays. It also develops novel cancer immunotherapies combining proprietary platforms; and provides tools and contract services to assist diagnosis of conditions in animals to enable faster treatment for veterinarians. The company has a research partnership with Moderna Therapeutics; research collaboration with pre|CISION technology incorporates a substrate that is sensitive to cleavage by fibroblast activation protein; co-development partnership agreement with Bach Biosciences LLP to develop Affimer drug conjugate therapies; drug development collaboration with LG Chem Life Sciences; a partnership with Selexis to develop cell line for clinical manufacturing, and with Tufts University School of Medicine for developing Affimer drug conjugate therapies; a collaboration with Cytiva to develop and manufacture an Affimer-based point-of-care rapid test; and a collaboration with Adeptrix to develop Affimer-based COVID-19 antigen tests. Avacta Group Plc was incorporated in 2003 and is based in Wetherby, the United Kingdom.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "FRA",
        "market": "dr_market",
        "country": "United Kingdom",
        "city": "Wetherby"
    },
    "RTRA.F": {
        "short_name": "TIZIANA LI.ADR /2 LS-,03",
        "long_name": "Tiziana Life Sciences PLC",
        "summary": "Tiziana Life Sciences Plc, a clinical stage biotechnology company, focuses on the discovery and development of molecules and related diagnostics to treat diseases in oncology and immunology in the United Kingdom. The company's product pipeline includes Foralumab (TZLS-401), a human anti-CD3 monclonal antibody for the treatment of autoimmune and inflammatory diseases, such GvHD, ulcerative colitis, Crohn's disease, multiple sclerosis, type-1 diabetes, inflammatory bowel diseases, psoriasis, and rheumatoid arthritis; and Milciclib (TZLS-201), which is an orally bioavailable, small molecule inhibitor of cyclin-dependent kinases and Src family kinases for the treatment of hepatocellular carcinoma. It also develops Anti IL-6r (TZLS-501), a human anti-interleukin-6 receptor monoclonal antibody for the treatment of IL6-induced inflammation, primarily to treat hospitalized COVID-19 patients with severe respiratory symptoms; and StemPrintER, a multi-gene signature assay intended for use in patients diagnosed with estrogen-receptor positive ER+/HER2 negative breast cancers. The company was founded in 2013 and is headquartered in London, the United Kingdom. Tiziana Life Sciences Plc is a subsidiary of Planwise Group Limited.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "FRA",
        "market": "dr_market",
        "country": "United Kingdom",
        "city": "London"
    },
    "RVKA.F": {
        "short_name": "OMEGA DIAGNOST.GR. LS-,04",
        "long_name": "Omega Diagnostics Group PLC",
        "summary": "Omega Diagnostics Group PLC, through its subsidiaries, develops, manufactures, and distributes medical diagnostics products in the United Kingdom, rest of Europe, North America, South/Central America, India, other Asian countries, Africa, and the Middle East. The company operates in three segments: Allergy and Autoimmune, Food Intolerance, and Infectious Diseases and Other. The Allergy and Autoimmune segment engages in the research, development, production, and marketing of in-vitro allergy and autoimmune tests used by doctors to diagnose patients with allergies and autoimmune diseases. This segment's product includes 69 CE-marked allergens. The Food Intolerance segment engages in the research, development, and production of kits to aid the detection of immune reactions to food under the Foodprint name. This segment also provides CNS laboratory services that offer clinical analysis to the general public, clinics, and health professionals, as well as supplies Food Detective, a consumer food test. The Infectious Diseases and Other segment is involved in the research, development, production, and marketing of kits that are used in the diagnosis of infectious diseases. This segment's products include VISITECT CD4, an in-vitro diagnostic test, which is used in the management of patients with pre-diagnosed HIV infection, as well as develops and manufactures COVID-19 antibody and antigen tests. The company offers its products to hospitals, clinics, and laboratories through distributors in approximately 75 countries worldwide. Omega Diagnostics Group PLC was founded in 1987 and is headquartered in Alva, the United Kingdom.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Medical Instruments & Supplies",
        "exchange": "FRA",
        "market": "dr_market",
        "country": "United Kingdom",
        "city": "Alva"
    },
    "RVW1.F": {
        "short_name": "PHYSIOMICS PLC  LS -,004",
        "long_name": "Physiomics Plc",
        "summary": "Physiomics Plc provides consulting services to pharmaceutical companies in the areas of outsourced quantitative pharmacology and computational biology in the United Kingdom, the European Union, and the United States. It offers modeling, simulation, and data analysis services covering various ranges of oncology research and development using its proprietary Virtual Tumour predictive software. The company also develops technology for use in the field of personalized medicine. Physiomics Plc was incorporated in 2001 and is based in Oxford, the United Kingdom.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "FRA",
        "market": "dr_market",
        "country": "United Kingdom",
        "city": "Oxford"
    },
    "S4BA.F": {
        "short_name": "F-STAR THERAPEUT.DL-,0001",
        "long_name": "F-star Therapeutics, Inc.",
        "summary": "F-star Therapeutics, Inc., a clinical-stage biopharmaceutical company develops tetravalent bispecific antibodies for cancer therapy. Its medicines used in immuno-oncology treatments. The company plans for the initiation of a Phase I, open label, first-in-human clinical study of FS222, a bispecific antibody targeting CD137 (4-1BB) and PD-L1. The company is based in Cambridge, the United Kingdom.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "FRA",
        "market": "dr_market",
        "country": "United Kingdom",
        "city": "Cambridge"
    },
    "SAR.L": {
        "short_name": "SAREUM HOLDINGS PLC ORD 0.025P",
        "long_name": "Sareum Holdings plc",
        "summary": "Sareum Holdings plc, a specialist drug development company, engages in the discovery and development of therapeutic drugs for cancer and autoimmune diseases. It develops small molecule therapeutic drugs based on its Sareum Kinase Inhibitor Library drug discovery platform. The company's product pipeline includes Checkpoint Kinase 1, Aurora+FLT3 kinase, and TYK2/JAK1 kinase. It has collaborations with Hebei Medical University Biomedical Engineering Center and Sierra Oncology, Inc. The company was founded in 2003 and is based in Cambridge, the United Kingdom.",
        "currency": "GBp",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "LSE",
        "market": "gb_market",
        "country": "United Kingdom",
        "city": "Cambridge"
    },
    "SBTX.L": {
        "short_name": "SKINBIOTHERAPEUTICS PLC ORD 1P",
        "long_name": "SkinBioTherapeutics Plc",
        "summary": "SkinBioTherapeutics plc, a life science company, engages in the research and development of lysates derived from the human microbiome on skin. The company focuses on the development of SkinBiotix technology for use in cosmetic, infection control, and eczema applications. It has an agreement with Croda International Plc for the design and manufacture of a new active cosmetic skincare ingredient based on its SkinBiotix skin microbiome technology. The company was formerly known as Skinbiotix Ltd and changed its name to SkinBioTherapeutics plc in December 2016. SkinBioTherapeutics plc was incorporated in 2015 and is based in Macclesfield, the United Kingdom.",
        "currency": "GBp",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "LSE",
        "market": "gb_market",
        "country": "United Kingdom",
        "city": "Macclesfield"
    },
    "SCLP.L": {
        "short_name": "SCANCELL HOLDINGS PLC ORD 0.1P",
        "long_name": "Scancell Holdings plc",
        "summary": "Scancell Holdings plc engages in the discovery and development of novel vaccines for the treatment of various cancers. The company's product candidates include SCIB1, which is in phase II clinical trial for the treatment of metastatic melanoma; SCIB2 that is in phase I/II combination trials for the treatment of non-small cell lung cancer; and Modi-1, which is in phase I/II clinical trials for the treatment of head and neck, triple negative breast, ovarian, and renal cancers. It also develops Modi-2 that is in pre-clinical trial for the treatment of multiple solid tumors. The company has a research collaboration agreement with BioNTech to develop T-cell receptor based therapeutics; licensing and collaboration agreement with ISA Pharmaceuticals B.V. to use ISA's AMPLIVANT adjuvant technology for the development and commercialization of Modi-1; and collaboration agreements with Cobra Biologics, Centre for Research on Global Virus Infections, the University of Nottingham, and the Nottingham Trent University to develop a vaccine for COVID-19. Scancell Holdings plc was founded in 1997 and is based in Oxford, the United Kingdom.",
        "currency": "GBp",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "LSE",
        "market": "gb_market",
        "country": "United Kingdom",
        "city": "Oxford"
    },
    "SCP.F": {
        "short_name": "SCANCELL HLDGS  LS -,001",
        "long_name": "Scancell Holdings plc",
        "summary": "Scancell Holdings plc engages in the discovery and development of novel vaccines for the treatment of various cancers. The company's product candidates include SCIB1, which is in phase II clinical trial for the treatment of metastatic melanoma; SCIB2 that is in phase I/II combination trials for the treatment of non-small cell lung cancer; and Modi-1, which is in phase I/II clinical trials for the treatment of head and neck, triple negative breast, ovarian, and renal cancers. It also develops Modi-2 that is in pre-clinical trial for the treatment of multiple solid tumors. The company has a research collaboration agreement with BioNTech to develop T-cell receptor based therapeutics; licensing and collaboration agreement with ISA Pharmaceuticals B.V. to use ISA's AMPLIVANT adjuvant technology for the development and commercialization of Modi-1; and collaboration agreements with Cobra Biologics, Centre for Research on Global Virus Infections, the University of Nottingham, and the Nottingham Trent University to develop a vaccine for COVID-19. Scancell Holdings plc was founded in 1997 and is based in Oxford, the United Kingdom.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "FRA",
        "market": "dr_market",
        "country": "United Kingdom",
        "city": "Oxford"
    },
    "SENS.L": {
        "short_name": "SENSYNE HEALTH PLC ORD 10P",
        "long_name": "Sensyne Health plc",
        "summary": "Sensyne Health plc, a healthcare technology company, develops software products that connects healthcare professionals with patients in the United Kingdom and the United States. Its products include CVm-Health, a web-based application for coronavirus self-monitoring; DBm-Health, which helps individuals monitor their blood glucose levels and share their readings with health care professionals; GDm-Health, a prescribed digital therapeutic for remote management of diabetes in pregnancy; and BPm-Health that allows pregnant women to self-monitor blood pressure during pregnancy. The company's products also include SEND, an early warning system for monitoring patient vital signs in hospital; EDGE, a prescribed digital therapeutic for monitoring chronic obstructive pulmonary disease at home; CleanSpace, a system for monitoring personal exposure to air pollution; and Support-HF, a prescribed digital therapeutic for monitoring heart failure at home. Sensyne Health has strategic research alliance with Bayer to develop new treatments using clinical artificial intelligence; research collaboration agreement with Bristol Myers Squibb to apply machine learning for rare blood disease research; and strategic research agreement with Milton Keynes University Hospital NHS Foundation Trust to enable the ethical application of clinical artificial intelligence research to improve patient care and research into new medicines; collaboration agreement with Bristol Myers Squibb to apply machine learning for rare blood disease research; and strategic research agreement with Hampshire Hospitals NHS Foundation Trust. Sensyne Health plc was incorporated in 2018 and is based in Oxford, the United Kingdom.",
        "currency": "GBp",
        "sector": "Healthcare",
        "industry": "Health Information Services",
        "exchange": "LSE",
        "market": "gb_market",
        "country": "United Kingdom",
        "city": "Oxford"
    },
    "SKDI": {
        "short_name": "SUN KISSED INDUSTRIES INC",
        "long_name": "Sun Kissed Industries Inc.",
        "summary": "DNA Dynamics, Inc., through its subsidiaries, develops mobile applications and games for smartphones and tablet devices. It develops and publishes games for Apple iPhone/iPad/iPod touch and Android platforms; and develops video games and applications for mobile devices and handheld consoles. The company develops games across seven platforms, including titles for TV brands and intellectual property holders. DNA Dynamics, Inc. was incorporated in 1981 and is headquartered in Leamington Spa, United Kingdom.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Drug Manufacturers\u2014Specialty & Generic",
        "exchange": "PNK",
        "market": "us_market",
        "country": "United Kingdom",
        "city": "Leamington Spa"
    },
    "SLN": {
        "short_name": "Silence Therapeutics Plc - Amer",
        "long_name": "Silence Therapeutics plc",
        "summary": "Silence Therapeutics plc focuses on the discovery, development, and delivery of novel RNA therapeutics in hematology, cardiovascular, and other rare and metabolic indications. The company designs short interfering RNA (siRNA) molecules that trigger the RNAi pathway and mediate the degradation of specific target messenger RNAs. It is developing various product candidates, including SLN124 for the treatment of iron overload disorders; SLN360 for the cardiovascular disease with high lipoprotein; and SLN500 for the treatment of complement-mediated diseases. Silence Therapeutics plc has a strategic collaboration with AstraZeneca to discover, develop, and commercialize small interfering RNA therapeutics for the treatment of cardiovascular, renal, metabolic, and respiratory diseases; and collaboration with Genomics England Limited. The company was formerly known as SR Pharma plc and changed its name to Silence Therapeutics plc in May 2007. Silence Therapeutics plc is headquartered in London, the United Kingdom.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "NMS",
        "market": "us_market",
        "country": "United Kingdom",
        "city": "London"
    },
    "SLN.L": {
        "short_name": "SILENCE THERAPEUTICS PLC ORD 5P",
        "long_name": "Silence Therapeutics plc",
        "summary": "Silence Therapeutics plc focuses on the discovery, development, and delivery of novel RNA therapeutics in hematology, cardiovascular, and other rare and metabolic indications. The company designs short interfering RNA (siRNA) molecules that trigger the RNAi pathway and mediate the degradation of specific target messenger RNAs. It is developing various product candidates, including SLN124 for the treatment of iron overload disorders; SLN360 for the cardiovascular disease with high lipoprotein; and SLN500 for the treatment of complement-mediated diseases. Silence Therapeutics plc has a strategic collaboration with AstraZeneca to discover, develop, and commercialize small interfering RNA therapeutics for the treatment of cardiovascular, renal, metabolic, and respiratory diseases; and collaboration with Genomics England Limited. The company was formerly known as SR Pharma plc and changed its name to Silence Therapeutics plc in May 2007. Silence Therapeutics plc is headquartered in London, the United Kingdom.",
        "currency": "GBp",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "LSE",
        "market": "gb_market",
        "country": "United Kingdom",
        "city": "London"
    },
    "SLNCF": {
        "short_name": "SILENCE THERAPEUTICS PLC",
        "long_name": "Silence Therapeutics plc",
        "summary": "Silence Therapeutics plc focuses on the discovery, development, and delivery of novel RNA therapeutics in hematology, cardiovascular, and other rare and metabolic indications. The company designs short interfering RNA (siRNA) molecules that trigger the RNAi pathway and mediate the degradation of specific target messenger RNAs. It is developing various product candidates, including SLN124 for the treatment of iron overload disorders; SLN360 for the cardiovascular disease with high lipoprotein; and SLN500 for the treatment of complement-mediated diseases. Silence Therapeutics plc has a strategic collaboration with AstraZeneca to discover, develop, and commercialize small interfering RNA therapeutics for the treatment of cardiovascular, renal, metabolic, and respiratory diseases; and collaboration with Genomics England Limited. The company was formerly known as SR Pharma plc and changed its name to Silence Therapeutics plc in May 2007. Silence Therapeutics plc is headquartered in London, the United Kingdom.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "PNK",
        "market": "us_market",
        "country": "United Kingdom",
        "city": "London"
    },
    "SN.L": {
        "short_name": "SMITH & NEPHEW PLC ORD USD0.20",
        "long_name": "Smith & Nephew plc",
        "summary": "Smith & Nephew plc develops, manufactures, and sells medical devices worldwide. The company offers knee implant products for specialized knee replacement procedures; hip implants for the reconstruction of hip joints; and trauma and extremities products that include internal and external devices used in the stabilization of severe fractures and deformity correction procedures. It also provides sports medicine joint repair products for surgeons, including an array of instruments, technologies, and implants necessary to perform minimally invasive surgery of the joints, such as the repair of soft tissue injuries and degenerative conditions of the knee, hip, and shoulder, as well as meniscal repair systems. In addition, the company offers arthroscopic enabling technologies comprising fluid management equipment for surgical access, high definition cameras, digital image capture, scopes, light sources, and monitors to assist with visualization inside the joints, radio frequency, electromechanical and mechanical tissue resection devices, and hand instruments for removing damaged tissue; and ear, nose, and throat solutions. Further, it provides advanced wound care products for the treatment and prevention of acute and chronic wounds, which comprise leg, diabetic and pressure ulcers, burns, and post-operative wounds; advanced wound bioactives, including biologics and other bioactive technologies for debridement and dermal repair/regeneration, as well as regenerative medicine products including skin, bone graft, and articular cartilage substitutes; and advanced wound devices, such as traditional and single-use negative pressure wound therapy, and hydrosurgery systems. It primarily serves the healthcare providers. Smith & Nephew plc was founded in 1856 and is headquartered in Watford, the United Kingdom.",
        "currency": "GBp",
        "sector": "Healthcare",
        "industry": "Medical Devices",
        "exchange": "LSE",
        "market": "gb_market",
        "country": "United Kingdom",
        "city": "Watford"
    },
    "SNG.L": {
        "short_name": "SYNAIRGEN PLC ORD 1P",
        "long_name": "Synairgen plc",
        "summary": "Synairgen plc discovers and develops drugs for respiratory diseases. It develops inhaled interferon beta (IFN-\u00c3\u009f), which is in Phase-II clinical trials for the treatment of asthma caused by the common cold and flu; IFN-\u00c3\u009f that is in Phase-II clinical trial for the treatment or prevention of chronic obstructive pulmonary disease exacerbations caused by the common cold and flu; and LOXL2 inhibitor, which has completed Phase I clinical trial for the treatment of idiopathic pulmonary fibrosis (IPF) and non-alcoholic fatty liver diseases. The company has a licensing and collaboration agreement with Pharmaxis Ltd. to develop a LOXL2 inhibitor; and a strategic collaboration with Parexel Biotech on pivotal Phase III trial for the study of inhaled COVID-19 treatment. Synairgen plc was incorporated in 2004 and is headquartered in Southampton, the United Kingdom.",
        "currency": "GBp",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "LSE",
        "market": "gb_market",
        "country": "United Kingdom",
        "city": "Southampton"
    },
    "SNN": {
        "short_name": "Smith & Nephew SNATS, Inc.",
        "long_name": "Smith & Nephew plc",
        "summary": "Smith & Nephew plc develops, manufactures, and sells medical devices worldwide. The company offers knee implant products for specialized knee replacement procedures; hip implants for the reconstruction of hip joints; and trauma and extremities products that include internal and external devices used in the stabilization of severe fractures and deformity correction procedures. It also provides sports medicine joint repair products for surgeons, including an array of instruments, technologies, and implants necessary to perform minimally invasive surgery of the joints, such as the repair of soft tissue injuries and degenerative conditions of the knee, hip, and shoulder, as well as meniscal repair systems. In addition, the company offers arthroscopic enabling technologies comprising fluid management equipment for surgical access, high definition cameras, digital image capture, scopes, light sources, and monitors to assist with visualization inside the joints, radio frequency, electromechanical and mechanical tissue resection devices, and hand instruments for removing damaged tissue; and ear, nose, and throat solutions. Further, it provides advanced wound care products for the treatment and prevention of acute and chronic wounds, which comprise leg, diabetic and pressure ulcers, burns, and post-operative wounds; advanced wound bioactives, including biologics and other bioactive technologies for debridement and dermal repair/regeneration, as well as regenerative medicine products including skin, bone graft, and articular cartilage substitutes; and advanced wound devices, such as traditional and single-use negative pressure wound therapy, and hydrosurgery systems. It primarily serves the healthcare providers. Smith & Nephew plc was founded in 1856 and is headquartered in Watford, the United Kingdom.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Medical Devices",
        "exchange": "NYQ",
        "market": "us_market",
        "country": "United Kingdom",
        "city": "Watford"
    },
    "SNNUF": {
        "short_name": "SMITH & NEPHEW",
        "long_name": "Smith & Nephew plc",
        "summary": "Smith & Nephew plc develops, manufactures, and sells medical devices worldwide. The company offers knee implant products for specialized knee replacement procedures; hip implants for the reconstruction of hip joints; and trauma and extremities products that include internal and external devices used in the stabilization of severe fractures and deformity correction procedures. It also provides sports medicine joint repair products for surgeons, including an array of instruments, technologies, and implants necessary to perform minimally invasive surgery of the joints, such as the repair of soft tissue injuries and degenerative conditions of the knee, hip, and shoulder, as well as meniscal repair systems. In addition, the company offers arthroscopic enabling technologies comprising fluid management equipment for surgical access, high definition cameras, digital image capture, scopes, light sources, and monitors to assist with visualization inside the joints, radio frequency, electromechanical and mechanical tissue resection devices, and hand instruments for removing damaged tissue; and ear, nose, and throat solutions. Further, it provides advanced wound care products for the treatment and prevention of acute and chronic wounds, which comprise leg, diabetic and pressure ulcers, burns, and post-operative wounds; advanced wound bioactives, including biologics and other bioactive technologies for debridement and dermal repair/regeneration, as well as regenerative medicine products including skin, bone graft, and articular cartilage substitutes; and advanced wound devices, such as traditional and single-use negative pressure wound therapy, and hydrosurgery systems. It primarily serves the healthcare providers. Smith & Nephew plc was founded in 1856 and is headquartered in Watford, the United Kingdom.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Medical Devices",
        "exchange": "PNK",
        "market": "us_market",
        "country": "United Kingdom",
        "city": "Watford"
    },
    "SPEC.L": {
        "short_name": "INSPECS GROUP PLC ORD 1P",
        "long_name": "Inspecs Group plc",
        "summary": "Inspecs Group PLC designs, produces, sells, markets, and distributes fashion eyewear and original equipment manufacturer products worldwide. It provides a range of prescription optical eyewear under the various brand names and private labels; sunglasses; and safety products under the Caterpillar brand. Inspecs Group PLC offers its products directly to retailers, specialist distributors, and brand partners. The company also sells its products through a network of approximately 30,000 points of sale in 80 countries worldwide. Inspecs Group PLC was founded in 1988 and is headquartered in Bath, the United Kingdom.",
        "currency": "GBp",
        "sector": "Healthcare",
        "industry": "Medical Instruments & Supplies",
        "exchange": "LSE",
        "market": "gb_market",
        "country": "United Kingdom",
        "city": "Bath"
    },
    "SPI.L": {
        "short_name": "SPIRE HEALTHCARE GROUP PLC ORD ",
        "long_name": "Spire Healthcare Group plc",
        "summary": "Spire Healthcare Group plc, together with its subsidiaries, owns and operates private hospitals and clinics in the United Kingdom. It offers various treatments in the areas of allergy and infectious diseases, blood tests, bones and joints, bowel treatments, breast screening, cancer investigations and treatments, cosmetic surgery, cyst removal, and dental surgery, as well as ear, nose, and throat treatments. The company also provides eye surgery and treatments, family planning, foreign visa medical exams, gastroenterology, general medicine, general surgery, haematology, hand surgery, hip and knee treatment, and heart and kidney treatments. In addition, it offers treatments in the areas of men's health, neurology, paediatrics, pain management, rehabilitation, sports, physiotherapy, podiatry, respiratory care, and rheumatology; and scans and investigations, skin treatments, spinal care, sports science, urology, vascular care, weight loss, and women's health. Further, the comapny owns and operates Perform, a sports medicine, physiotherapy, and rehabilitation brand; and offers MRI/CT scanning, pathology, and consulting services. As of December 31, 2019, it offered diagnostics, in-patient, daycase, and out-patient care services through 39 hospitals and 8 clinics across England, Wales, and Scotland. Spire Healthcare Group plc was founded in 2007 and is headquartered in London, the United Kingdom.",
        "currency": "GBp",
        "sector": "Healthcare",
        "industry": "Medical Care Facilities",
        "exchange": "LSE",
        "market": "gb_market",
        "country": "United Kingdom",
        "city": "London"
    },
    "SSYNF": {
        "short_name": "SENSYNE HEALTH PLC",
        "long_name": "Sensyne Health plc",
        "summary": "Sensyne Health plc, a healthcare technology company, develops software products that connects healthcare professionals with patients in the United Kingdom and the United States. Its products include CVm-Health, a web-based application for coronavirus self-monitoring; DBm-Health, which helps individuals monitor their blood glucose levels and share their readings with health care professionals; GDm-Health, a prescribed digital therapeutic for remote management of diabetes in pregnancy; and BPm-Health that allows pregnant women to self-monitor blood pressure during pregnancy. The company's products also include SEND, an early warning system for monitoring patient vital signs in hospital; EDGE, a prescribed digital therapeutic for monitoring chronic obstructive pulmonary disease at home; CleanSpace, a system for monitoring personal exposure to air pollution; and Support-HF, a prescribed digital therapeutic for monitoring heart failure at home. Sensyne Health has strategic research alliance with Bayer to develop new treatments using clinical artificial intelligence; research collaboration agreement with Bristol Myers Squibb to apply machine learning for rare blood disease research; and strategic research agreement with Milton Keynes University Hospital NHS Foundation Trust to enable the ethical application of clinical artificial intelligence research to improve patient care and research into new medicines; collaboration agreement with Bristol Myers Squibb to apply machine learning for rare blood disease research; and strategic research agreement with Hampshire Hospitals NHS Foundation Trust. Sensyne Health plc was incorporated in 2018 and is based in Oxford, the United Kingdom.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Health Information Services",
        "exchange": "PNK",
        "market": "us_market",
        "country": "United Kingdom",
        "city": "Oxford"
    },
    "STX.L": {
        "short_name": "SHIELD THERAPEUTICS PLC ORD 1.5",
        "long_name": "Shield Therapeutics plc",
        "summary": "Shield Therapeutics plc, a specialty pharmaceutical company, engages in the development and commercialization of late-stage pharmaceuticals to treat unmet medical needs. The company's lead product is Ferric Maltol, marketed in the European Union as Feraccru, a non-salt based novel therapy for the treatment of iron deficiency anemia in patients with inflammatory bowel disease. Its advanced pipeline asset is PT20, a novel therapy that has completed its Phase II pivotal study for the treatment of hyperphosphatemia in patients with chronic kidney disease. The company also develops PT30 to treat hypo-allergenic IV iron therapy; and PT40, the first generic version of iron sucrose. Shield Therapeutics plc was founded in 2008 and is based in Gateshead, the United Kingdom.",
        "currency": "GBp",
        "sector": "Healthcare",
        "industry": "Drug Manufacturers\u2014Specialty & Generic",
        "exchange": "LSE",
        "market": "gb_market",
        "country": "United Kingdom",
        "city": "Gateshead"
    },
    "SUN.L": {
        "short_name": "SURGICAL INNOVATIONS GROUP PLC ",
        "long_name": "Surgical Innovations Group plc",
        "summary": "Surgical Innovations Group plc designs, develops, manufactures, and sells devices for use in minimally invasive surgery (SI) and precision engineering markets in the United Kingdom, Europe, the Asia Pacific, the United States, and internationally. It operates through three segments: SI Brand, Original Equipment Manufacturer (OEM), and Distribution. The SI Brand segment researches, develops, manufactures, and distributes SI branded minimally invasive devices. This segment also offers YelloPort Elite and YelloPort +plus laparoscopic port access systems; LogiRange resposable laparoscopic instrument systems; FastClamp laparoscopic clamping systems; and QuickRange single use laparoscopic instrumentation. The OEM segment researches, develops, manufactures, and distributes minimally invasive devices for third party medical device companies through own label or co-branding. This segment also provides design and development solutions for producing a final device; and researches, develops, manufactures, and sells minimally invasive technology products for precision engineering applications. The Distribution segment distributes medical products through Elemental Healthcare Ltd. The company also designs and manufactures autologous blood products. It sells its products through independent healthcare distributors, as well as its own label products through OEM relationships. Surgical Innovations Group plc was founded in 1992 and is based in Leeds, the United Kingdom.",
        "currency": "GBp",
        "sector": "Healthcare",
        "industry": "Medical Devices",
        "exchange": "LSE",
        "market": "gb_market",
        "country": "United Kingdom",
        "city": "Leeds"
    },
    "SYGGF": {
        "short_name": "SYNAIRGEN",
        "long_name": "Synairgen plc",
        "summary": "Synairgen plc discovers and develops drugs for respiratory diseases. It develops inhaled interferon beta (IFN-\u00c3\u009f), which is in Phase-II clinical trials for the treatment of asthma caused by the common cold and flu; IFN-\u00c3\u009f that is in Phase-II clinical trial for the treatment or prevention of chronic obstructive pulmonary disease exacerbations caused by the common cold and flu; and LOXL2 inhibitor, which has completed Phase I clinical trial for the treatment of idiopathic pulmonary fibrosis (IPF) and non-alcoholic fatty liver diseases. The company has a licensing and collaboration agreement with Pharmaxis Ltd. to develop a LOXL2 inhibitor; and a strategic collaboration with Parexel Biotech on pivotal Phase III trial for the study of inhaled COVID-19 treatment. Synairgen plc was incorporated in 2004 and is headquartered in Southampton, the United Kingdom.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "PNK",
        "market": "us_market",
        "country": "United Kingdom",
        "city": "Southampton"
    },
    "TILS.L": {
        "short_name": "TIZIANA LIFE SCIENCES PLC ORD 3",
        "long_name": "Tiziana Life Sciences PLC",
        "summary": "Tiziana Life Sciences Plc, a clinical stage biotechnology company, focuses on the discovery and development of molecules and related diagnostics to treat diseases in oncology and immunology in the United Kingdom. The company's product pipeline includes Foralumab (TZLS-401), a human anti-CD3 monclonal antibody for the treatment of autoimmune and inflammatory diseases, such GvHD, ulcerative colitis, Crohn's disease, multiple sclerosis, type-1 diabetes, inflammatory bowel diseases, psoriasis, and rheumatoid arthritis; and Milciclib (TZLS-201), which is an orally bioavailable, small molecule inhibitor of cyclin-dependent kinases and Src family kinases for the treatment of hepatocellular carcinoma. It also develops Anti IL-6r (TZLS-501), a human anti-interleukin-6 receptor monoclonal antibody for the treatment of IL6-induced inflammation, primarily to treat hospitalized COVID-19 patients with severe respiratory symptoms; and StemPrintER, a multi-gene signature assay intended for use in patients diagnosed with estrogen-receptor positive ER+/HER2 negative breast cancers. The company was founded in 2013 and is headquartered in London, the United Kingdom. Tiziana Life Sciences Plc is a subsidiary of Planwise Group Limited.",
        "currency": "GBp",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "LSE",
        "market": "gb_market",
        "country": "United Kingdom",
        "city": "London"
    },
    "TLSA": {
        "short_name": "Tiziana Life Sciences plc - Ame",
        "long_name": "Tiziana Life Sciences PLC",
        "summary": "Tiziana Life Sciences Plc, a clinical stage biotechnology company, focuses on the discovery and development of molecules and related diagnostics to treat diseases in oncology and immunology in the United Kingdom. The company's product pipeline includes Foralumab (TZLS-401), a human anti-CD3 monclonal antibody for the treatment of autoimmune and inflammatory diseases, such GvHD, ulcerative colitis, Crohn's disease, multiple sclerosis, type-1 diabetes, inflammatory bowel diseases, psoriasis, and rheumatoid arthritis; and Milciclib (TZLS-201), which is an orally bioavailable, small molecule inhibitor of cyclin-dependent kinases and Src family kinases for the treatment of hepatocellular carcinoma. It also develops Anti IL-6r (TZLS-501), a human anti-interleukin-6 receptor monoclonal antibody for the treatment of IL6-induced inflammation, primarily to treat hospitalized COVID-19 patients with severe respiratory symptoms; and StemPrintER, a multi-gene signature assay intended for use in patients diagnosed with estrogen-receptor positive ER+/HER2 negative breast cancers. The company was founded in 2013 and is headquartered in London, the United Kingdom. Tiziana Life Sciences Plc is a subsidiary of Planwise Group Limited.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "NMS",
        "market": "us_market",
        "country": "United Kingdom",
        "city": "London"
    },
    "TLY.L": {
        "short_name": "TOTALLY PLC ORD 10P",
        "long_name": "Totally plc",
        "summary": "Totally plc, through its subsidiaries, provides out-of-hospital healthcare services in the United Kingdom and Ireland. It operates through Urgent Care and Other segments. The company offers a range of treatment and advice for musculoskeletal injuries and conditions, such as physiotherapy and podiatry to NHS patients; occupational health and ergonomic services to corporate and private clients. It also provides dermatology and referral management services; urgent care services; and clinical health coaching services to educate patients to self-manage their conditions, such as chronic obstructive pulmonary disease; and hospital insourcing services, as well as IT healthcare solutions; and provision for online health and safety risk assessments. The company was incorporated in 1999 and is based in Derby, the United Kingdom.",
        "currency": "GBp",
        "sector": "Healthcare",
        "industry": "Medical Care Facilities",
        "exchange": "LSE",
        "market": "gb_market",
        "country": "United Kingdom",
        "city": "Derby"
    },
    "TRX.L": {
        "short_name": "TISSUE REGENIX GROUP PLC ORD 0.",
        "long_name": "Tissue Regenix Group plc",
        "summary": "Tissue Regenix Group plc, a medical technology company, develops and commercializes platform technologies in the field of tissue engineering and regenerative medicine in the United States and internationally. It operates through BioSurgery, Orthopaedics & Dental, Cardiac, and GBM-V divisions. The company provides dCELL technology, a soft tissue decellularisation process that removes DNA and cellular material from biological tissues, the patient's cells can repopulate and colonise, creating new, like-for-like tissue, which is recognized and accepted by the body by reducing the risk of rejection, and stimulating a natural healing process. It also offers BioRinse technology, a natural bone filler solution for osteoinductive to stimulate and regenerate native bone growth. In addition, the company provides DermaPure, a decellularised dermal allograft for orthopaedics, trauma, and woundcare; and SurgiPure XD, a Decellularised xenograft tissue for the repair of hernias and/or body wall defects, which require the use of reinforcing or buttressing material to obtain the desired surgical outcome. Further, it offers OrthoPure XT, a scaffold to replace the damaged tissue that will re-populate with the patient's own cells; ConCelltrate 100, a verified osteoinductive bone matrix; MatrixCellect 100, a demineralised bone matrix; Matrix IQ Dermis, a human-derived dermal graft, which is decellularised to remove cellular components and preserve the biological properties that promote revascularisation, repair, and augmentation of damaged tissue; and Matrix OI FlexIt, a thin pliable demineralised cortical allograft bone sheet. Additionally, the company provides DentalFix, a mineralized particulate allograft that offer osteoconductive properties of natural bone; and develops CardioPure product. The company was incorporated in 2006 and is based in Garforth, the United Kingdom.",
        "currency": "GBp",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "LSE",
        "market": "gb_market",
        "country": "United Kingdom",
        "city": "Garforth"
    },
    "TSTL.L": {
        "short_name": "TRISTEL PLC ORD 1P",
        "long_name": "Tristel plc",
        "summary": "Tristel plc develops, manufactures, and supplies infection and contamination control, and hygiene products in the United Kingdom and internationally. The company operates through three segments: Hospital Medical Device Decontamination, Hospital Environmental Surface Disinfection, and Other. It offers medical instrument disinfection products under the Tristel brand; surface cleaning and disinfection products used in areas, such as hospitals, rescue vehicles, care homes, hospices, dentists, and GP surgeries under the Cache brand; contamination control products for pharmaceutical and personal care industries under the Crystel brand; and animal health infection prevention and control products under the Anistel brand. Tristel plc was founded in 1993 and is based in Snailwell, the United Kingdom.",
        "currency": "GBp",
        "sector": "Healthcare",
        "industry": "Medical Instruments & Supplies",
        "exchange": "LSE",
        "market": "gb_market",
        "country": "United Kingdom",
        "city": "Snailwell"
    },
    "UKXA.F": {
        "short_name": "TOTALLY PLC  LS -,10",
        "long_name": "Totally plc",
        "summary": "Totally plc, through its subsidiaries, provides out-of-hospital healthcare services in the United Kingdom and Ireland. It operates through Urgent Care and Other segments. The company offers a range of treatment and advice for musculoskeletal injuries and conditions, such as physiotherapy and podiatry to NHS patients; occupational health and ergonomic services to corporate and private clients. It also provides dermatology and referral management services; urgent care services; and clinical health coaching services to educate patients to self-manage their conditions, such as chronic obstructive pulmonary disease; and hospital insourcing services, as well as IT healthcare solutions; and provision for online health and safety risk assessments. The company was incorporated in 1999 and is based in Derby, the United Kingdom.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Medical Care Facilities",
        "exchange": "FRA",
        "market": "dr_market",
        "country": "United Kingdom",
        "city": "Derby"
    },
    "UROV": {
        "short_name": "Urovant Sciences Ltd.",
        "long_name": "Urovant Sciences Ltd.",
        "summary": "Urovant Sciences Ltd., a clinical-stage biopharmaceutical company, focuses on developing and commercializing therapies for urologic conditions in the United States. The company's lead product candidate is vibegron, an oral small molecule beta-3 agonist for the treatment of overactive bladder (OAB), OAB in men with benign prostatic hyperplasia, and abdominal pain due to irritable bowel syndrome. It is also developing URO-902, a gene therapy for patients with OAB who have failed oral pharmacological therapy. The company was formerly known as Thalavant Sciences Ltd. and changed its name to Urovant Sciences Ltd. in January 2017. Urovant Sciences Ltd. was founded in 2016 and is based in London, the United Kingdom. Urovant Sciences Ltd. operates as a subsidiary of Sumitovant Biopharma Ltd.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "NMS",
        "market": "us_market",
        "country": "United Kingdom",
        "city": "London"
    },
    "V4TA.F": {
        "short_name": "VECTURA GROUP LS -,000271",
        "long_name": "Vectura Group plc",
        "summary": "Vectura Group plc engages in the design, development, and supply of pharmaceutical products for the treatment of airways-related diseases worldwide. The company's in-market products include Seebri, Breezhaler and Neohaler, a DPI device and bronchodilator; AirFluSal Forspiro for the treatment of asthma and chronic obstructive pulmonary disease (COPD); Breelib for the treatment of pulmonary arterial hypertension; Relvar Ellipta/Breo Ellipta that is used in treating asthma and COPD; and Incruse Ellipta, Anoro Ellipta, and Trelegy Ellipta for the treatment of COPD. It is also developing VR315 (US) for the treatment of asthma and COPD.In addition, the company offers dry powder inhalers, pressurized metered dose inhalers, and nebulized devices. Vectura Group plc was founded in 1997 and is headquartered in Chippenham, the United Kingdom.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Drug Manufacturers\u2014General",
        "exchange": "FRA",
        "market": "dr_market",
        "country": "United Kingdom",
        "city": "Chippenham"
    },
    "VAL.L": {
        "short_name": "VALIRX PLC ORD 0.1P",
        "long_name": "ValiRx plc",
        "summary": "ValiRx plc, a biotechnology oncology focused company, engages in developing novel therapeutics and associated biomarkers for cancer in the United Kingdom. The company's lead drug candidates include VAL201, an anti-cancer therapeutic that is in Phase I/II trials for the treatment of prostate cancer and other indications of hormone induced unregulated growth, including endometriosis; VAL301, a reformulation of VAL201, which is in pre-clinical development for the treatment of women with endometriosis; and VAL401, a reformulation of generic drug Risperidone, which has completed Phase II clinical trial for the treatment of non-small cell lung cancer. Its drug candidates also comprise VAL101, a candidate produced by GeneICE technology platform to modulate BCl2 expression \u00c2\u0096 implicated in cancers. ValiRx plc has collaboration agreement with Oncolytika Limited and Black Cat Bio Limited to develop and evaluate BC201 for patients suffering a hyperimmune response to Coronavirus SARS-CoV2 infection. The company was incorporated in 2000 and is based in Hatfield, the United Kingdom.",
        "currency": "GBp",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "LSE",
        "market": "gb_market",
        "country": "United Kingdom",
        "city": "Hatfield"
    },
    "VEC.L": {
        "short_name": "VECTURA GROUP PLC ORD 0.0271P",
        "long_name": "Vectura Group plc",
        "summary": "Vectura Group plc engages in the design, development, and supply of pharmaceutical products for the treatment of airways-related diseases worldwide. The company's in-market products include Seebri, Breezhaler and Neohaler, a DPI device and bronchodilator; AirFluSal Forspiro for the treatment of asthma and chronic obstructive pulmonary disease (COPD); Breelib for the treatment of pulmonary arterial hypertension; Relvar Ellipta/Breo Ellipta that is used in treating asthma and COPD; and Incruse Ellipta, Anoro Ellipta, and Trelegy Ellipta for the treatment of COPD. It is also developing VR315 (US) for the treatment of asthma and COPD.In addition, the company offers dry powder inhalers, pressurized metered dose inhalers, and nebulized devices. Vectura Group plc was founded in 1997 and is headquartered in Chippenham, the United Kingdom.",
        "currency": "GBp",
        "sector": "Healthcare",
        "industry": "Drug Manufacturers\u2014General",
        "exchange": "LSE",
        "market": "gb_market",
        "country": "United Kingdom",
        "city": "Chippenham"
    },
    "VEGPF": {
        "short_name": "VECTURA GROUP",
        "long_name": "Vectura Group plc",
        "summary": "Vectura Group plc engages in the design, development, and supply of pharmaceutical products for the treatment of airways-related diseases worldwide. The company's in-market products include Seebri, Breezhaler and Neohaler, a DPI device and bronchodilator; AirFluSal Forspiro for the treatment of asthma and chronic obstructive pulmonary disease (COPD); Breelib for the treatment of pulmonary arterial hypertension; Relvar Ellipta/Breo Ellipta that is used in treating asthma and COPD; and Incruse Ellipta, Anoro Ellipta, and Trelegy Ellipta for the treatment of COPD. It is also developing VR315 (US) for the treatment of asthma and COPD.In addition, the company offers dry powder inhalers, pressurized metered dose inhalers, and nebulized devices. Vectura Group plc was founded in 1997 and is headquartered in Chippenham, the United Kingdom.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Drug Manufacturers\u2014General",
        "exchange": "PNK",
        "market": "us_market",
        "country": "United Kingdom",
        "city": "Chippenham"
    },
    "VICA": {
        "short_name": "RAFINA INNOVATIONS INC",
        "long_name": "Rafina Innovations Inc.",
        "summary": "Rafina Innovations Inc. engages in the research, development, commercialization, and marketing of medical technologies. It operates through two segments, Clinics and Technology. The company also operates prosthetics and orthotics, and diabetic foot total rehabilitation clinics in Southern Europe, the Middle East, and North Africa. In addition, it is involved in the research, development, and commercialization of medical devices, methods, and products in the fields of prosthetics, orthotics, rehabilitation, bioengineering, mobility, diabetes, diabetic foot, tissue mechanics, ultrasonics, medical signal processing and analysis, medical technology, orthopedics, and robotic surgery; and licensing of its proprietary technologies. The company was formerly known as HCi Viocare and changed its name to Rafina Innovations Inc. in July 2018. Rafina Innovations Inc. was founded in 2007 and is based in Glasgow, the United Kingdom.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Medical Devices",
        "exchange": "PNK",
        "market": "us_market",
        "country": "United Kingdom",
        "city": "Glasgow"
    },
    "VLG.L": {
        "short_name": "VENTURE LIFE GROUP PLC ORD 0.3P",
        "long_name": "Venture Life Group plc",
        "summary": "Venture Life Group plc develops and commercializes oral care products, food supplements, medical devices, and dermo-cosmetics for the ageing population in the United Kingdom, Italy, Switzerland, rest of Europe, and internationally. It operates through Brands, and Development and Manufacturing segments. The company offers neurology products, including NeuroAge, NeuroAge Sleep, and NeuroAge NRG food supplements to enhance mental alertness, cognitive function, and mental performance in ageing brain; and Original Bioscalin to treat and prevent hair loss, hair thinning, and baldness. It also provides Fungal Nail Solution, which helps to treat and prevent fungal infections; and Fungal Nail Cleanser for the hygiene of hands and feet prone to fungal nail infections under the Myco Clear brand name. In addition, the company offers UltraDEX Original and UltraDEX Sensitive for bad breath; Dently Dual Action, a mouthwash, which lifts and removes plaque and bacteria from the teeth and mouth; and Procto-eze for anal irritation, including haemorrhoids conditions. Further, it provides women healthcare products comprising vonalei bacterial vaginosis, a refreshing gel; vonalei Vaginal Atrophy, a vaginal cream; vonalei candidiasis, a soothing cream-gel for thrush; and vonalei intimate cleansing foam. Additionally, it offers Cleansing Foam, Cleansing Cream, and Serum under the Rosa calma brand name; and skincare ranges to hydrate, nourish, and recondition the skin, as well as to prevent the lines and wrinkles under the Lubatti Classic and the Lubatti Anti-age brand names. Venture Life Group plc sells its products through a network of healthcare partners, as well as grocery multiple retailers. The company was incorporated in 2005 and is headquartered in Bracknell, the United Kingdom.",
        "currency": "GBp",
        "sector": "Healthcare",
        "industry": "Drug Manufacturers\u2014Specialty & Generic",
        "exchange": "LSE",
        "market": "gb_market",
        "country": "United Kingdom",
        "city": "Bracknell"
    },
    "VRCI.L": {
        "short_name": "VERICI DX PLC ORD GBP0.001",
        "long_name": "Verici Dx plc",
        "summary": "Verici Dx plc engages in developing and commercializing clinical diagnostics kidney transplant tests. The company was incorporated in 2020 and is based in Penarth, United Kingdom. As of July 10, 2020, Verici Dx plc is a former subsidiary of Renalytix AI plc.",
        "currency": "GBp",
        "sector": "Healthcare",
        "industry": "Diagnostics & Research",
        "exchange": "LSE",
        "market": "gb_market",
        "country": "United Kingdom",
        "city": "Penarth"
    },
    "VRNA": {
        "short_name": "Verona Pharma plc",
        "long_name": "Verona Pharma plc",
        "summary": "Verona Pharma plc, a clinical stage biopharmaceutical company, focuses on develops and commercializes therapies for the treatment of respiratory diseases with unmet medical needs. Its product candidate, ensifentrine (RPL554), is an inhaled, dual inhibitor of the enzymes phosphodiesterase 3 and 4 that acts as both a bronchodilator and an anti-inflammatory agent in a single compound. The formulations of ensifentrine are under development for the treatment chronic obstructive pulmonary disease (COPD): nebulized ensifentrine is in Phase 2b clinical development for the maintenance treatment of COPD; and a dry powder inhaler and a pressurized metered-dose inhaler. The company also focuses on developing ensifentrine for the treatment of cystic fibrosis and asthma. Verona Pharma plc was founded in 2005 and is headquartered in London, the United Kingdom.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "NMS",
        "market": "us_market",
        "country": "United Kingdom",
        "city": "London"
    },
    "WRHLF": {
        "short_name": "WORLD HIGH LIFE PLC",
        "long_name": "World High Life Plc",
        "summary": "World High Life Plc formerly known as World High Life Limited, is a private equity and venture capital firm specializing in acquisition, early stage and mature companies. It may invest as debt or equity, in either quoted or unquoted securities, and made by direct acquisition of an interest in companies, partnerships or joint ventures, or direct interests in projects, or by way of licensing arrangements. It typically invests in companies operating in the Cannabidiol (CBD) wellness and medicinal cannabis, hemp including the industrial hemp with focus on therapeutic cannabis derivatives including nutraceuticals, dietary supplements and cosmetic products. The firm also seeks to invest in the cultivation of cannabis and hemp, the manufacture and distribution of medicinal cannabis, hemp and CBD products, pharmacology commercialization of medicinal cannabis, hemp and CBD, professional prescription by practitioners and after care as it relates to medicinal cannabis, statistical management, laboratory testing and compliance in respect of medicinal cannabis, hemp and CBD sectors, and the development of CBD within the wellness sector including retail products such as patches, topical ointments, tinctures, beverages, powdered supplements as well as vaping capsules, e-liquids and oils. The firm typically invests in Europe, Canada, Africa and South America, Israel and Asia. The firm will hold investments for the medium to long term, although where opportunities exist for shorter-term investments, it may undertake such investments. The firm typically acquire control in certain situations, although it may also consider acquiring non-controlling positions. The firm seeks to take majority stake. World High Life Plc was founded on 30th January 2019 and is based in London, United Kingdom.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Drug Manufacturers\u2014Specialty & Generic",
        "exchange": "PNK",
        "market": "us_market",
        "country": "United Kingdom",
        "city": "London"
    },
    "XRP1.F": {
        "short_name": "SILENCE THERAPEUT. LS-,05",
        "long_name": "Silence Therapeutics plc",
        "summary": "Silence Therapeutics plc focuses on the discovery, development, and delivery of novel RNA therapeutics in hematology, cardiovascular, and other rare and metabolic indications. The company designs short interfering RNA (siRNA) molecules that trigger the RNAi pathway and mediate the degradation of specific target messenger RNAs. It is developing various product candidates, including SLN124 for the treatment of iron overload disorders; SLN360 for the cardiovascular disease with high lipoprotein; and SLN500 for the treatment of complement-mediated diseases. Silence Therapeutics plc has a strategic collaboration with AstraZeneca to discover, develop, and commercialize small interfering RNA therapeutics for the treatment of cardiovascular, renal, metabolic, and respiratory diseases; and collaboration with Genomics England Limited. The company was formerly known as SR Pharma plc and changed its name to Silence Therapeutics plc in May 2007. Silence Therapeutics plc is headquartered in London, the United Kingdom.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "FRA",
        "market": "dr_market",
        "country": "United Kingdom",
        "city": "London"
    },
    "XRP2.F": {
        "short_name": "SILENCE THERAP. SP.ADR/1",
        "long_name": "Silence Therapeutics plc",
        "summary": "Silence Therapeutics plc focuses on the discovery, development, and delivery of novel RNA therapeutics in hematology, cardiovascular, and other rare and metabolic indications. The company designs short interfering RNA (siRNA) molecules that trigger the RNAi pathway and mediate the degradation of specific target messenger RNAs. It is developing various product candidates, including SLN124 for the treatment of iron overload disorders; SLN360 for the cardiovascular disease with high lipoprotein; and SLN500 for the treatment of complement-mediated diseases. Silence Therapeutics plc has a strategic collaboration with AstraZeneca to discover, develop, and commercialize small interfering RNA therapeutics for the treatment of cardiovascular, renal, metabolic, and respiratory diseases; and collaboration with Genomics England Limited. The company was formerly known as SR Pharma plc and changed its name to Silence Therapeutics plc in May 2007. Silence Therapeutics plc is headquartered in London, the United Kingdom.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "FRA",
        "market": "dr_market",
        "country": "United Kingdom",
        "city": "London"
    },
    "YGEN.L": {
        "short_name": "YOURGENE HEALTH PLC ORD 0.1P",
        "long_name": "Yourgene Health Plc",
        "summary": "Yourgene Health Plc, a molecular diagnostic company, researches, develops, and commercializes gene analysis techniques for prenatal screening and other applications in the United Kingdom, Europe, and internationally. The company develops the IONA Test, an in vitro diagnostic non-invasive pre-natal test (NIPT) screening for pregnant women to estimate Down's syndrome and other genetic disorders. The IONA test enables clinical laboratories to perform their own NIPT screening service. It also offers Cystic Fibrosis screening test; genetic disease screening products; and reproductive health products that include polymerase chain reaction -based screening tests for male factor infertility, recurrent pregnancy loss, and thrombosis. The company was formerly known as Premaitha Health PLC and changed its name to Yourgene Health Plc in November 2018. The company was incorporated in 2000 and is headquartered in Manchester, the United Kingdom.",
        "currency": "GBp",
        "sector": "Healthcare",
        "industry": "Diagnostics & Research",
        "exchange": "LSE",
        "market": "gb_market",
        "country": "United Kingdom",
        "city": "Manchester"
    }
}